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Despite their limited size, viruses can have a massive impact on their hosts on both 
the individual and population level. For example, one can think of the devastating 
effects on the human body of Ebola virus infection, the worldwide societal and eco-
nomic unrest caused by the SARS-coronavirus pandemic in 2002-2003, or the millions 
of deaths associated with the Spanish flu pandemic in the early 20th century. These 
events become even more fascinating when taking into consideration the nature of 
viral particles, essentially being lifeless entities. Viruses are incapable of replicating 
outside of a cellular context and thus depend entirely on interactions with their host 
for their reproduction. These interactions take place at numerous and very diverse 
steps in the viral “life cycle”. For example, they range from the use of cellular recep-
tors for viral entry into the cell to hitching a ride on the cellular secretory pathway 
to facilitate egress, and from viral hijacking of the cellular translation machinery to 
counteracting cellular antiviral defence systems. A complete understanding of viral 
biology, if ever attainable, therefore relies for a large part on unravelling the interplay 
between viruses and their hosts.
In the case of positive-strand (+) RNA viruses, virus-encoded proteases provide an 
excellent tool to manipulate the intracellular environment. Especially mammalian 
+RNA viruses commonly express (part of) their proteome in the form of large poly-
proteins that are co- and posttranslationally cleaved into their respective functional 
subunits by internal protease domains. Interestingly, many virus-encoded proteases 
have been found to exert a dual function, targeting both the viral polyprotein and 
host proteins. For example, the hepatitis C virus main protease, which is critical for 
replication because of its role in polyprotein maturation, has been shown to cleave 
and thereby inactivate the innate immune signalling adaptor protein MAVS (1, 2). To 
broaden our understanding of viral protease-mediated manipulation of the intracellu-
lar environment, this thesis focuses on elucidating the interaction between a protease 
encoded by a particular group of +RNA viruses, the arteriviruses (order Nidovirales), 
and the cellular ubiquitin system, both of which will be introduced in detail below.
tHe NidOViRUS ORdeR
Taxonomy
The order Nidovirales includes a collection of animal viruses that are characterized by 
a common expression strategy and genome organization, and by the presumed com-
mon ancestry of key replicative enzymes (for reviews, see (3, 4)). Its name derives from 
the nested set (the Latin nidus means nest) of subgenomic mRNAs that forms a com-
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mon feature of nidovirus genome expression (5). At the moment, the nidovirus order 
is subdivided into four families: the arteriviruses, coronaviruses, mesoniviruses, and 
roniviruses (4, 6). The arterivirus family currently consists of one genus and includes 
four species: the family prototype equine arteritis virus (EAV), porcine reproductive 
and respiratory syndrome virus (PRRSV), lactate dehydrogenase-elevating virus (LDV), 
and simian hemorrhagic fever virus (SHFV) (7). In nature, these viruses each display 
a strikingly narrow host range by infecting equids, swine, mice, or monkeys, respec-
tively. Two genotypes of PRRSV (type I and II) are currently recognized and these show 
such low levels of sequence similarity (60-70% at the nucleotide sequence level (8)) 
that they will likely be classified as separate species upon future taxonomic revi-
sions. Furthermore, the recently identified wobbly possum disease virus (WPDV) (9) 
and several newly recognized monkey viruses distantly related to SHFV (10) are now 
tentatively placed within the arterivirus family.
The coronavirus family has a more complicated internal taxonomic structure and, 
contrary to the arteriviruses, does contain a number of human viruses. It includes 
two subfamilies, coronavirinae and torovirinae, the former including a total of four 
genera: the alpha-, beta-, gamma-, and deltacoronaviruses (11). Coronaviruses infect 
a wide variety of animals, including for example white bream, chicken, beluga whales, 
bats, mice, swine, and humans. Whereas human coronaviruses, such as NL63 and 
229E, are responsible for a percentage of (often mild) cases of common cold, two 
zoonotic betacoronaviruses cause much more severe disease in humans. These are 
the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) (12-14) 
and the recently emerged Middle East respiratory syndrome coronavirus (MERS-CoV) 
(15). Finally, the mesonivirus family consists of several species of insect virus (16-18) 
and the ronivirus family consists of two prawn virus species (19-21).
The work described in this thesis mainly focuses on EAV, which is the prototype 
arterivirus and has been studied for a considerable number of years since its dis-
covery in the late 1950s (22, 23). Since PRRSV is considered an economically highly 
relevant pathogen with a major impact on swine farming industries worldwide (24), 
and because some of the work described in this thesis relates to possibilities for its 
improved control, it will also be included in this introduction. LDV, SHFV, and the novel 
arteriviruses will not be discussed further here (for a recent review, see (25)). Instead, 
some attention will be given to the distantly related SARS- and MERS-coronaviruses 
because of their relevance for public health and the functional similarities with the 






Although the majority of infections with EAV remain subclinical, outbreaks of the 
associated disease equine viral arteritis (EVA) are sometimes observed (26-29). The 
symptoms characterizing this disease are inflammation of the small muscular arter-
ies (arteritis), fever, depression, anorexia, and oedema in adult horses, abortion in 
pregnant mares, and interstitial pneumonia in young foals (for a recent review, see 
(30)). An important factor in the epidemiology and spread of EAV appears to be the 
occurrence of persistent infection in the ampulla of the reproductive tract of breeding 
stallions, which allows for venereal transmission of the virus through infected semen 
(31). Alternatively, infection can occur via the respiratory tract through inhalation of 
virus-containing aerosols from respiratory secretions or urine (32). Prevention of EVA 
mainly relies on vaccination (33), for which currently two types of vaccine are com-
mercially available: a modified live virus (MLV) and an inactivated virus vaccine called 
ARVAC and Artervac, respectively (both marketed by Zoetis, NJ, USA). The former is 
considered more effective than the latter vaccine type, but some issues pertaining to 
the use of the MLV do exist. Firstly, it is not recommended for use in pregnant mares 
during the last two months of gestation (32). In addition, and more importantly, even 
though vaccination with the MLV prevents the onset of clinical EVA, limited replication 
of field strains in vaccinated animals, combined with occasional shedding of infectious 
virus, has been observed (34). Since the spread of EAV potentially has a profound 
impact on horse breeding and performance industries, due to for example the loss 
of foals, decreased value of carrier stallions, and cancellation of equestrian events 
(33), its effective control is of significant importance. A combination of vaccination 
and prevention strategies based on screening for and isolation of infected animals 
currently appear to be effective in containing EAV, although there is certainly room 
for improvement of the efficacy and safety of the available vaccines against this virus.
The syndrome associated with PRRSV infection is characterized by abortions in 
pregnant sows and severe respiratory illness in young pigs (for a review, see (35)). 
Especially the emergence of highly virulent strains of PRRSV in China in 2006 is as-
sociated with very severe illness and high mortality rates (36-38). In addition, PRRSV 
infection is characterized by a long-lasting viraemia, caused by persistent infection 
of the tonsils, lungs, and lymphoid organs (39-41). Importantly, PRRSV causes con-
siderable losses to swine farming industries worldwide, with estimates of at least 
half a billion dollar per year in the United States alone (24). Currently, a number of 
PRRSV vaccines are commercially available, of which the MLVs are considered to be 
most effective. However, like the EAV MLV, these vaccines appear to only avert the 
clinical manifestation of subsequent PRRSV infection without completely preventing 
replication of field strains (for reviews, see (42, 43)). In addition, these vaccines offer 
little to no protection against heterologous strains, even those belonging to the same 
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genotype. Taken together, there is a great need for improved PRRSV vaccines, prefer-
ably in the form of novel MLVs that provide better protection against heterologous 
field strains than currently available vaccines.
Until 2002, coronaviruses were only known to cause mild respiratory illness upon 
infection of otherwise healthy humans. However, that year witnessed the emergence 
of the zoonotic SARS-CoV as a novel and highly pathogenic human pathogen (12-14, 
44). It quickly spread across the globe and was responsible for the death of ap-
proximately 800 people worldwide, resulting in a mortality rate of about 10% (for a 
review, see (45)). Although no vaccines have been approved for clinical use to date, 
the pandemic was quickly contained using strict quarantine measures (for reviews, 
see (45-47)). More recently, in 2012, another zoonotic coronavirus emerged which 
was later named Middle East respiratory syndrome coronavirus (MERS-CoV) after its 
geographical origin and associated pathology (15). As of July 2014, more than 800 
laboratory-confirmed MERS cases had been reported to the World Health Organisa-
tion, resulting in 289 deaths (source: www.who.org). Although this novel addition to 
the coronavirus family appears to spread less rapidly than the SARS-CoV, it does cause 
severe pathology with high mortality rates (currently about 35%) in susceptible indi-
viduals and it remains to be seen how it will evolve in the near future.
General features of nidovirus replication
Nidoviruses are enveloped +RNA viruses with a non-segmented genome ranging in 
size from approximately 13 (EAV) to 30 (SARS- and MERS-CoVs) kilobases (kb). Upon 
infection, the viral RNA is released into the cytoplasm where the two largest open 
reading frames (ORF1a and ORF1b), covering the 5’-proximal two-thirds to three-
quarters of the viral genome, are immediately translated into two overlapping rep-
licase polyproteins: pp1a and pp1ab (figure I-1). The latter is produced via a -1 pro-
grammed ribosomal frameshift (PRF), which occurs with a frequency of approximately 
15-20% when tested in a reporter system for EAV (48, 49). The replicase polyproteins 
consist of the viral nonstructural proteins (nsps), which are released via extensive 
autoproteolytic processing (discussed below) and include key replicative enzymes 
such as the RNA-dependent RNA polymerase and helicase. Together, the nsps form the 
membrane-bound replication and transcription complex (RTC) which is responsible 
for the replication of viral genomic RNA and the transcription of subgenomic mRNAs 
(5). This complex localizes to endoplasmic reticulum (ER)-derived membrane struc-
tures consisting predominantly of double-membrane vesicles (DMVs) (50, 51) whose 
induction, in the case of EAV, can be mimicked by the combined expression of nsp2 
and nsp3 (52, 53). The nidovirus structural proteins (nucleocapsid and envelope pro-
teins) and, in the case of coronaviruses, several group-specific accessory proteins are 




region of the viral genome. Encapsidation of the viral genome is followed by budding 
into the smooth ER, ERGIC or Golgi complex, where the viral envelope proteins appear 
to be retained (54, 55). Newly formed viral particles are then probably transported to 
the plasma membrane via the secretory pathway and released from the cell.
The essential role of nidovirus proteases
As mentioned above, the nidovirus nsps are expressed as two large and partially over-
lapping polyproteins (figure I-1). Their co- and posttranslational cleavage is strictly 
ordered and is presumed to be entirely mediated by internal protease domains. Each 
nidovirus replicase gene encodes one main protease domain, which is a chymotrypsin-
like serine protease (SP) in arteriviruses and torovirinae and a chymotrypsin-like cys-
teine protease (CP) in coronavirinae, mesoni- and roniviruses (3, 18, 56). In addition, 
the arteri- and coronaviruses encode one or more accessory protease domains, which 
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figure I-1: Nidovirus replicase polyproteins. Schematic representations of the replicase polyprot-
eins (pp1ab) of (A) equine arteritis virus (EAV), (B) porcine respiratory and reproductive syndrome 
virus (PRRSV), (C) transmissible gastroenteritis virus (TGEV), (D) mouse hepatitis virus (MHV), and 
(e) severe acute respiratory syndrome-associated coronavirus (SARS-CoV). Key replicative enzymes 
(RNA-dependent RNA polymerase and helicase), ribosomal frameshift sites, (putative) transmem-
brane domains, main and accessory protease domains, and protease cleavage sites are indicated 
(see also in-fi gure legend). Proteins are drawn to scale, individual domains are not. Abbreviations: 
aa, amino acids; CP, cysteine protease; ExoN, exonuclease; HEL, helicase; MT, methyltransferase; N, 
uridylate-specifi c endoribonuclease (NendoU); nsp, nonstructural protein; nsp2N, truncated pro-
tein encompassing the N-terminal part of nsp2; nsp2TF, transframe fusion product of nsp2; ORF, 
open reading frame; PLP/PLpro, papain-like protease; pp, polyprotein; RdRp, RNA-dependent RNA 
polymerase; SP, serine protease; TMD, transmembrane domain.
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are papain-like cysteine proteases designated PLP or PLpro, respectively. Especially 
the proteolytic processing of the EAV replicase polyproteins has been extensively 
studied, and will be discussed here as an example. The first cleavage event in EAV 
polyprotein maturation is mediated by the PLP1β domain located in nsp1, which 
co-translationally cleaves the junction between nsp1 and nsp2 and thereby releases 
nsp1 from the nascent polyprotein (57, 58). The next cleavage is mediated by the PLP2 
domain, which is located in the N-terminal region of nsp2 and is responsible for the 
processing of the nsp2|nsp3 junction (59). Finally, the nsp4 SP domain is responsible 
for the remaining cleavages in pp1a and pp1ab (58, 60-62), in which the sequence 
and outcome of cleavages in the nsp3-8 region can follow either one of two mutually 
exclusive pathways (63). In the majority of polyproteins, processing starts with cleav-
age of the nsp4|nsp5 junction. This is then followed by cleavage of the remaining 
sites, except for the nsp5|nsp6 and nsp6|nsp7 junctions, which remain unprocessed. 
This scheme is referred to as the major processing pathway. Alternatively, in the minor 
processing pathway, the nsp4|nsp5 junction is not cleaved. Instead, processing takes 
place at all of the other junctions, including the nsp5|nsp6 and nsp6|nsp7 cleavage 
sites. It appears that cleavage of the nsp4|nsp5 junction in the major processing path-
way strongly depends on the presence of cleaved nsp2, which thus seems to act as a 
co-factor to the main protease during this particular cleavage event (63). Importantly, 
viral replication heavily depends on the correct and timely processing of the replicase 
polyproteins and mutagenesis of the active site residues or cleavage sites of the main 
and accessory arterivirus proteases has profound and generally lethal consequences 
for viral replication (53, 61, 62, 64).
A BrIef INTrODUCTION TO UBIqUITIN
Ubiquitination and linkage types
Ubiquitin is a small (8.5-kDa) protein with a characteristic β-grasp fold. It can be 
covalently attached to lysine side-chains or the N terminus of target proteins via its 
C-terminal glycine residue. This process, referred to as ubiquitination, occurs via an 
enzymatic cascade that is mediated by an E1 activating enzyme, an E2 conjugating 
enzyme, and an E3 ligase. Ubiquitination plays an important regulatory role in a 
wide array of cellular processes, including for example the proteasomal degradation 
pathway, the DNA damage response, autophagy, and innate immunity (for reviews, see 
(65-68)). In order to modulate such a variety of processes, ubiquitination can occur in 
many different forms (for a recent review, see (69)). In its simplest form, referred to 
as monoubiquitination, a single ubiquitin molecule is attached to one lysine residue 




molecules are attached to an equal number of lysine residues in a target protein (fig-
ure I-2B). In the case of polyubiquitination, target proteins are decorated with chains 
consisting of two or more inter-linked ubiquitin molecules (figure I-2C). Importantly, 
these polyubiquitin chains can take different forms as well, depending on the ubiqui-
tin residue that is used to attach the C terminus of the adjoining ubiquitin molecule. 
Of the 76 amino acid residues that make up the ubiquitin molecule, eight can be 
involved in the formation of polyubiquitin chains. These residues are Met1 (resulting 
in linear polyubiquitin chains), Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, and Lys63, and 
all of these linkages have been detected in cells (70, 71). Interestingly, polyubiquitin 
chains of different linkage types have been shown to be structurally distinct, allowing 
for differential interactions (72-76). As a final means of variation, these polyubiquitin 
chains can be built up using only one linkage type (homogeneous chains; figure I-2D), 
different linkage types in successive ubiquitin molecules (mixed chains; figure I-2e), 
or even different linkage types in the same ubiquitin molecule (branched chains; fig-
ure I-2f). Whereas the function of branched chains remains unknown, mixed chains 












Homogeneous chains Mixed chains Branched chains
Figure i-2: different forms of ubiquitination. Schematic representation of (A) monoubiquitination, 
(B) multimonoubiquitination, (C) polyubiquitination, (D) homogeneous polyubiquitin chains, (e) 
mixed polyubiquitin chains, and (f) branched polyubiquitin chains. Adapted from reference (69). 
Abbreviations: Ub, ubiquitin; 48/63, Lys48/63-linked.
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The ubiquitin-like protein ISG15
A number of ubiquitin-like proteins have been described that share both structural 
and functional similarities with ubiquitin (for review, see (81)). In the context of this 
thesis, the interferon-stimulated gene-encoded protein of 15 kDa (ISG15) is of par-
ticular interest. This protein consists of two domains with a ubiquitin-like β-grasp fold 
and has the exact same C-terminal sequence motif as ubiquitin (Leu-Arg-Leu-Arg-Gly-
Gly or LRLRGG). Like ubiquitin, ISG15 can be covalently attached to target proteins via 
its C terminus, a process which is referred to as ISGylation. Poly-ISG15 chains do not 
appear to be formed however. Functionally, ISG15 is considered to act as an antiviral 
molecule, although its exact mechanisms of action remain to be determined (for 
reviews, see (82, 83)). For example, unconjugated ISG15 has been suggested to act 
as an immunomodulatory cytokine (84), whereas ISGylation of newly translated viral 
proteins has been proposed to interfere with viral replication via steric hindrance of 
their interactions (85). In addition, ISGylation seems to be involved in the regulation 
of innate immune signalling factors and antiviral effector molecules (86, 87). Notably, 
the (ectopic) expression of ISG15, either free or conjugated, has been shown to inhibit 
replication of a wide variety of viruses (for a review, see (83)). In the case of arteri-
viruses, it has been shown that ectopic expression of conjugation-competent ISG15 
(Gly-Gly C terminus), but not of conjugation-defective ISG15 (Ala-Ala C terminus), 
decreased replication of PRRSV in a cell culture-based assay (88).
reversal of ubiquitination by deubiquitinases
One of the reasons why ubiquitination is such a useful regulatory posttranslational 
modification is the fact that it is readily reversible. Ubiquitin can be removed from tar-
get proteins by the action of deubiquitinases (DUBs) that cleave directly downstream 
of its C-terminal Gly-Gly motif, thus leaving no trace of its former ubiquitinated state 
on the target. Some DUBs are metalloproteases which use a Zn2+ ion for catalysis and 
possess a ubiquitin protease domain known as a JAB1/MPN/Mov34 (JAMM) domain. 
Most DUBs, however, are cysteine proteases and thus rely on a catalytic cysteine resi-
due for proteolytic activity. These DUBs are grouped into four classes, based on the 
three-dimensional structure of their catalytic domains: the ubiquitin-specific prote-
ases (USPs), the ovarian tumor proteases (OTUs), the ubiquitin C-terminal hydrolases 
(UCHs), and the Machado-Joseph disease proteases (MJDs) (for reviews, see (89, 90)). 
Even though all DUBs process the same C-terminal sequence motif of ubiquitin (LRL-
RGG), which is present in all ubiquitinated proteins, it appears that eukaryotic DUBs 
generally target a specific (set of) substrates (89, 90). This specificity might depend on 
several factors, including (the linkage type of) the ubiquitin or ubiquitin-like protein 
involved, the ubiquitinated target involved, protein localization, and the presence of 




display a distinct preference for one or two types of polyubiquitin chain linkage 
(91). In addition, it has been shown that the protease USP18 specifically targets the 
ubiquitin-like protein ISG15 (92). It is likely that the overall specificity of each DUB is 
determined by a combination of the factors mentioned above.
Ubiquitin and innate immunity
The innate immune response forms the first line of defence against invading patho-
gens and is, in addition to phosphorylation, extensively regulated through ubiquitina-
tion (for reviews, see (66, 68)). It relies on the recognition of pathogen-associated 
molecular patterns (PAMPs), such as viral proteins or nucleic acids, by cellular pattern 
recognition receptors (PRRs). Two main classes of PRRs exist in mammalian cells: 
the membrane-bound receptors, such as Toll-like receptors (TLRs) and C-type lectin 
receptors (CLRs), and the cytosolic receptors, including the NOD-like receptors (NLRs), 
pyrin and HIN domain-containing (PYHIN) family members, the RIG-I-like receptors 
(RLRs), and a variety of newly described nucleic acid sensors such as cGAS (for a 
review, see (93)). Since the RLRs recognize cytosolic viral RNA (94-98), they are of 
particular importance for the recognition of invading RNA viruses (99, 100). The RLR 
family consists of three members called retinoic-acid inducible gene-encoded protein 
I (RIG-I), melanoma differentiation-associated protein 5 (MDA5), and laboratory of 
genetics and physiology protein 2 (LGP2). Although LGP2 was initially suggested to 
be a negative regulator of RLR-mediated signalling (101), later work suggests that it 
acts upstream of RIG-I/MDA5 and is in fact required for their activation, particularly 
in the case of picornavirus infection (102, 103). Upon recognition of viral RNA by 
RIG-I and MDA5, they bind to the adaptor molecule mitochondrial antiviral signalling 
protein (MAVS) (104). This molecule then forms large prion-like aggregates on the 
mitochondrial membrane (105), by which it initiates divergent signalling cascades 
that ultimately lead to the activation of the transcription factors interferon regulatory 
factor 3 (IRF3) and nuclear factor κB (NF-κB). These in turn induce the transcription of 
genes encoding type I interferons (IFNs) and other proinflammatory cytokines, which 
together are responsible for the induction of an antiviral state (for reviews, see (106, 
107)). Upon its release from the cell, IFN binds to its cognate receptor through which 
it activates the JAK/STAT signalling pathway. In combination with IRF9, activated 
STAT1/2 transcription factors form a heterotrimeric complex called IFN-stimulated 
gene factor 3 (ISGF3). This complex is translocated to the nucleus where it binds to 
promoter regions encompassing IFN-stimulated response elements (ISREs) that direct 
the transcription of a myriad of IFN-stimulated genes including for example ISG15. 
figure I-3 provides a schematic overview of the RLR-mediated signalling pathways.
The innate immune signalling cascades rely on ubiquitin during many steps, two of 
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figure I-3: Schematic overview of the rLr-mediated signalling pathways. Recognition of viral 
RNA by RIG-I and MDA5 leads to the activation of divergent signalling pathways that ultimately 
result in the transcription of genes encoding IFN-β and other proinflammatory cytokines. Following 
secretion, IFN-β binds to the IFN receptor and thereby activates the JAK-STAT signalling cascade 
that leads to the expression of interferon-stimulated genes. Abbreviations: CBP, CREB-binding pro-
tein; IFN-β, interferon beta; IFNR, interferon receptor; IKK, IκB kinase; IκBα, inhibitor of NF- κB; IRF, 
interferon regulatory factor; ISGF3, interferon-stimulated gene factor 3; JAK/STAT, janus kinase/
signal transducers and activators of transcription; KPNA1, karyopherin alpha 1; MAVS, mitochon-
drial antiviral signalling protein; MDA5, melanoma differentiation-associated protein 5; NEMO, NF-
κB essential modulator; NF-κB, nuclear factor kappa B; RIG-I, retinoic acid-inducible gene-encoded 
protein I; RLR, RIG-I-lile receptors; STAT1/2, signal transducers and activators of transcription 1/2; 




dependent on the presence of Lys63-linked polyubiquitin chains, although the exact 
nature of these chains remains debated. According to one view, recognition of viral 
RNA leads to the Lys63-linked ubiquitination of the C-terminal regulatory domain of 
RIG-I by the E3 ligase Riplet (108, 109). This induces a conformational change that 
exposes the two N-terminal caspase recruitment domains (CARDs) of RIG-I for Lys63-
linked ubiquitination on Lys172 by the E3 ligase tripartite motif containing protein 
25 (TRIM25) (110, 111). The latter ubiquitination event is thought to be essential for 
the interaction of RIG-I with MAVS and thus for the activation of downstream signal-
ling. However, according to other studies, noncovalent binding of activated RIG-I 
(and MDA5) to unanchored short Lys63-linked polyubiquitin chains is responsible 
for an oligomerization-mediated interaction with MAVS and subsequent downstream 
signalling (112-114). Recent work suggests that it is likely a combination of covalent 
and noncovalent interactions with Lys63-linked polyubiquitin chains that results in 
full-blown activation of RIG-I (115). A second example of the role of ubiquitin in in-
nate immunity lies in the activation of the transcription factor NF-κB. This protein 
is normally retained in the cytoplasm by the inhibitor of NF-κB protein alpha (IκBα). 
However, activation of innate immune signalling cascades leads to the Lys48-linked 
ubiquitination of IκBα, which is subsequently degraded by the proteasome (116). NF-
κB is thus released from the inhibitory complex and free to translocate to the nucleus 
where it can induce the transcription of its target genes. Although there are many 
more examples of ubiquitination in innate immune signalling, these two nicely under-
line how innate immune signalling cascades can be influenced by both degradative 
and non-degradative ubiquitination.
Since the inappropriate activation, either in timing or magnitude, of innate immune 
signalling pathways can have disastrous effects, many mechanisms are in place to 
prevent this from happening. One of these is the presence of cellular DUBs that are 
involved in downregulating innate immune activation. For example, the ubiquitin-
specific protease cylindromatosis (CYLD) has been shown to deubiquitinate RIG-I and 
various other innate immune signalling factors, thus preventing downstream signal-
ling (117, 118). In addition, the OTU proteases otubain 1 and 2 (OTUB1/2) have been 
shown to deubiquitinate and thus inactivate the innate immune adaptor proteins TNF 
receptor-associated factor (TRAF) 3 and 6 (119). These are only two examples of how 
cellular DUBs are employed to keep innate immune signalling from running out of 
bounds, but many more have been documented (68, 118).
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NIDOvIrUS DeUBIqUITINASeS
Considering the importance of ubiquitination in cellular homeostasis in general and 
the activation of innate immune signalling in particular, it is perhaps not surpris-
ing that many viruses encode proteins that interact with the ubiquitin system (for 
reviews, see (66, 120)). Indeed it was shown that several of the accessory protease 
domains encoded by arteri- and coronaviruses act as DUBs in addition to mediating 
specific steps in the proteolytic maturation of the replicase polyproteins (121-130). 
For arteriviruses, the first indication that PLP2 might possess DUB activity came from 
a bioinformatics analysis that revealed a remote sequence similarity between this 
enzyme and members of the OTU superfamily of proteases (131). Experimental sup-
port for this hypothesis later came from Frias-Staheli et al., who showed that ectopic 
expression of either EAV or PRRSV nsp2, which encompasses the PLP2 domain, results 
in an overall decrease in cellular ubiquitination (121). In the case of the coronavi-
ruses, the DUB activity of SARS-CoV PL2pro was initially predicted based on structural 
models that revealed similarity with DUBs of the USP class (132) and this hypothesis 
was subsequently confirmed using in vitro cleavage assays (123, 124). Following this 
discovery, DUB activity was also confirmed for PL2pro of human coronavirus NL63 
(125), mouse hepatitis virus (MHV) (126), porcine epidemic diarrhea virus (PEDV) 
(128), and MERS-CoV (127, 129), and PL1pro of transmissible gastroenteritis virus 
(TGEV) (122). Since ubiquitin is such an important player in innate immune regulation, 
many studies have proposed a role for arteri- and coronavirus DUBs in innate immune 
evasion (88, 121, 126-130, 133-137). However, since all of these enzymes (PLP2, 
PL1pro, and PL2pro) are also essential for viral replicase maturation and can therefore 
not be easily mutated without affecting virus viability, it has been impossible to show 
that their DUB activity is important for the evasion of innate immune signalling in the 
context of a nidovirus infection.
OUtliNe OF tHiS tHeSiS
The work described in this thesis provides novel insights into the structural features 
and function of arterivirus PLP2 and into the role of its DUB activity in the evasion of 
ubiquitin-regulated innate immune signalling. The experiments described in Chap-
ter 2 show that PLP2 DUB activity is conserved among EAV, PRRSV-I, PRRSV-II, LDV, 
and SHFV. In addition, it is shown that arterivirus PLP2 can decrease ubiquitination 
of RIG-I upon ectopic expression, suggesting that this is one of the mechanisms by 
which arteriviruses evade innate immunity. In Chapter 3 a fluorescence polarization-




identification of several inhibitors of PLP2 activity that limit EAV replication in cell 
culture. Chapter 4 presents the crystal structure of the EAV PLP2 domain in complex 
with ubiquitin, which forms the basis for the design of PLP2 mutants that are defec-
tive in DUB activity but have retained the ability to process the nsp2|3 junction in 
the viral replicase polyproteins. These mutants were subsequently employed to show 
that PLP2 DUB activity is indeed important for the inhibition of innate immune signal-
ling during EAV infection of primary equine cells. Chapter 5 provides the results of 
a small-scale vaccination trial in horses where the level of protection provided by 
a PLP2 DUB-negative vaccine virus was compared with its DUB-competent parental 
strain. Although the PLP2-mutant virus appeared to provide slightly better protection 
against challenge than its parental counterpart, no firm conclusions could be drawn 
from the data. Chapter 6 contains a structural and functional comparison of OTU DUBs 
encoded by widely different RNA virus groups (arteri-, nairo-, and tymoviruses). Finally, 
Chapter 7 encompasses a general discussion that places the novel findings described 
in this thesis in the framework of existing knowledge on arterivirus proteases and im-
mune evasion strategies and in which some future research directions concerning the 
target specificity and putative deISGylating activity of arterivirus PLP2 are delineated.
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ABSTrACT
The innate immune response constitutes the first line of defence against viral infec-
tion and is extensively regulated through ubiquitination. The removal of ubiquitin 
from innate immunity signalling factors by deubiquitinating enzymes (DUBs) there-
fore provides a potential opportunity for viruses to evade this host defence system. 
It was previously found that specific proteases encoded by the unrelated arteri- and 
nairoviruses resemble the ovarian tumor domain-containing (OTU) family of DUBs. 
In arteriviruses, this domain has been characterized before as a papain-like protease 
(PLP2) that is also involved in replicase polyprotein processing. In nairoviruses, the 
DUB resides in the polymerase protein but is not essential for RNA replication. Using 
both in vitro and cell-based assays, we now show that PLP2 DUB activity is conserved 
in all members of the arterivirus family, and that both arteri- and nairovirus DUBs 
inhibit RIG-I-mediated innate immune signalling when overexpressed. The potential 
relevance of RIG-I-like receptor (RLR) signalling for the innate immune response 
against arterivirus infection is supported by our finding that in mouse embryonic 
fibroblasts, the production of interferon-beta primarily depends on the recognition 
of arterivirus RNA by the pattern-recognition receptor MDA5. Interestingly, we also 
found that both arteri- and nairovirus DUBs inhibit RIG-I ubiquitination upon over-
expression, suggesting that both MDA5 and RIG-I have a role in countering infection 
by arteriviruses. Taken together, our results support the hypothesis that arteri- and 
nairoviruses employ their deubiquitinating potential to inactivate cellular proteins 
involved in RLR-mediated innate immune signalling, as exemplified by the deubiqui-
tination of RIG-I.




The first line of defence against viral infection is formed by the innate immune re-
sponse. This system relies on a series of pattern-recognition receptors (PRRs) whose 
activation by pathogen-associated molecular patterns (PAMPs) ultimately leads to 
the transcription of genes encoding type I interferons (IFNs) and pro-inflammatory 
cytokines. In turn, these cytokines stimulate the expression of a myriad of effector 
molecules, the presence of which results in a cellular microenvironment that is hos-
tile to viral replication. To date, four families of PRRs have been implicated in the 
response to viral infection: the membrane-bound Toll-like receptors (TLRs), and the 
cytosolic Nod-like receptors (NLRs), HIN-200 protein family members, and RIG-I-like 
receptors (RLRs) (1, 2).
Upon recognition of viral RNA by the RLRs RIG-I and MDA5, these sensors bind to the 
mitochondrially located adaptor protein MAVS, which is also known as IPS1, VISA, or 
Cardif. This interaction activates two divergent signalling pathways. The first involves 
the adaptor protein TRAF3 and triggers the activation of the TBK1-IKKε kinase complex 
which then phosphorylates IRF3. Upon subsequent dimerization, this transcription 
factor translocates to the nucleus to initiate transcription of the gene encoding IFN-β, 
a type I IFN. The second pathway downstream of MAVS involves the adaptor protein 
TRAF6 and the NEMO-IKKα/β complex, of which the latter is responsible for the phos-
phorylation event preceding the degradation of the NF-κB-inhibitor IκB. With IκB no 
longer present, NF-κB is free to translocate to the nucleus and initiate the transcrip-
tion of genes encoding pro-inflammatory cytokines and, together with activated IRF3, 
IFN-β. Through autocrine and paracrine signalling routes, IFN-β induces the transcrip-
tion of numerous interferon-stimulated genes (ISGs), including those encoding the 
PRRs RIG-I and MDA5, and the antiviral effector molecules OAS, PKR, ISG15, and the Mx 
proteins, whose concerted action limits the spread of viral infection (3, 4).
In addition to phosphorylation, the signalling pathways involved in innate immunity 
are extensively regulated through ubiquitination (5, 6). Ubiquitin (Ub) is an 8.5-kDa 
protein moiety that can be covalently attached to a lysine in a target protein. Sub-
strates can be tagged either by a single Ub moiety (monoubiquitination) or by a chain 
of Ub moieties that are linked by isopeptide bonds between their C-terminal glycine 
residue and an internal lysine residue (polyubiquitination). The configuration of the 
polyubiquitin chain can vary, depending on which one of the lysines present in the 
ubiquitin protein is used for conjugation. Of the possible configurations, Lys48- and 
Lys63-linked polyubiquitination have been studied most extensively. Lys48-linked 
polyubiquitination induces translocation of the target protein to the proteasome, 
where degradation will follow. In contrast, Lys63-linked ubiquitination results in 
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activation or relocation of the target, which for example plays a role in signalling 
cascades.
Innate immune signalling is regulated through ubiquitination at multiple levels. For 
example, the IKKα/β-induced degradation of IκB relies on its Lys48-linked ubiquitina-
tion (7). In addition, a number of proteins involved in signal transduction were recently 
shown to be activated by Lys63-linked ubiquitination. This list includes: RIG-I, MAVS, 
TBK1/IKKε, and TRAF3 and 6 (8-11). Notably, this ubiquitin-mediated regulation poses 
an excellent opportunity for negative feedback and viral immune evasion since ubiq-
uitination is a reversible process, with the deconjugation of ubiquitin being performed 
by deubiquitinating enzymes (DUBs). For example, the mammalian DUBs OTUB1 and 
OTUB2 downregulate the innate immune response through the deubiquitination of 
TRAF3 and 6 (12). In addition, Cezanne (13), DUBA (14) and A20 (9, 15) are mammalian 
DUBs that negatively regulate innate immune signalling.
DUBs can be grouped into five subclasses, based on their structural characteristics 
(16). Previously, members of two unrelated groups of RNA viruses, the arteri- and 
nairoviruses, were found to encode a protease that resembles the ovarian tumor 
domain-containing (OTU) subclass of DUBs (17). Interestingly, all of the above-
mentioned mammalian DUBs that control the innate immune response also belong 
to this particular subclass. For this reason, Frias-Staheli et al. (2007) hypothesized 
that arteri- and nairoviral OTU-DUBs are involved in the negative regulation of innate 
immune signalling in order to support viral replication (18).
The arterivirus family, together with the corona- and ronivirus families, belongs to 
the order of the Nidovirales and currently comprises four species: equine arteritis 
virus (EAV), porcine reproductive and respiratory syndrome virus (PRRSV), lactate 
dehydrogenase-elevating virus (LDV), and simian hemorrhagic fever virus (SHFV). Of 
these pathogens, PRRSV poses the greatest burden on society, with regular outbreaks 
in pigs causing major economic losses especially in North America and Southeast 
Asia (19, 20). PRRSV isolates are divided into two quite distant genotypes: European 
(type I) and North American (type II). Arteriviruses are positive-sense RNA viruses, 
with a 13-16 kb non-segmented genome. Their cytoplasmic replication starts with 
the translation of the genomic RNA to produce two large replicase polyproteins, pp1a 
and pp1ab. In the case of EAV, the proteolytic maturation of these polyproteins, which 
is directed by three internal proteinases, releases at least 13 nonstructural proteins, 
most of which assemble into a membrane-bound replication complex (21, 22). Eight 
structural proteins have been identified in arteriviruses, which are produced by syn-
thesis and translation of a nested set of subgenomic mRNAs (23-25).
The arterivirus DUB domain resides in the N-terminal region of nonstructural protein 
2 (nsp2) and was previously shown to direct the proteolytic processing of the nsp2|3 
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site (26, 27). In addition to its resemblance to OTU-DUBs, the nsp2 protease belongs 
to the papain-like protease (PLP) family and will therefore be referred to as PLP2-DUB 
in this paper. Interestingly, the (predicted) nsp2|3 junction in most arteriviruses only 
moderately resembles the LXGG↓ consensus motif commonly recognized by DUBs. In 
fact, only the EAV nsp2|3 site (LIGG) contains the consensus Leu residue at position 
P4, whereas PRRSV-I (TTGG), PRRSV-II (PSGG), LDV (VSGG), and SHFV (VVGG) merely 
share the double glycine motif occupying the P1 and P2 position of the cleavage 
site. This observation suggests that the arterivirus-encoded PLP2-DUBs constitute 
a unique protease subgroup that has evolved an intriguing specificity towards both 
viral and cellular substrates.
The nairovirus genus of the bunyavirus family currently consists of seven species, 
including the prototypic Dugbe virus (DUGV) and Crimean-Congo hemorrhagic fever 
virus (CCHFV), the causative agent of a severe hemorrhagic fever with case fatality 
rates of up to 30% in humans (28). CCHFV is one of the most widespread medically 
relevant arboviruses, being surpassed in geographical distribution only by dengue 
virus (29). CCHFV infections occur sporadically throughout Africa, Asia, the Middle-
East, and Southeastern Europe, and are correlated with the natural distribution of its 
preferred vector, ticks of the genus Hyalomma (28). Nairoviruses have a tripartite RNA 
genome of negative polarity, with the largest segment encoding the L protein which 
harbors the RNA-dependent RNA polymerase (RdRp). The nairovirus DUB domain is 
situated in the N-terminal region of the L protein, but in contrast to its arteriviral 
counterpart it is not involved in autoproteolysis and its catalytic activity is dispens-
able for RdRp activity (30).
In line with their hypothesis about a role in immune evasion, Frias-Staheli et al. (2007) 
showed that expression of DUBs from two arteriviruses (EAV and PRRSV) and two 
nairoviruses (DUGV and CCHFV) negatively affected the TNFα-induced activation of 
NF-κB. Furthermore, transgenic mice expressing the N-terminal part of the CCHFV L 
protein displayed an increased susceptibility to Sindbis virus infection (18). They also 
showed that these viral DUBs, unlike their mammalian counterparts, have the ability 
to target both ubiquitin and ISG15, a 15-kDa interferon-stimulated Ub-like modifier 
that plays an important role in antiviral defence (31). The recently solved crystal 
structure of the CCHFV DUB-domain provided a structural basis for this observed 
catalytic promiscuity (32-34). In the arterivirus family, overexpression of the PRRSV 
PLP2-DUB was found to inhibit the Sendai virus-induced innate immune response 
(35, 36). Based on in vitro assays, Sun et al. (2010) proposed that this effect at least 
partially relies on the deubiquitination of IκBα, which would prevent the degradation 
of IκB and the subsequent nuclear translocation of NF-κB (36).
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Here we report the characterization of the immune evasive properties of arteri- and 
nairovirus DUBs. We show for the first time that the DUB activity of the PLP2 domain 
is a conserved feature of all members of the arterivirus family and that it can inhibit 
the RLR-mediated immune response. We investigated the role of this pathway in the 
sensing of arteriviral RNA and found that in mouse embryonic fibroblasts (MEFs) 
the induction of IFN-β by EAV RNA is MAVS-dependent and that the recognition of 
EAV RNA relies primarily on the PRR MDA5. Interestingly, we were able to show that 
overexpression of both arteri- and nairovirus DUBs inhibits RIG-I ubiquitination, sug-
gesting that also RIG-I is likely involved in the response to arterivirus infection. Taken 
together, our data support the concept that the DUB-mediated immune evasion in 
arteri- and nairoviruses is, at least in part, the result of the removal of ubiquitin from 
RIG-I and likely also from other innate immune signalling factors in the RLR pathway.
MateRialS aNd MetHOdS
Plasmids
Nsp2 of the EAV Bucyrus strain (NCBI accession number NC_002532) comprises resi-
dues Gly261 to Gly832 of the EAV pp1a/pp1ab replicase polyproteins. Polyprotein 
amino acid numbers will be used throughout this paper. For bacterial expression of EAV 
nsp2(N), a cDNA fragment encoding amino acids 261 to 427 was cloned downstream of 
the maltose-binding protein (MBP) fusion partner into the pMalT-vector (New England 
Biolabs). Active site mutants C270A, H332A and C270A/H332A, the latter from here 
on referred to as C/H>A, were engineered by site-directed mutagenesis using Pfu DNA 
polymerase (Fermentas). Primer sequences are available upon request.
Mammalian expression constructs encoding the PLP2-DUB domains of all arterivi-
ruses were made by cloning the following sequences, encoding the indicated amino 
acids (aa) of the respective replicase polyproteins, and placing them in-frame with an 
N-terminal HA-tag in the pcDNA3.1-vector (Invitrogen): aa 261-1064 for EAV nsp2-3, 
aa 261-435 for EAV nsp2(N), aa 385-578 for PRRSV-I nsp2(N), aa 383-782 for PRRSV-II 
nsp2(N), aa 381-576 for LDV nsp2(N), and aa 480-829 for SHFV nsp2(N). The latter two 
inserts were synthesized by GeneArt (Invitrogen) and based on NCBI accession num-
bers NC_001639 and NC_003092, respectively. For PRRSV-I nsp2(N) a sequence from 
the European SD-01-08 strain was used, which was amplified from pCAGGS-nsp2 (36). 
The PRRSV-II nsp2(N) construct encodes the North American prototype VR-2332 strain. 
For the mammalian expression constructs of the CCHFV DUB domain, a fragment en-
coding aa 1-169 of the L protein was transferred from pCAGGS-HA-L(1-169) wild-type 
and C40A/H151A (18) to the pcDNA3.1-vector. An insert containing the enhanced GFP 
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gene from pEGFP-N1 (Clontech) was placed into the multiple cloning site of pcDNA3.1 
to generate plasmid pcDNA-eGFP. All constructs were verified by sequence analysis.
The following expression plasmids were described elsewhere: pLuc-IFN-β (37), pRL-
TK (Promega), pEBG-RIG-I(2CARD) (8), pcDNA-FLAG-MAVS (38), pEGFP-C1-IRF3(5D) (39), 
and pRBG4-CW7-myc-ubiquitin (40).
viruses, cells, and antibodies
The Bucyrus strain of EAV was propagated and concentrated by polyethylene glycol 
precipitation essentially as described previously (41). Propagation of mengovirus, 
derived from the pM16.1 full-length cDNA clone, was described before (42). Recom-
binant Newcastle disease virus (NDV), derived from the Hitchner B1 vaccine strain and 
containing a GFP insertion, was described elsewhere (43).
MEFs isolated from transgenic MAVS-/-, MDA5-/-, or RIG-I-/- mice and their respective 
wild-type littermate controls were described previously (44-46). MEFs, HEK293T, and 
Vero-E6 cells were all cultured in Dulbecco’s Modified Eagle Medium (Lonza) supple-
mented with 10% Fetal Bovine Serum (Bodinco BV), 100 units/ml each of penicillin/
streptomycin (Lonza) and 2 mM L-glutamine (Lonza).
The antibodies used were anti-GST (sc459, Santa Cruz), anti-HA (ab18181, Abcam), 
anti-c-myc (9E10, Roche), anti-TFR (H68.4, Invitrogen), and anti-GFP from rabbits im-
munized with purified recombinant GFP.
In vitro DUB activity assay
E. coli strain BL21(DE3) transformed with wild-type or mutant pMalT-EAV-nsp2(N) was 
grown to an OD600 of 0.6 in standard LB Broth. Protein expression was then induced by 
the addition of IPTG to a final concentration of 1 mM. After 3 h at 37°C, bacteria were 
resuspended in buffer A (20 mM Tris, 200 mM NaCl, 1 mM EDTA, pH 7.5) and lysed 
by sonication. After removal of cellular debris by centrifugation, the supernatant 
was incubated for 2 h with Amylose resin (New England Biolabs). The resin was then 
washed 4 times with buffer A and protein was eluted using buffer B (20 mM Tris, 200 
mM NaCl, 1 mM EDTA, 10 mM Maltose, pH 7.5). Protein concentration and purity were 
determined using Bradford reagent (Bio-Rad) and SDS-PAGE analysis, respectively.
For an in vitro DUB activity assay, 1 μg of purified recombinant EAV nsp2(N) was 
incubated with 2.5 μg Lys48- or Lys63-linked polyubiquitin chains (Boston Biochem) 
in a final volume of 10 μl assay buffer (50 mM Tris, 5 mM MgCl2, 2 mM DTT, pH 7.5) 
for 2 h at 37°C. For nsp2(N) dilution series, a range of two-fold dilutions starting at 0.5 
μg per reaction was used. As a positive control, isopeptidase T (Boston Biochem) was 
included. The reaction was terminated by the addition of 3.5 μl 4x Laemmli sample 
buffer (4xLSB; 500 mM Tris, 4% SDS, 40% Glycerol, 0.02% Bromophenol Blue, 2 mM 
DTT, pH 6.8). Proteins were separated in a 15% SDS-PAGE gel and visualized using 
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Coomassie brilliant blue staining. Gels were scanned using a GS-800 calibrated den-
sitometer (Bio-Rad).
dUB activity assay in HeK293t cells
HEK293T cells, grown to 80% confluency in 12-well plates, were transfected with a 
combination of plasmids encoding myc-ubiquitin (0.25 μg), GFP (0.25 μg), and the 
different viral proteins (1.5 μg) using the CaPO4 transfection method (47). Total DNA 
amounts were kept constant by the addition of empty vector. After 16 h at 37°C, cells 
were lysed in 250 μl 2xLSB (250 mM Tris, 2% SDS, 20% glycerol, 0.01% Bromophenol 
Blue, 1 mM DTT, pH 6.8). Samples were loaded on SDS-PAGE gels, which were blotted 
to Hybond-P PVDF membranes (GE Healthcare) using a Semi-dry Transfer Cell (Bio-
Rad). After incubation with the appropriate antibodies, protein bands were visualized 
using the Amersham ECL plus detection reagent (GE Healthcare).
quantitative real-time PCr
Vero-E6 cells, grown to 90% confluency in 6-well plates, were infected at an MOI of 
10 with EAV, mengovirus, or NDV, or were mock-infected. Total RNA was isolated at 16 
h post infection using TRIZOL reagent (Invitrogen). Subsequently, MEFs lacking MAVS, 
MDA5, or RIG-I and their respective wild-type controls, seeded at a density of 200.000 
cells per well in 6-well plates the previous day, were transfected with 4 μg of the 
aforementioned total RNA using Lipofectamine2000 (Invitrogen). Three hours post 
transfection (p.t.), total RNA was isolated from these cells using the Nucleospin RNA II 
kit (Machery-Nagel) and used as a template for cDNA synthesis using M-MuLV reverse 
transcriptase (Fermentas) and oligo d(T)20 primer. Finally, samples were assayed by 
quantitative reverse transcriptase PCR analysis (qRT-PCR) using commercially avail-
able Gene Expression Assays for mouse IFN-β and GAPDH (Mm00439552_s1 and 
Mm99999915_g1, respectively; Applied Biosystems). PCR was performed using a 
7900HT Fast Real-Time PCR System and analyzed with SDS2.4 software (both from 
Applied Biosystems). PCR efficiencies were determined to be 86 and 93% for IFN-β 
and GAPDH respectively, which allowed for analysis using the comparative CT method 
(48). In addition, it was established that GAPDH expression did not differ between 
MEFs transfected with total RNA from infected or mock-infected Vero cells.
Luciferase-based IfN-β reporter assay
HEK293T cells, grown to 80% confluency in 24-well plates, were transfected in 
quadruplo with a combination of plasmids encoding firefly luciferase under control 
of the IFN-β promoter (50 ng), Renilla luciferase (5 ng), RIG-I(2CARD), MAVS, or IRF3(5D) 
(25 ng), and the various viral proteins (1000 ng) using Lipofectamine2000. For dose 
range experiments, two-fold serial dilutions of viral protein-encoding plasmids were 
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used, starting at 1000 ng of DNA. Total DNA amounts were kept equal by the addition 
of empty vector. At 12 h p.t., three out of four wells were lysed in 100 μl Passive 
Lysis Buffer (Promega) and samples were assayed for luciferase activity using the 
Dual-Luciferase Reporter Assay system (Promega) on a Mithras LB 940 multimode 
reader (Berthold Technologies). The remaining well was lysed in 150 μl 2xLSB and 
these samples were loaded onto SDS-PAGE gels and analyzed by Western blotting as 
described above.
An unpaired two-tailed Student’s t-test was used to determine the statistical 
significance of the results obtained with the luciferase assays. P-values <0.05 were 
considered to be statistically significant.
rIG-I ubiquitination assay
HEK293T cells, grown to 80% confluency in 6-well plates, were transfected with a 
combination of plasmids encoding myc-ubiquitin (0.5 μg), GFP (0.5 μg), GST-RIG-
I(2CARD) (1.5 μg), and the various viral proteins (1.5 μg) using the CaPO4 transfection 
method. Total DNA amounts were kept constant by the addition of empty vector. At 
16 h p.t., cells were lysed for 1 h in buffer C (50 mM Tris, 5 mM MgCl2, 0.5% NP40, 
25 mM N-ethylmaleimide, 1 mM 4-(2-aminoethyl)-benzenesulfonyl fluoride, 5 μg/ml 
Leupeptin, pH 7.5). After removal of cellular debris by centrifugation, one tenth of 
the lysate was mixed 1:1 with 2xLSB. The remaining lysate was incubated at 4°C for 
3 h with Glutathione Sepharose 4B resin (GE Healthcare). The resin was subsequently 
washed 3 times with buffer C and proteins were eluted by addition of 2xLSB and 
incubation at 96°C for 5 minutes. Samples were then loaded on SDS-PAGE gel and 
analyzed by Western blotting as described above.
reSULTS
recombinant eAv PLP2-DUB exhibits in vitro DUB activity, which is abolished by 
mutagenesis of active site residues. It was previously shown by Frias-Staheli et al. 
(2007) that overexpression of EAV and PRRSV nsp2 in mammalian cells resulted in 
a general decrease of the level of ubiquitinated proteins (18). In addition, Sun et 
al. (2010) showed that PRRSV-I PLP2, when immunoprecipitated from mammalian 
cells, cleaved Lys48-linked polyubiquitin chains (36). To confirm that the observed 
activities of nsp2 derive from the bona fide DUB activity of its protease, and to exclude 
the possibility that these observations were caused by an indirect effect on cellular 
ubiquitination processes, a recombinant N-terminal fragment of EAV nsp2 containing 
the predicted PLP2-DUB domain (nsp2(N)) was purified from E. coli and tested in an 
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figure II-1. The eAv PLP2-DUB cleaves both Lys63- and Lys48-linked polyubiquitin chains. A) To 
establish the bona fide DUB activity of the EAV PLP2-DUB, an in vitro activity assay was developed 
using polyubiquitin chains as a substrate. To this end, a dose range consisting of two-fold serial di-
lutions starting at 0.5 μg of purified recombinant wild-type EAV nsp2(N) per reaction was incubated 
with Lys48- or Lys63-linked polyubiquitin chains for 2 h at 37°C. The established DUB isopepti-
dase T (0.5 μg per reaction) was included as a positive control (76). B) The effect of mutagenesis 
of the putative active site residues (Cys270 and His332) of EAV PLP2-DUB was investigated by 
incubating Lys48- and Lys63-linked polyubiquitin chains with 1 μg of purified recombinant wild-
type EAV nsp2(N) or mutant proteins in which one or both of these residues were replaced by Ala. 
Abbreviations: IsoT, isopeptidase T; Ub, ubiquitin.
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incubated with Lys48- or Lys63-linked polyubiquitin chains. figure II-1A shows that 
EAV nsp2(N) efficiently cleaved both types of substrate, while showing a slight prefer-
ence for Lys63-linked chains in this assay. In addition, mutagenesis to Ala of the puta-
tive catalytic residues Cys270 and His332 (27) completely abolished the cleavage of 
ubiquitin chains of both linkage-types (figure II-1B). These results clearly establish 
that the PLP2-DUB domain present in EAV nsp2 possesses genuine DUB activity in the 
absence of other viral or cellular proteins.
all arterivirus nsp2 proteins show dUB activity when overexpressed in HeK293t 
cells. Comparative sequence analysis previously showed that all arterivirus nsp2 
proteins contain sequences resembling the EAV PLP2-DUB domain (17, 27). To confirm 
that these proteins indeed possess DUB activity, mammalian expression constructs 
were made for the PLP2-DUB domains of all known arteriviruses. It soon became clear, 
however, that expression of the conserved core PLP2-DUB domain did not suffice 
for catalytic activity in the case of the PRRSV-II, LDV and SHFV proteins. Therefore, 
expression constructs of variable length were designed, starting at the predicted 
N-terminal residue of nsp2 and gradually extending downstream of the C-terminal 
border of the PLP2-DUB core domain (figure II-2C). The different nsp2(N) proteins were 
subsequently assayed for DUB activity by co-transfecting the expression plasmids 
encoding them together with a myc-ubiquitin expression vector into HEK293T cells. 
figure II-2A illustrates that in the case of LDV and SHFV, the nsp2(N) proteins displayed 
catalytic activity towards ubiquitinated cellular substrates only upon inclusion of a 
minimal stretch of residues flanking the core PLP2-DUB domain, while figure II-2B 
shows that, at least for PRRSV-II, inclusion of the minimal required flanking sequence 
did not guarantee catalytic activity per se. Since all constructs expressed similar levels 
of protein, the observed lack of activity represented the expression of an inactive 
enzyme (data not shown).
figure II-3A presents an overview of the arterivirus PLP2-DUB constructs used 
throughout the rest of the paper. For each arterivirus, overexpression of nsp2(N) pro-
teins of sufficient length decreased the level of ubiquitinated proteins in transfected 
cell cultures (figure II-3B lanes, 3 and 5-8). It is clear from figure II-3B that the PLP2-
DUB domains of the various arteriviruses do not show the same level of DUB activity. 
Since these domains were taken out of their natural full-length protein context for 
this experiment, this assay cannot be used to judge whether these differences are 
due to, for example, the use of suboptimal domain borders in these constructs or, 
alternatively, whether they might reflect an intrinsic property of the respective PLP2-
DUBs. As expected, overexpression of a catalytically inactive double mutant (C/H>A) 
of EAV nsp2(N) did not result in a decrease in ubiquitinated protein levels (figure II-3B, 
compare lanes 3 and 4). Although these experiments do not formally exclude the pos-
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sibility that the observed eff ects are due to indirect eff ects on cellular ubiquitination 
events, they strongly suggest that all arterivirus nsp2 proteins are genuine DUBs, 
especially when taking the in vitro activity observed for recombinant EAV nsp2(N) into 
account (figure II-1).
In the infected cell, the arterivirus PLP2-DUB domain resides in a membrane-
anchored viral replication and transcription complex, which is associated with 
double-membrane structures in the perinuclear area of the cell (49, 50). However, the 
C-terminally truncated nsp2(N) proteins used above did not contain the transmembrane 
domain of nsp2 and therefore localized to the cytosol (data not shown). To mimic the 







































































































































































































































































































































Figure ii-2. delineation of the minimal fl anking sequences required for ldV, SHFV, and pRRSV-ii 
PLP2-DUB activity. A and B) Since expression of the core PLP2-DUB domain did not suffi  ce for 
catalytic activity in the case of the LDV, SHFV, and PRRSV-II proteins, constructs of variable length 
were designed, starting at the predicted N-terminal residues of the respective nsp2 proteins and 
gradually extending downstream of the predicted core PLP2-DUB domains. HEK293T cells were 
subsequently transfected with a combination of plasmids encoding myc-ubiquitin and the indicat-
ed viral proteins. Samples were subjected to SDS-PAGE and Western blot analysis, and probed with 
anti-myc antibody to assess the levels of cellular protein ubiquitination. Ub, ubiquitin. C) Sche-
matic representation of the constructs tested for PRRSV-II, LDV, and SHFV. Protein fragments were 
drawn to scale, except where a thinner line was used. Proteins that are represented in a lighter 
shade proved to be inactive. Indicated are the N- and C-terminal residues, the putative catalytic 
residues and in blue the predicted PLP2-DUB domain. Numbering is based on amino acid positions 
of the respective replicase polyproteins.
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Mutated catalytic residue 
LIGG832/W833
figure II-3. All arterivirus nsp2 proteins possess deubiquitinating activity. A) Schematic represen-
tation of arterivirus nsp2 constructs used. Indicated are the N- and C-terminal residues, putative 
catalytic residues and mutations thereof, and the EAV nsp2|3 junction (LIGG832/W833). Number-
ing is based on amino acid positions of the respective replicase polyproteins. Protein fragments 
were drawn to scale, except for those parts of the depicted proteins that are to the right of the 
dashed line. TM, transmembrane. B) To assess the effect of overexpression of arterivirus PLP2-DUBs 
on the level of cellular protein ubiquitination, HEK293T cells were transfected with a combination 
of plasmids encoding myc-ubiquitin, GFP, and the indicated viral proteins. Cells were lysed at 16 h 
p.t. and samples were subjected to SDS-PAGE and Western blot analysis, using the indicated anti-
bodies. C) To further investigate the effect of overexpression of both arteri- and nairovirus DUBs on 
the level of cellular protein ubiquitination, HEK293T cells were transfected with plasmids encod-
ing wild-type or catalytically inactive mutants (C/H>A) of EAV nsp2-3, EAV nsp2(N), or CCHFV L(N) in 
combination with plasmids encoding myc-ubiquitin and GFP. Results were analyzed as described 
for B. Abbreviation: TFR, transferrin receptor.
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using a self-cleaving, full-length EAV nsp2-3 polyprotein. A catalytically inactive de-
rivative (C/H>A) of this protein, which does not process the nsp2|3 site, served as a 
negative control. figure II-3C shows that overexpression of both the wild-type and C/
H>A forms of EAV nsp2-3 decreased the expression of the GFP transfection control. 
This suggested a general adverse effect on protein expression in this particular assay, 
which may also have affected the abundance of myc-ubiquitin. Nonetheless, a clear 
difference was observed between the wild-type and C/H>A nsp2-3 proteins with 
regard to their effect on protein ubiquitination (figure II-3C, upper panel, compare 
lanes 3 and 4), suggesting that at least part of the observed decrease in ubiquitination 
is due to the protease activity of EAV nsp2.
Finally, the DUB domain present in the L protein of the nairovirus CCHFV and a 
catalytically inactive mutant of this protein were included in this experiment (figure 
II-3C). As was expected on the basis of previous work (18), overexpression of wild-
type CCHFV L(N) decreased ubiquitinated protein levels while overexpression of the C/
H>A mutant did not (figure II-3C, upper panel, lanes 7 and 8).
The induction of IfN-β by eAv rNA in mefs is mAvS-dependent and the recognition 
of eAv rNA relies primarily on mDA5. Since arteriviruses target a variety of tissues 
(51), it is likely that in vivo many of the infected cells have an operational RLR path-
way that will trigger an antiviral response. To investigate the involvement of the RLR 
pathway in sensing EAV infection, we used MEFs isolated from transgenic mice lacking 
MAVS, MDA5, or RIG-I. Using qRT-PCR, we compared the IFN-β response in these MEFs 
with that in control cells derived from their respective wild-type littermates. MEFs 
are permissive to EAV infection, although the number of cells that can be infected 
is generally low, possibly due to differential expression of suitable receptors (data 
not shown). Moreover, low induction of IFN-β was observed upon infection, probably 
also due to innate immune suppressing activities of the virus. Therefore, the IFN-β 
response was induced by transfecting these cells with total RNA isolated from EAV-
infected Vero cells. As positive controls we employed total RNA isolated from Vero 
cells infected with mengovirus or NDV. Using the comparative CT method (48), IFN-β 
expression levels were normalized to GAPDH as an internal standard and compared 
to the IFN-β expression levels in MEFs transfected with total RNA from mock-infected 
Vero cells.
Our results show that transfecting wild-type MEFs with total RNA isolated from EAV-
infected Vero cells induced a 100- to 300-fold increase of IFN-β expression compared 
to cells transfected with RNA from mock-infected cells (figure II-4A). The absence of 
MAVS almost completely abolished this IFN-β response, indicating that, at least in MEFs, 
the RLR pathway is indeed involved in sensing EAV RNA. In addition, while a lack of RIG-I 
had no significant effect, the absence of MDA5 had a profound negative effect on the 






figure II-4. Induction of IfN-β by eAv rNA in mefs is mAvS-dependent and the recognition of eAv 
rNA primarily relies on the Prr mDA5. To investigate the role of RLR sensors in the recognition of 
arteriviral RNA, mouse embryonic fibroblasts (MEFs) lacking MAVS, MDA5, or RIG-I (black bars) and 
their respective wild-type controls (white bars) were transfected with total RNA isolated from Vero 
cells infected with A) EAV, B) mengovirus, or C) Newcastle disease virus (NDV). At 3 h p.t., total RNA 
was isolated from these cells and used as a template for cDNA synthesis. Gene expression levels of 
IFN-β and GAPDH were subsequently determined by means of qRT-PCR. Using the comparative CT 
method, the gene expression levels of IFN-β were normalized to those of GAPDH, which was used 
as internal standard, and compared to the gene expression levels of IFN-β in MEFs transfected with 
total RNA from mock-infected Vero cells. This experiment was performed three times indepen-
dently with similar outcomes. Bars represent the mean of PCR-triplicates from one representative 
experiment ± standard deviation.
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IFN-β response (figure II-4A). However, in MDA5 knockout cells the IFN-β response was 
not completely suppressed, unlike what was observed when RNA from mengovirus-in-
fected cells was used (figure II-4B), suggesting that either RIG-I or an as yet unidentified 
MAVS-dependent PRR can trigger an IFN-β response in the absence of MDA5. Consistent 
with the published literature, figures II-4B and C clearly show that mengovirus RNA was 
exclusively recognized by MDA5, while NDV RNA was solely recognized by RIG-I (45).
Arteri- and nairovirus DUBs inhibit the rIG-I-mediated IfN-β response. After estab-
lishing that the RLR pathway is indeed involved in the recognition of arteriviral RNA, 
we continued to investigate the immune evasive properties of the arteri- and nairoviral 
DUBs in more detail. To this end, we designed a luciferase-based reporter assay to in-
vestigate inhibition of RLR signalling by the various viral proteins. Plasmids encoding 
constitutively active RIG-I(2CARD), wild-type MAVS, or constitutively active IRF3(5D) were 
transfected to induce IFN-β expression. In addition, cells were co-transfected with a 
reporter plasmid encoding firefly luciferase under control of the IFN-β promoter, and 
Renilla luciferase was included as a transfection control. As anticipated, expression of 
either RIG-I(2CARD), MAVS, or IRF3(5D) strongly induced reporter gene expression, which 
was set to 100% (figure II-5A to C and 6A and B, leftmost bar of each graph). Western 
blots were included for all experiments to confirm correct transfection and expression 
of viral proteins (figure II-5D to f and 6C and D).
figure II-5A clearly shows that expression of each of the arterivirus nsp2(N) con-
structs, as well as the EAV nsp2-3 and CCHFV L(N) constructs, significantly decreased 
reporter gene activation upon induction by RIG-I(2CARD). This indicated that each of 
these proteins is able to inhibit the RLR-mediated immune response at the level of 
RIG-I or downstream of RIG-I. Consistent with its lower general DUB activity upon 
overexpression in HEK293T cells, PRRSV-II nsp2(N) showed a significant but relatively 
low inhibitory activity, which may be due to the use of suboptimal domain borders in 
this construct or may reflect an intrinsic property of this specific arterivirus PLP2-DUB. 
figure II-5B illustrates a comparable inhibition of MAVS-induced reporter gene activa-
tion by all DUB-containing proteins, which is suggestive of inhibition at the level of 
MAVS or downstream of MAVS.
To confirm that the observed effects on reporter gene expression indeed resulted 
from the specific inhibition of RLR signalling, a similar reporter assay was set up in 
which constitutively active IRF3(5D) was used to activate the reporter gene. Since the 
expression of constitutively active IRF3(5D) results in direct and presumably ubiquitin-
independent reporter gene activation, one would not expect this induction to be af-
fected by the expression of viral DUBs. Surprisingly however, EAV nsp2(N) considerably 
inhibited reporter gene activation by IRF3(5D) (figure II-5C), although the inhibition 
was less pronounced than that observed upon activation by RIG-I(2CARD) (figure II-5A) or 


































































































































































EAV nsp2-3 EAV nsp2(N)
figure II-5. Overexpression of arteri- and nairoviral DUBs inhibits the rLr-mediated innate im-
mune response. To investigate the effect of overexpression of the various viral DUBs on RLR-me-
diated signalling, a luciferase-based reporter assay was designed. To this end, HEK293T cells were 
transfected with a reporter plasmid encoding firefly luciferase under control of the IFN-β promoter. 
A plasmid encoding Renilla luciferase was included as a transfection control and RLR signalling was 
induced by the co-transfection of plasmids encoding A) RIG-I(2CARD), B) MAVS, or C) IRF3(5D). Dose 
ranges in panel C consist of two-fold serial dilutions where the highest amount of DUB-encoding 
plasmid DNA corresponds with the amounts used in panels A and B. At 12 h p.t., three wells were 
used to perform a dual-luciferase assay, while every fourth well was used for Western blot analysis 
to verify the correct expression of viral proteins by probing with the indicated antibodies (D-f). 
Comparable experiments were performed at least twice with similar results. Bars represent the 
mean of triplicates from one representative experiment ± standard deviation. Abbreviations: NS, 
not statistically significant; TFR, transferrin receptor.
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MAVS (figure II-5B). Interestingly, EAV nsp2-3 only marginally affected reporter gene 
expression upon IRF3(5D)-mediated activation (figure II-5C), while its effect on RIG-I or 
MAVS-induced IFN-ß expression was comparable to that of EAV nsp2(N) (figure II-5A 
and B). This supports the assumption that the subcellular localization of the PLP2-DUB 
is an important determinant of the natural range of substrates that is accessible to the 
enzyme in the infected cell.
To further investigate the DUB-dependency of the observed inhibitory effects, the 
dose-dependent activities of wild-type and catalytically inactive (C/H>A) mutants of 
EAV nsp2(N) and nsp2-3 were compared (figure II-6A and B). As expected, wild-type EAV 




























figure II-6. Inhibition of rLr-mediated signalling by eAv nsp2-3 depends only in part on its deu-
biquitinating activity. To further investigate the DUB-dependency of the observed inhibitory ac-
tivities of EAV nsp2(N) and nsp2-3, a luciferase-based reporter assay was performed using both 
wild-type and catalytically inactive forms of these proteins. To this end, HEK293T cells were trans-
fected with a reporter plasmid encoding firefly luciferase under control of the IFN-β promoter. A 
plasmid encoding Renilla luciferase was included as a transfection control and RLR signalling was 
induced by the co-transfection of a plasmid encoding RIG-I(2CARD). In addition, cells were co-trans-
fected in quadruple with two-fold serial dilutions of plasmids encoding wild-type (white bars) or 
C/H>A (black bars) EAV A) nsp2(N), or B) nsp2-3. At 12 h p.t., three wells were used to perform a 
dual-luciferase assay, while every fourth well was used for Western blotting to control for correct 
expression of viral proteins by probing with the indicated antibodies (C and D). Comparable exper-
iments were performed at least twice with similar results. Bars represent the mean of triplicates 
from one representative experiment ± standard deviation. Abbreviation: TFR, transferrin receptor.
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upon induction by RIG-I(2CARD), while EAV nsp2(N) C/H>A did not significantly inhibit with 
any of the tested amounts of transfected DNA. In contrast, although clearly decreased 
compared to the wild-type control, EAV nsp2-3 C/H>A still significantly inhibited RIG-
I-mediated reporter gene activity, suggesting that this protein harbors one or more ad-
ditional immune inhibitory functions that are not strictly dependent on its DUB activity.
Arteri- and nairovirus DUBs can inhibit the ubiquitination of rIG-I. RIG-I is a key PRR 
in the RLR pathway and, unlike MDA5, its activation depends on ubiquitination (8). 
In addition, our data suggested a role for RIG-I in the recognition of arterivirus RNA 
and showed that arteri- and nairoviral DUBs can inhibit the RLR pathway at the level 
of RIG-I or downstream of RIG-I (figure II-5A). This led us to examine whether these 
viral DUBs are capable of inhibiting RIG-I ubiquitination. We therefore co-transfected 
HEK293T cells with plasmids encoding GST-RIG-I(2CARD), myc-ubiquitin, GFP, and the 
indicated viral proteins and performed a GST pull-down experiment, followed by a 
Western blot analysis. In the absence of viral proteins, several bands representing 
(poly-)ubiquitinated RIG-I(2CARD) could be observed upon overexpression of this protein 
in combination with myc-ubiquitin (figure II-7A-B, upper panel, lane 3). Notably, un-
like others, our experiments were performed in the absence of proteasome inhibitors, 
which would merely have resulted in the accumulation of Lys48-linked substrates 
rather than the activating Lys63-linked form we were interested in (52). Gack et al. 
(2007) previously used a similar approach to visualize ubiquitinated RIG-I(2CARD) and 
showed comparable band patterns, which they subsequently confirmed to be the 
Lys63-linked polyubiquitinated form using mass spectrometry analysis (8).
figure II-7A shows that co-expression of wild-type EAV, PRRSV-I, LDV, or SHFV 
nsp2(N) resulted in the nearly complete disappearance of ubiquitinated RIG-I(2CARD) 
(figure II-7A). PRRSV-II nsp2(N) exhibited only a modest effect (figure II-7A, lane 7), 
in line with the other results obtained with this protein (figure II-3B and 5A). The 
inhibitory effect of EAV nsp2(N) was clearly reduced upon mutagenesis of the catalytic 
residues (figure II-7A, lane 5). Additionally, figure II-7B shows that also wild-type EAV 
nsp2-3 completely inhibited RIG-I(2CARD) ubiquitination (figure II-7B, upper panel, lane 
4). Expression of EAV nsp2-3 C/H>A resulted in an attenuated but nevertheless clear 
reduction of ubiquitinated RIG-I(2CARD) levels (figure II-7B, upper panel, compare lanes 
3, 4 and 5). This observation might however be explained by the fact that the overall 
amount of RIG-I(2CARD) appeared to be decreased in the presence of either wild-type or 
catalytically inactive EAV nsp2-3 (figure II-7B, 2nd and 3rd panel from the top, lanes 4 
and 5). Finally, also the expression of wild-type CCHFV L(N) resulted in the complete 
disappearance of ubiquitinated RIG-I, an effect that was clearly suppressed upon 
mutagenesis of the protease’s catalytic residues (figure II-7B, upper panel, compare 
lanes 3, 8 and 9).
54 Chapter 2
DISCUSSION
In this paper, using both in vitro and cell-based assays, we document for the first time 
that the nsp2 replicase subunits of all arteriviruses harbor a DUB activity that is likely 
used to counter RLR-mediated innate immune signalling. In addition, we established 
that the DUB-domains of both arteri- and nairoviruses are capable of inhibiting RIG-I 
ubiquitination, suggesting that the deconjugation of ubiquitin from this PRR consti-
tutes one of the mechanisms by which DUB-containing proteins from these viruses in-
terfere with the innate immune response. The recent finding that also a DUB encoded 
by Kaposi’s sarcoma-associated herpesvirus, a DNA virus, reduced IFN-β expression 
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figure II-7. Arteri- and nairovirus DUBs inhibit the ubiquitination of rIG-I upon overexpression. 
A and B) The effect of overexpression of the arteri- and nairovirus DUBs on RIG-I ubiquitination 
was assessed by co-transfecting HEK293T cells with a combination of plasmids encoding GST-
RIG-I(2CARD), myc-ubiquitin, GFP and the indicated viral proteins. Following lysis at 16 h p.t., a GST 
pull-down experiment was performed and ubiquitination of RIG-I was subsequently analyzed by 
means of SDS-PAGE and Western blot analysis, using the indicated antibodies. Abbreviations: PD, 
pull-down; TFR, transferrin receptor; Ub, ubiquitin; WCL, whole cell lysate.
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viruses at large (53). Since the viral DUBs studied here were also capable of inhibit-
ing MAVS-mediated IFN-β induction, it stands to reason that the deubiquitination of 
MAVS or other signalling molecules downstream of this factor also plays a role in the 
immune evasion mediated by these viral proteins.
To date, our knowledge concerning the role of innate PRRs in the recognition of arteri-
virus infection is limited. There is some evidence to suggest that TLR3 is important 
(54), but our study yielded the first indication for the involvement of the RLRs in 
the recognition of arteriviral RNA. By transfecting MEFs with total RNA isolated from 
EAV-infected Vero cells, we have shown that the absence of MAVS, a central factor 
in RLR signalling, almost completely abrogated IFN-β expression, indicating that in 
these cells MAVS-mediated signalling is pivotal in the response to EAV infection 
(figure II-4A). In addition, the absence of MDA5 strongly attenuated IFN-β induction 
compared to wild-type MEFs (figure II-4A), suggesting that this sensor is the main RLR 
responsible for the recognition of arteriviral RNA. Since arteriviruses infect numerous 
different tissues and cell-types during infection in vivo (51), it is likely that many of 
these indeed rely on the RLR-mediated antiviral response, supporting the relevance 
of our data acquired in MEFs. Considering our findings, it seems counterintuitive that 
an arteriviral protein would target RIG-I in order to evade host immune signalling. 
However, in contrast to what was observed for mengovirus, the absence of MDA5 re-
producibly failed to cause a complete loss of EAV-induced IFN-β expression (compare 
figure II-4A and B). This suggests that another PRR, likely RIG-I, can mount an immune 
response against EAV infection in the absence of MDA5. In fact West Nile virus (55), 
dengue virus (56) and the coronavirus murine hepatitis virus (57) were previously 
found to be recognized by both MDA5 and RIG-I. Alternatively, not RIG-I but another 
PRR might be responsible for the observed residual level of IFN-β expression in the 
absence of MDA5. For example, recent work by Sabbah et al. (2009) showed that the 
NLR Nod2 detected viral RNA and that subsequent signalling by this molecule was 
also MAVS-dependent (58). Nevertheless, the fact that both MDA5 and RIG-I are ISGs 
suggests a role for these proteins during later stages of infection, which might be 
distinct from their initial activities as PRRs and would explain why a virus that is not 
primarily detected by RIG-I would still benefit from inhibiting its activation. This hy-
pothesis is further supported by the finding that several picornaviruses induce RIG-I 
degradation despite the fact that they are commonly believed to be recognized solely 
by MDA5 (59, 60).
As in the case of arteriviruses, little is known about the innate immunity signal-
ling pathways involved in the recognition of nairoviruses. Nevertheless, Habjan et al. 
(2008) showed that CCHFV and the related bunyavirus Hantaan virus process the 5’ 
end of their genomes, likely to prevent recognition by RIG-I (61). In addition, there 
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is recent evidence that infection with Hantaan virus can indeed be sensed by RIG-I 
(62). Since viruses belonging to the same family are often recognized by the same 
PRRs, these findings suggests that also CCHFV is recognized by RIG-I. In nairoviruses, 
the deubiquitination of RIG-I might therefore be an additional mechanism to further 
inhibit RLR-mediated signalling.
Notably, our results showed that inhibition of the innate immune response by EAV 
nsp2-3, in contrast to EAV nsp2(N), is not strictly dependent on its DUB activity. Al-
though the inhibitory activity of EAV nsp2-3 is clearly reduced upon mutagenesis of 
the protease’s active site residues, it is not completely abolished (figure II-6B). In 
contrast, mutagenesis of the same catalytic residues in EAV nsp2(N) almost completely 
abrogated its inhibitory activity (figure II-6A). These observations are consistent 
with results previously obtained by others for coronavirus DUBs (63, 64). Arteri- and 
coronaviruses both belong to the order Nidovirales and share a similar genome or-
ganization and expression strategy. Coronavirus nsp3, which can to a certain extent 
be considered the functional equivalent of arterivirus nsp2, contains two papain-like 
protease domains (PLP1 and PLP2). In some coronavirus species, however, PLP1 has 
lost its proteolytic activity or the entire PLP1 domain is missing. In these cases, PLP2 
is the only active protease domain in nsp3 and is therefore referred to as PLpro. PLP2/
PLpro of severe acute respiratory syndrome-associated coronavirus (SARS-CoV), mu-
rine hepatitis virus A59 (MHV-A59), human coronavirus NL63 (HCoV-NL63), and PLP1 
of transmissible gastroenteritis virus (TGEV) were all shown to possess DUB activity 
in addition to their role in the autoproteolytic maturation of the replicase polypro-
teins (63, 65-68). Notably, the coronavirus DUBs are of the USP subclass instead of 
the OTU subclass of DUBs. Like the arterivirus PLP2-DUB, the PLP2/PLpro domains 
of various coronaviruses were found to inhibit the innate immune response (63, 64, 
68, 69). While the immune inhibitory activity of MHV-A59 PLP2 was claimed to be 
completely dependent on its DUB activity, that of HCoV-NL63 and SARS-CoV PLP2/
PLpro was shown to only partially depend on its proteolytic activity. These observa-
tions suggest that both arteri- and coronavirus replicase proteins harbor additional 
immune evasive features that may be linked to, but are not strictly dependent on the 
DUB activity present in their nsp2 or nsp3 subunits, respectively. It is conceivable 
that a catalytically inactive DUB would still be able to bind ubiquitin or ubiquitinated 
proteins, thereby hindering interactions necessary for signal transduction. In addition, 
our results suggest that expression of both wild-type and catalytically inactive EAV 
nsp2-3 decreases the overall amount of RIG-I(2CARD), which may explain the mutant’s 
inhibitory potential (figure II-7B, 3rd panel from the top, lanes 4 and 5). Further re-
search is needed to elucidate whether these DUB-containing viral proteins possess 
additional immune evasive properties.
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Contrary to our expectations, we found that arterivirus nsp2(N), which localizes to the 
cytosol, inhibited the IRF3-mediated activation of IFN-β expression (figure II-5C). 
In contrast, IRF3-mediated IFN-β induction was hardly affected by the expression of 
EAV nsp2-3, which is membrane-anchored and localizes to the perinuclear region of 
the cell, while EAV nsp2(N) and nsp2-3 showed comparable inhibitory potential upon 
activation of signalling by RIG-I(2CARD) or MAVS (compare figure II-5A to C). Similar re-
sults were previously obtained for SARS-CoV PLpro, of which a soluble form inhibited 
IRF3-mediated activation of IFN-β expression (69), while a membrane-anchored form 
did not (64). Taken together, these results suggest that the subcellular localization 
of these proteins is an important determinant of the range of substrates that is 
accessible to them. Since expression of the full-length nsp2 protein together with 
nsp3 more accurately reflects the situation in the infected cell, it is likely that during 
infection inhibition also takes place upstream of IRF3. This would be consistent with 
previous observations by Luo et al. (2008), which showed that inhibition of the RLR 
pathway during PRRSV infection occurred at the level of MAVS or upstream of this key 
factor (70).
Still, the question remains by what mechanism, albeit artificial, cytosolic EAV nsp2(N) 
is able to inhibit IRF3 signalling, since to date there is no evidence for activation of 
this transcription factor by Lys63-linked polyubiquitination. On the contrary, it is well 
established that IRF3 is negatively regulated by Lys48-linked polyubiquitination, the 
removal of which would appear counterproductive in view of controlling IFN signal-
ling (71-74). Interestingly, Shi et al. (2010) recently showed that ISGylation, i.e. the 
conjugation of ISG15 to a target protein, of IRF3 positively regulated its activation 
by preventing Lys48-linked polyubiquitination (75). In light of previous findings by 
Frias-Staheli et al. (2007) that arteri- and nairovirus DUBs can deconjugate ISG15 (18), 
it is tempting to speculate that cytosolic nsp2(N), in contrast to membrane-anchored 
full-length nsp2, is able to de-ISGylate IRF3. However, IRF3 ISGylation per se was 
shown not to be activating, but merely increased the signalling potential of IRF3 by 
preventing its proteasomal degradation. Consequently, if a viral DUB would indeed 
de-ISGylate IRF3 to promote its degradation, it would at the same time need to refrain 
from removing any Lys48-linked polyubiquitin chains. This problem emphasizes 
that viral DUBs are likely capable to distinguish between activating and inactivating 
Ub(-like) modifications. How viral DUBs make this distinction, and how they would 
achieve a balance between the removal of the ‘right’ and ‘wrong’ modifiers, poses an 
interesting question for future research.
Another interesting feature of viral DUBs is their apparent tendency to deubiquitinate 
all cellular proteins in a seemingly random fashion (figure II-3B and C). In this respect 
they differ from their mammalian counterparts, which generally have a more narrow 
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specificity (18). A possible explanation for this observed promiscuity, which is seen 
for arteri-, nairo-, and coronavirus DUBs (18, 69), is the fact that the enzymes were 
often only studied as isolated domains, taken out of their natural full-length protein 
context. For this reason, we have also studied PLP2-DUB in the context of EAV nsp2-3, 
of which the membrane-associated subcellular localization is similar to that observed 
during EAV infection. Although EAV nsp2-3 did seem to be more restricted than nsp2(N) 
in the inhibition of IRF3-mediated IFN-β induction (figure II-5C), PLP2-DUB also 
showed general DUB activity when overexpressed as part of full-length nsp2 (figure 
II-3C). This suggests that the observed promiscuity is indeed an intrinsic property of 
these viral DUBs, although on the other hand it should be noted that most of our 
experiments involved systems in which the DUBs were overexpressed. Future studies 
will aim to elucidate the role of viral DUB activity during the course of infection, for 
example by using reverse genetics to engineer a virus that lacks this activity. Unfor-
tunately, we have thus far been unable to create a viable mutant with this phenotype, 
mainly due to the intimate link between the DUB activity and polyprotein processing 
functions of PLP2.
Taken together, our results strongly suggest that arteriviruses as well as nairoviruses 
encode DUBs that are used to inactivate cellular proteins involved in innate immune 
signalling, as exemplified by the deubiquitination of RIG-I documented here. Strik-
ingly, related DUBs from the OTU family seem to have been acquired and adapted for 
this purpose by apparently unrelated RNA viruses, the positive-stranded arteriviruses 
and the negative-stranded nairoviruses, thereby highlighting the selective advan-
tages that must be linked to OTU-DUB acquisition and the general plasticity of RNA 
virus genomes.
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ABSTrACT
Inhibition of protease activity forms a successful approach in the design of antivirals, 
in particular for positive-stranded RNA viruses. These viruses commonly express part 
of their proteome in the form of large polyproteins that are co- and posttranslationally 
cleaved into their respective functional subunits by internal protease domains. Inter-
estingly, some of these proteases have been found to also possess deubiquitinase 
(DUB) activity, which is thought to be important for the inhibition of innate immunity. 
Here we assessed whether a fluorescence polarization-based DUB assay can be em-
ployed to identify compounds that inhibit viral protease activity and virus replication. 
To this end, we screened a library of 335 suspected DUB inhibitors in vitro for activity 
against recombinant papain-like protease 2 of equine arteritis virus (EAV). The hits 
obtained were subsequently tested for inhibiting the replication of a GFP-expressing 
EAV reporter virus in cell-culture. Our preliminary results suggest that it is indeed pos-
sible to identify antiviral hits using this DUB-based screening approach. Future work 
will now focus on DUB-encoding human pathogens, including for example zoonotic 
coronaviruses like the agents causing MERS and SARS.




Inhibition of viral proteases forms a successful approach in the search for antiviral 
compounds for the treatment of infection with in particular positive-stranded (+) 
RNA viruses (for reviews see (1, 2)). These viruses commonly express (part of) their 
proteome in the form of polyproteins that are co- and posttranslationally cleaved 
into functional subunits by internal protease domains. The fact that the replication 
of all mammalian +RNA viruses critically depends on correct and timely polyprotein 
maturation renders them vulnerable to inhibition of the viral enzymes involved in 
this process. An important recent development underlining the validity of such an 
approach is the 2011 approval by US Food and Drug Administration (FDA) and Euro-
pean Medicines Agency of two novel drugs for the treatment of hepatitis C virus (HCV) 
infection (3). These compounds, boceprevir and telaprevir, both target the viral main 
protease (NS3/4a) and are now included in standard-care combination therapy.
The structural variation among viral protease classes and the accompanying sub-
strate diversity seem to demand an individualized approach for the identification of 
inhibitors for each of these enzyme classes (for a review see (2)). Notably, many +RNA 
viral proteases have been found to be multifunctional enzymes, targeting both viral 
and host proteins. A telling example is the targeting of the cellular innate immune fac-
tor MAVS by the HCV NS3/4a main protease (4, 5). In addition, several proteases that 
are responsible for polyprotein maturation in picorna-, corona-, and arteriviruses have 
been found to possess deubiquitinase (DUB) activity (6-17). Given the fact that both 
protease functions, polyprotein maturation and DUB activity, rely on the same active 
site, inhibitors of the latter activity might also prevent viral replication. Interestingly, 
DUBs have been identified in an even wider variety of viruses, including a particular 
genus of negative-stranded (-) RNA viruses (12, 18-20) and several DNA viruses (21-
26). Although, in contrast to +RNA viral DUBs, these enzymes are most probably not 
involved in the proteolytic maturation of viral proteins (27), several have been sug-
gested to play a role in evading or delaying innate immune activation (12, 13, 28-31). 
Inhibition of these viral DUBs might thus be used to boost the immune response trig-
gered by an infection with these viruses and thereby promote viral clearance by the 
host. The shared specificity of these viral enzymes for ubiquitinated substrates might 
form the basis for a generalized screening approach to identify protease inhibitors 
targeting different virus groups using a similar experimental set-up.
In vitro DUB activity can be (semi-)quantitatively assessed using assays containing 
one of various ubiquitin-based substrates. Of these, ubiquitin (Ub) coupled to 7-ami-
no-4-methylcoumarin (AMC) is the most widely used and relies on the activation of 
AMC-fluorescence upon its release from Ub by an active DUB. Although Ub-AMC can 
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be readily produced, it is not particularly suitable for use in high-throughput inhibitor 
screens since the excitation wavelength of AMC (380 nm) overlaps with that of a large 
proportion of screening compounds, resulting in aberrant readings (32). An alternative 
DUB substrate that is more appropriate for use in high-throughput inhibitor screens 
is Ub coupled to 5-carboxytetramethylrhodamine (TAMRA), which has an excitation 
wavelength of 550 nm. An additional advantage is the fact that, compared to Ub-AMC, 
Ub-TAMRA more closely resembles naturally occurring DUB substrates because of the 
isopeptide bond between Ub moiety and fluorophore (32). Unlike AMC, TAMRA is an 
active fluorophore when coupled to Ub. The experimental read-out in Ub-TAMRA as-
says therefore has to rely on the changes in fluorescence polarization that occur upon 
release of the TAMRA-moiety from Ub (see also (32, 33)). In short, compared to the 
large Ub-TAMRA complex, the increased mobility of the liberated TAMRA fluorophore 
will reduce the degree of polarization of the emitted light, which can be quantitatively 
assessed. Despite the many advantages, the cumbersome enzymatic preparation of 
Ub-TAMRA has prevented its wide-spread use as a DUB substrate. Recently however, 
we and others have developed a novel chemical ligation method that has greatly 
enhanced the ease of production of this conjugate, allowing for its more general use 
(34-36).
Although the polyprotein cleavage and DUB activities of the multifunctional +RNA 
viral proteases mentioned above rely on the same active site, the latter activity is not 
required for virus viability. Indeed, it has recently been shown that, in principle, DUB 
activity can be disabled through mutagenesis of the Ub-binding region without af-
fecting viral replication (37). The primary aim of this pilot study was therefore to test 
whether an in vitro experimental set-up that assesses inhibition of viral DUB activity 
is a useful tool to identify compounds that also inhibit overall viral replication. To this 
end, we have used the DUB encoded by equine arteritis virus (EAV) as a model system. 
This virus is the prototype species of the arterivirus family, which also includes por-
cine reproductive and respiratory syndrome virus (PRRSV), that together with among 
others the distantly related coronavirus family belongs to the order Nidovirales. Both 
EAV and PRRSV cause reproductive failure in female animals and respiratory disease in 
young offspring (for reviews, see (38, 39)), and especially PRRSV has a major economic 
impact (40), affecting swine-farming industries worldwide. Importantly, these viruses 
harbour a papain-like protease (PLP2) that is critical for viral replication because of its 
role in polyprotein maturation and simultaneously functions as a DUB (12-14, 41-43). 
As an additional example of a viral DUB, we also assessed the in vitro inhibition of 
the OTU protease of the -RNA virus Crimean-Congo hemorrhagic fever virus, which 
belongs to the nairovirus genus of the family Bunyaviridae. This tick-borne virus can 
cause severe disease in humans, with a mortality rate ranging from 5 to 80%, and 
currently no vaccines or specific antivirals are available to prevent or treat infection 
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with this emerging virus (44). Because of the BSL4 classification of CCHFV, we were 
only able to test the OTU protease in our in vitro assays and could not assess a possible 
effect on viral replication or innate immune activation during infection.
Theoretically, compounds that inhibit multifunctional +RNA viral DUBs could belong 
to one of three categories. Those belonging to category 1 would inhibit both the DUB 
and polyprotein processing functions of the protease and it is this category that we 
aim to identify using our DUB-based screen. These compounds would likely (but not 
necessarily) target the active site, since both functions rely on this part of the prote-
ase. Category 2 would consist of compounds that exclusively affect the DUB activity of 
the protease, likely by targeting the Ub-binding interface. A DUB-based screen would 
also identify such compounds, which are however unlikely to inhibit viral replica-
tion directly. Finally, category 3 would consist of compounds that inhibit only the 
polyprotein processing function of the protease, for example by interfering with the 
interaction between that substrate and the protease. Such inhibitors would of course 
remain unidentified when using a DUB-based screen. Regardless of some of these 
limitations, a DUB-based screen may provide a quick, easy, and generally applicable 
tool to make an initial selection of hits from larger libraries of potential protease 
inhibitors, before proceeding to more time-consuming and complicated experiments 
involving live virus. In addition, compounds belonging to category 2 might prove to be 
useful research tools to study the role of these enzymes in innate immune evasion. As 
mentioned above, DUBs encoded by -RNA and DNA viruses supposedly do not have a 
role in proteolytic maturation of viral proteins and their inhibition would only hamper 
their DUB-related function(s), e.g. evasion of the innate immune response.
To optimize the experimental conditions, we purified recombinant EAV PLP2 (13) 
and CCHFV OTU (12) as described previously and assayed their activity at different 
concentrations (0.39-12.5 nM or 0.1-1.56 nM, respectively) in a fluorescence polar-
ization-based DUB assay using Ub-TAMRA (100 nM) as a substrate. The reaction buffer 
consisted of 50 mM Tris-HCl pH 7.6, 100 mM NaCl, 1 mg/mL CHAPS, 0.5 mg/mL bovine 
gamma globulins, and 2 mM DTT and a total volume of 15 μl per well was used. The 
assay was performed at 37°C in a 384-wells plate and fluorescence polarization was 
measured every minute for 90 min using an EnVision Multilabel Reader (PerkinElmer). 
As expected, a concentration-dependent gradual decrease in polarization over time 
could be observed (figure III-1A and B). We then screened a library of 335 potential 
DUB inhibitors (compounds that were previously shown to inhibit DUB activity and 
analogues thereof) for activity against EAV PLP2 and CCHFV OTU using a similar ex-
perimental set-up. The enzyme (final concentration 10 nM or 0.5 nM, respectively) 
was first incubated for 30 min with each compound (final concentration 10 μM) before 
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addition of the substrate (final concentration 100 nM). Duplicate measurements were 
performed at selected time points and are summarized in figures III-1C and D for 
the compounds (designated A-I) that had the strongest inhibitory effect, ranging from 
~65-100% inhibition of enzyme activity. The inhibitory activity of these compounds 
was subsequently confirmed in an additional, independent experiment (data not 
shown). Structural formulas of compounds A, B, C, and E can be found in figure III-2. 
Compounds D and F-I could not be released due to a confidentiality agreement with 
a third party.
Considering the fact that EAV PLP2 and CCHFV OTU are structurally similar (both 







































A (101.7 ± 0.8%)
B (99.0 ± 0.5%)
D (80.1 ± 3.2%)
C (93.2 ± 4.2%)












































A (102.0 ±  0.3%)
B (100.1 ±  0.7%)
C (100.2 ±  0.1%)
D (92.8 ±    4.3%)
Compounds (10 µM)
G (77.1 ±  5.5%)
F (78.1 ±  13.5%)
H (65.8 ±  2.8%)
I (64.6 ±  1.3%)
Figure iii-1. Fluorescence polarization-based dUB inhibitor screen. Optimal assay conditions were 
determined by testing a range of A) EAV PLP2 concentrations (0.39-12.5 nM) and B) CCHFV OTU 
concentrations (0.1-1.56 nM). Proteolytic cleavage of the Ub-TAMRA substrate by these enzymes 
resulted in a gradual decrease in fluorescence polarization over time due to the release of the 
TAMRA-fluorophore. The TAMRA-KG control consists of uncoupled, hence unpolarised, fluorophore. 
Measurements were obtained every minute for 90 min on an EnVision Multilabel Reader (PerkinEl-
mer). A library of suspected DUB inhibitors (n=335) was screened for activity against C) EAV PLP2 
and D) CCHFV OTU using Ub-TAMRA as a substrate. The final DMSO concentration was 4%. Assay 
results for all hits with >60% inhibition (designated compound A-I) are depicted here. The figure 
legend shows the percentage inhibition of enzyme activity ± standard deviation between brack-
ets. Measurements were obtained in duplo for the indicated data-points on an EnVision Multilabel 
Reader. Abbreviations: CCHFV, Crimean-Congo haemorrhagic fever virus; DMSO, dimethylsulfox-
ide; EAV, equine arteritis virus; OTU, ovarian tumor protease; PLP2, papain-like protease 2; TAMRA-
KG, 5-carboxytetramethylrhodamine-Lysine-Glycine; Ub-TAMRA, ubiquitin coupled to TAMRA-KG.
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overlap in the hits obtained in both screens. The most potent inhibitors (compounds 
A-D) target both EAV PLP2 and CCHFV OTU. Although the possibility of a pan-specific 
inhibitor is a tempting prospect, such broadly acting compounds are more likely 
than others to display (potentially harmful) off-target effects. Indeed, some of these 
compounds have been found to also target cellular DUBs in vitro (unpublished data, 
P.P. Geurink et al.). Alternatively, additional research efforts can focus on compounds 
with a less potent but more specific in vitro inhibitory profile, i.e. compound E in the 
case of EAV PLP2 and compounds F-I for CCHFV OTU. In both cases however, additional 
experimental work is required to establish whether these compounds may also inhibit 
cellular enzymes and whether this might preclude their use as therapeutic agents.
To assess whether inhibition of DUB activity by these compounds correlated with 
antiviral activity, we asked whether the identified compounds also inhibited EAV 
replication in cell culture. To answer this question, we infected BHK-21 cells grown 
in 96-well plates with GFP-expressing EAV (45) at a multiplicity of infection (MOI) of 
5. Different inhibitor concentrations were given at 1 h post infection (hpi) and cells 
were incubated for another 17 h at 37°C. After fixation with 3% paraformaldehyde, 
GFP fluorescence was measured using a Mithras LB940 Multimode Reader (Berthold). 
In parallel, uninfected cells in control plates were incubated with the same inhibitor 




































figure III-2. Chemical features of selected eAv PLP2 inhibitors. Structural formulas, chemical 
formulas and molecular mass of compounds A) (E)-N’-(9H-indeno[1,2-b][1,2,5]oxadiazolo[3,4-e]
pyrazin-9-ylidene-4-methyl-1,2,5-oxadiazole-3-carbohydrazide, B) 1,4-diphenyl-10H-inde-
no[1’,2’:5,6]pyrazino[2,3-d]pyridazin-10-one, C) 9-oxo-9H-indeno[1,2-b]pyrazine-2,3-dicarboni-
trile, and e) 4,5,6,7-tetrachloro-1H-indene-1,3(2H)-dione. Abbreviation: Da, dalton.
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their effect on cell viability. Individual experiments were performed in quadruplicate, 
and each compound was tested in 2 to 5 independent experiments.
figure III-3 shows the effect of the top-five hits (compounds A-E) identified in the 
EAV PLP2 screen on replication of EAV-GFP (black bars) and cell viability (grey bars). 
MTS activity was not significantly affected compared to the DMSO-controls at any of 
the compound concentrations shown (Student’s t-test, p>0.05). Whereas compound 
A has only a marginal effect on viral replication at non-toxic concentrations (figure 
III-3A), compounds B and D decrease the GFP signal to approximately 50% of the 
control at the highest non-toxic concentrations (figure III-3B and D). Compounds C 
and E display an even greater and nicely dose-dependent effect on viral replication at 
concentrations that do not affect cell viability (figure III-3C and e). It should be noted 
though that the concentration of compound E needed to reach the desired effect is 
quite high (90 μM), compared to that required for compound C (5 μM). This might be 
due to differences in cell permeability for these two compounds, which might also 
underlie the rather limited effect of the compound with the strongest inhibitory activ-
ity in vitro (compound A). However, assuming that both compound C and E are equally 
capable of entering target cells, the differences in the required concentrations are 
consistent with their relative in vitro inhibitory activity (93.2 versus 65.9%, respec-
tively; figure III-1C). Alternatively, the discrepancies between in vitro inhibitory 
activity and inhibition of viral replication by the identified compounds might indicate 
that these compounds belong to “category 2” and thus do not affect the polyprotein 
processing function of the protease.
These preliminary experiments suggested that it is indeed possible to identify 
compounds that inhibit replication of a DUB-encoding virus using a DUB-based high-
throughput screen. Additional experimental work is required however to determine 
whether the identified compounds also inhibit replication of wild-type virus and to 
assess whether the observed inhibition is indeed to a direct effect on PLP2 proteolytic 
activity. Although cell viability appears unaffected by these compounds, based on an 
assessment of MTS activity, there might be more subtle off-target effects that could 
non-specifically affect viral replication. Additional (more sensitive) cell viability as-
says in combination with an assessment of the effect of these compounds on PLP2 
activity in an ectopic expression system might reveal whether the observed effect is 
indeed due to a direct effect on the viral enzyme.
In conclusion, a fluorescence polarization-based screen for DUB inhibitory activity can 
serve as a starting point for the identification of antiviral hits. It would certainly be of 
interest to employ this experimental set-up to screen larger libraries for compounds 
that are effective against important human DUB-encoding pathogens, including for 
example zoonotic coronaviruses like the agents causing MERS and SARS.



































































































































































































































































































































































figure III-3. validation of the inhibitory activ-
ity of compounds A-e using GfP-expressing 
reporter eAv. BHK-21 cells grown in 96-well 
plates were infected with EAV-GFP at an MOI 
of 5. The indicated concentration of each 
compound (A-e) was added 1 h post infection 
(hpi) and cells were incubated for another 17 
h at 37°C. After fixation with 3% paraformal-
dehyde, GFP-fluorescence (black bars) was 
measured using a Mithras LB940 Multimode 
Reader (Berthold). In parallel, uninfected cells 
were incubated with the same compound 
concentrations and viability (grey bars) was 
assessed at the time of fixation of infected 
cells using the CellTiter 96 AQueous MTS As-
say (Promega) and a Mithras LB940 Reader. 
All values were normalized to those obtained 
for untreated control cells and DMSO-con-
trols were exposed to equal concentrations 
of DMSO as cells incubated with the highest 
compound concentration. Individual experi-
ments were performed in quadruplicate and 
bars represent the means and standard devia-
tion of the results obtained in the indicated 
number (n=2/3/5) of independent experi-
ments. Abbreviations: EAV-GFP, green fluores-
cent protein-expressing equine arteritis virus; 
DMSO, dimethylsulfoxide; MTS, CellTiter 96 
AQueous MTS viability assay.
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ABSTrACT
Protein ubiquitination regulates important innate immune responses. The discovery 
of viruses encoding deubiquitinating enzymes (DUBs) suggests they remove ubiqui-
tin to evade ubiquitin-dependent antiviral responses; however, this has never been 
conclusively demonstrated in virus-infected cells. Arteriviruses are economically 
important positive-stranded RNA viruses that encode an ovarian tumor (OTU) domain 
DUB known as papain-like protease 2 (PLP2). This enzyme is essential for arterivirus 
replication by cleaving a site within the viral replicase polyproteins, and also removes 
ubiquitin from cellular proteins. To dissect this dual specificity, which relies on a 
single catalytic site, we determined the crystal structure of equine arteritis virus PLP2 
in complex with ubiquitin (1.45 Å). PLP2 binds ubiquitin using a zinc finger that is 
uniquely integrated into an exceptionally compact OTU-domain fold that represents a 
new subclass of zinc-dependent OTU DUBs. Notably, the ubiquitin-binding surface is 
distant from the catalytic site, which allowed us to mutate this surface to significantly 
reduce DUB activity without affecting polyprotein cleavage. Viruses harboring such 
mutations exhibited wild-type replication kinetics, confirming that PLP2-mediated 
polyprotein cleavage was intact, but the loss of DUB activity strikingly enhanced in-
nate immune signalling. Compared to wild-type virus infection, beta-interferon mRNA 
levels in equine cells infected with PLP2 mutants were increased by nearly an order 
of magnitude. Our findings not only establish PLP2 DUB activity as a critical factor 
in arteriviral innate immune evasion, the selective inactivation of DUB activity also 
opens new possibilities for developing improved live attenuated vaccines against 
arteriviruses and other viruses encoding similar dual-specificity proteases.
SIGNIfICANCe STATemeNT
Many viruses encode proteases that cleave both viral and host substrates. Arterivi-
ruses encode such a dual-specificity protease (PLP2) that removes ubiquitin from 
cellular proteins involved in host immunity. Based on a 3D-structure of PLP2, we en-
gineered the protease to have diminished deubiquitinating activity without affecting 
its activity towards its viral substrate. Viruses expressing such engineered proteases 
displayed a significantly weakened ability to evade host immune responses. This 
demonstrates a crucial role for PLP2 in arterivirus immune evasion and opens new 
possibilities for developing improved attenuated virus vaccines against economically 
important arteriviruses and other viruses encoding similar dual-specificity proteases.




The synthesis and post-translational cleavage of polyproteins is a common genome 
expression strategy employed by positive-stranded (+) RNA viruses of eukaryotes. It is 
used to cope with the consequences of cytoplasmic replication and the limitations of 
the eukaryotic translation machinery, which essentially preclude the use of (nuclear) 
RNA splicing and polycistronic mRNAs, respectively (1). The critical cleavage of these 
viral polyproteins into their functional subunits is mediated by internal virus-encoded 
proteases (2-5), many of which have been found to also target cellular substrates in 
order to promote virus replication or subvert host antiviral responses. Well-known 
examples of such dual-specificity proteases are the poliovirus 2A and hepatitis C virus 
NS3/4A enzymes that, in addition to the viral polyprotein, target host cell proteins 
involved in translation and innate immune signalling, respectively (6-10).
Arteriviruses are +RNA viruses that, together with the corona- and roniviruses, belong 
to the order Nidovirales and include equine arteritis virus (EAV) and porcine repro-
ductive and respiratory syndrome virus (PRRSV). EAV is the family prototype and can 
cause abortion in pregnant mares, pneumonia in neonatal foals, and influenza-like 
illness in adult horses (11). PRRSV ranks among the most important swine pathogens 
and infections are characterized by reproductive failure in sows and severe respira-
tory disease in young pigs (12). As in all nidoviruses, the synthesis and cleavage of the 
replicase polyproteins (pp1a and pp1ab) are critical first steps in arterivirus infection. 
They are encoded by the 5’-proximal three-quarters of the 13-16 kb arterivirus ge-
nome and are the precursors of the nonstructural proteins (nsps) required for genome 
replication and transcription. In the case of EAV, at least 13 nsps are produced when 
the replicase polyproteins are cleaved by three virus-encoded proteases (13, 14), one 
of which is a papain-like protease (PLP2) located in the N-terminal region of nsp2 (15, 
16). This enzyme cleaves the nsp2|nsp3 junction in pp1a and pp1ab, an event that 
is essential for virus replication since an EAV PLP2 active site mutant was previously 
found to be nonviable (17). In addition to this critical role in viral polyprotein matura-
tion, arterivirus PLP2 was proposed to contribute to the evasion of host innate im-
mune responses by removing ubiquitin (Ub) from cellular targets (18). Ub is an 8-kDa 
protein moiety that can be covalently attached to lysine residues of target proteins 
in a number of structurally different configurations, either by monoubiquitination or 
through the formation of polyubiquitin chains (19, 20). The effects of ubiquitination 
can range from targeting substrates for proteasomal degradation to initiating signal-
ling cascades and - importantly - they can be reversed by deubiquitinating enzymes 
(DUBs), which thus allow for negative regulation of Ub-activated processes (21-24). 
The latter include the innate immune signalling cascades triggered by invading RNA 
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viruses (25, 26), which ultimately lead to the transcription of genes encoding beta 
interferon (IFN-β) and other pro-inflammatory cytokines (27, 28).
Arterivirus PLP2 and a protease domain found in the unrelated nairovirus Crimean-
Congo hemorrhagic fever virus (CCHFV), were first identified as potential members 
of the ovarian tumor domain-containing (OTU) superfamily of DUBs on the basis 
of comparative sequence analysis (29). Several laboratories, including our own, 
subsequently confirmed that arterivirus PLP2s indeed have DUB activity that may 
be employed to remove Ub from innate immune signalling factors to suppress the 
induction of an antiviral state (18, 30, 31). The potential benefits of this strategy are 
highlighted by the fact that proteases from virus groups as diverse as arteri-, corona-, 
nairo-, picorna-, hepadna-, and herpesviruses have all been implicated in DUB-based 
innate immune evasion (18, 32-37). Thus far, however, direct evidence linking DUB 
activity to the suppression of innate immune responses in virus-infected cells has not 
been reported for any of these proteases.
Since the DUB activity of arterivirus PLP2 depends on the same active site mediating 
the critical nsp2|nsp3 cleavage, it has not been possible to independently study the 
role of PLP2 in polyprotein processing and immune evasion in the context of virus 
infection. Here we present the crystal structure of EAV PLP2 in complex with Ub at 
1.45 Å resolution. The complex reveals a distinctly compact conformation compared 
to other OTU superfamily members and the incorporation of a unique zinc finger 
within the OTU-fold. Given these features, arterivirus PLP2 represents a novel sub-
class of zinc-dependent OTU DUBs. Importantly, the PLP2 active site is distant from 
its Ub-binding surface, allowing for the introduction of mutations in this region that 
dramatically reduced DUB activity, yet did not affect nsp2|nsp3 cleavage. Compared 
to wild-type EAV, viruses carrying these mutations elicited a significantly enhanced 
innate immune response in primary equine cells, while displaying wild-type replica-
tion kinetics. Taken together, our results demonstrate that PLP2 DUB activity indeed 
mediates innate immune suppression during arterivirus infection. The ability to 
selectively inactivate the PLP2 DUB function may thus contribute to the engineering 
of improved live attenuated vaccines against arteriviruses and other virus families 
encoding proteases with similar dual specificities.
reSULTS
eaV plp2 adopts a compact OtU-domain fold with a unique integral zinc finger. 
Previously, EAV PLP2 was identified and characterized by a combination of bioinfor-
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matics analysis and site-directed mutagenesis, and two residues in particular were 
implicated in catalysis: Cys270 and His332 (16). Throughout this paper, amino acid 
numbers refer to the sequence of full-length EAV pp1a. The crystal structure of EAV 
PLP2 (residues 261-392; 13.6 kDa) was determined as a covalent complex with the 
mechanism-based inhibitor Ub(1−75)–3–bromopropylamine (Ub–3Br) (38, 39). Since 
the conservation of multiple cysteine residues and their demonstrated importance 
for protease function suggested that PLP2 could bind zinc (16), the crystal structure 
of the complex was determined by a multi-wavelength anomalous dispersion (MAD) 
phasing experiment using X-ray diffraction data collected over the zinc absorption 
edge (Table Iv-S1). The resulting electron density map revealed residues 261-387 
of PLP2 bound to a complete Ub molecule and allowed a model of the complex to be 
built and refined (Rwork= 0.16, Rfree= 0.18) to 1.45 Å resolution (figures Iv-1A and B).
The protease adopts a compact, two-domain fold with a shallow Ub-binding surface 
that directs the C-terminus of the bound Ub molecule (the ‘distal’ Ub in a Ub dimer) 
towards a solvent exposed active site that indeed includes Cys270 and His332 (fig-
ures Iv-1A and B). Domain I of PLP2 (residues 267-307 and 365-387) consists of a 
three-helix bundle (a1, a2, a4) packed against a two-stranded antiparallel sheet (β2↑ 
β6↓). Domain II centers on a four-stranded β-sheet (β1↑ β5↓ β4↑ β3↑) and an a-helix 
(a3) that together pack against helices a1 and a2 of domain I. Domain II comprises 
the majority of the Ub-binding surface, which is stabilized by four cysteine residues 
(Cys 319, 349, 354, 356) that coordinate a zinc ion with tetrahedral geometry (figure 
Iv-1C). Their arrangement forms a C4 zinc finger that resembles a C-terminal type 
zinc necklace motif (40). A large insertion between positions C1 (Cys319) and C2 
(Cys349), which includes His332, appears to extend the stabilizing effect of the zinc 
finger throughout much of domain II. A fifth cysteine (Cys344) is located near the zinc 
ion but does not coordinate with it, consistent with other zinc necklace motifs that 
have been described (40) and with previous findings showing that a Cys344 to alanine 
mutation had no effect on catalytic activity of PLP2 (16). Three of the cysteines (Cys 
319, 349, and 354) are fully conserved in arteriviruses, and mutational analysis of 
these residues and Cys356 demonstrated zinc binding to be essential for catalytic 
activity (16). Given its distance from the active site however (~25 Å) (figure Iv-1B), 
the zinc finger appears to play a structural role as opposed to participating in cataly-
sis. Expression of PLP2 in E. coli grown in the absence of zinc (M9 medium) yielded 
insoluble protein, supporting the idea that the zinc finger is structural and is likely 
required for correct folding of the protease.
Consistent with OTU DUBs and papain-like cysteine proteases in general, the PLP2 
active site contains a catalytic cysteine nucleophile (Cys270) and histidine (His332) 
residue, along with an asparagine (Asn263) that hydrogen bonds with the imidazole 


























































































Figure iV-1: Structure of the eaV plp2-Ub complex and superposition with yeast OtU1 and CCHFV 
OTU. A) Structure of EAV PLP2 (blue) bound to Ub (orange) showing the two-domain fold. B) 90 
degree rotation of complex shown in panel A. C) Electron density for the C4 zinc fi nger motif. Blue 
density is a maximum-likelihood weighted 2Fo-Fc map contoured at 1.0σ. Green density about the 
zinc atom (grey) is a Fo-Fc omit map contoured at 5.0σ. D) The catalytic triad of the EAV PLP2 active 
site. Blue density is a maximum-likelihood weighted 2Fo-Fc map contoured at 1.0σ. The cysteine 
nucleophile (Cys270) is covalently linked to Ub via the 3NC linker, which replaces Gly76 of Ub. 
Asn263, which orients the imidazole ring of His332, occurs in two alternate conformations. e) Su-
perposition of EAV PLP2 (blue), CCHFV OTU (cyan) and yeast OTU1 (red). PLP2 shares a conserved 
core of two central helices and a four-stranded beta sheet with CCHFV OTU and yeast OTU1. Topol-
ogy diagrams for EAV PLP2, CCHFV OTU and yeast OTU1 are shown in panels F, g, and H, respective-
ly. The region that is conserved amongst the enzymes is outlined (dashed box). Structural images 
were prepared using PyMOL (89).
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coupled to the C-terminus of Ub via the 3-propylamine (3CN) modification, mimick-
ing the acyl-enzyme intermediate step of the catalytic reaction and confirming the 
identity of Cys270 as the catalytic nucleophile.
Fold analysis of the PLP2 structure using the DALI server (41) revealed that its clos-
est structural homologues indeed belong to the OTU superfamily of DUBs (29, 42). 
The most significant matches were to yeast Otu1 (38) (Z-score: 5.1) and the viral OTU 
protease from CCHFV (43-45) (Z-score: 4.6) (figure Iv-1e), followed by Otubain1 from 
human (46) and Caenorhabditis elegans (47) (Z-scores: 4.1 and 4.0, respectively), and 
the OTU-domain of human DUBA (48) (Z-score: 3.9). The sequence identity of the PLP2 
regions that aligned with these OTU proteases was low (ranging from 9% for yeast 
Otu1 to 21% for human Otubain1); however, they accounted for ~60% of the total 
PLP2 structure and superposed well with the equivalent regions in the above proteins, 
with an average rmsd of ~2.8 Å. The greatest structural similarity between PLP2 and 
members of the OTU superfamily occurs at the active site and adjoining channel that 
binds the C-terminal RLRGG-tail of Ub.
the plp2 zinc finger motif plays a central role in Ub binding. Arterivirus PLP2 and 
nairovirus OTU enzymes differ from eukaryotic OTU DUBs in that they also remove the 
Ub-like antiviral protein Interferon Stimulated Gene 15 (ISG15) from target proteins, 
a process also known as deISGylation (18, 49). ISG15 conjugation has been postulated 
to interfere with proper viral protein function, possibly through steric hindrance, 
although the exact mechanism underlying its antiviral activity is unknown (50). For 
CCHFV OTU, cross-reactivity with ISG15 arises primarily from a unique b-hairpin on the 
Ub-binding surface. The hairpin modifies the surface so that the viral enzyme binds 
the b-grasp folds of Ub and the C-terminal Ub-like domain of ISG15 in an orientation 
that is rotated nearly 75° with respect to that observed for Ub bound to a represen-
tative eukaryotic OTU DUB from yeast (Otu1) (43, 44). Surprisingly, the b-hairpin is 
absent in EAV PLP2 and replaced by helix a3 of the zinc finger motif (figure Iv-2A). 
However, in keeping with the role of the b-hairpin in CCHFV OTU, residues of helix a3 
bind to the hydrophobic ‘Ile44 patch’ of Ub, a site commonly targeted by Ub-binding 
proteins (51), and they also assist in positioning Ub in a rotated manner equivalent to 
that observed for CCHFV OTU (figure Iv-2B and C).
Structure-guided decoupling of PLP2 deubiquitinase and polyprotein cleavage 
activities. Given the distance of helix a3 from the PLP2 active site (figure Iv-1B), we 
hypothesized that mutations could be introduced into this region of the Ub-binding 
surface that would selectively disrupt PLP2 DUB activity without affecting EAV poly-
protein cleavage at the putative nsp2|nsp3 junction (RLIGG¯). While this sequence 
closely resembles the C-terminal tail of Ub (RLRGG¯), we postulated that the nsp2 
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sequence immediately upstream of the nsp2|nsp3 junction does not adopt a Ub-like 
fold and that the majority of the PLP2 Ub-binding surface is therefore not required 
for its cleavage. To test our hypothesis, we used the crystal structure to select three 
positions within the PLP2 Ub-binding surface (Thr312, Ile313, and Ile353), and en-
gineered a panel of (combined) mutations (figures Iv-2B and C). Ile353 is located at 
the C-terminal end of helix a3 next to C3 (Cys354) of the zinc fi nger motif. It projects 
directly into the Ile44 patch of Ub where it makes extensive van der Waals interactions 
with Ile44, Val70, and Leu8. Given that Ile353 is located on the Ub-binding surface, 
we aimed to disrupt Ub binding by introducing various other residues at this position, 
including large bulky residues such as arginine and tryptophan. Thr312 and Ile313 are 
located closer to the active site, where they make additional hydrophobic interactions 
with Leu8, Leu71, and Leu73 of Ub. In an attempt to further disrupt the interaction 
between PLP2 and Ub, the mutations Thr312Ala and Ile313Val were also combined 
with changes at position Ile353. Given the close proximity of Ile313 to Leu73 of the 
RLRGG motif of Ub, mutation to valine was chosen to minimize adverse eff ects on 
nsp2|nsp3 cleavage.
Before proceeding to infection experiments with mutant viruses, we used ectopic 
expression of PLP2 and an in vitro enzymatic assay to characterize the eff ect of vari-
ous mutations at the positions described above on polyprotein processing and DUB 































figure Iv-2: Ub-binding surface of eAv PLP2. A) Superposition of EAV PLP2 (blue) and CCHFV OTU 
(cyan) in complex with Ub. Both enzymes grasp Ub in a similar orientation, with the C4 zinc fi nger 
motif of EAV PLP2 replacing the b-hairpin of CCHFV OTU. B) EAV PLP2 (blue) bound to Ub (or-
ange), showing the 612 Å2 Ub-binding surface. Residues targeted for mutational analysis to disrupt 
DUB activity are indicated by arrows. C) Close-up of the EAV PLP2-Ub binding surface. EAV PLP2 
residue Ile353 forms van der Waals interactions with Ile44, Leu8, and Val70 of Ub, whereas resi-
dues Thr312 and Ile313 interact with a hydrophobic patch on Ub (formed by residues Leu8, Val70, 
Leu71, and Ile73) closer to the active site of PLP2.
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encoding a self-cleaving nsp2-3 polyprotein carrying an N-terminal HA-tag. Upon 
expression of nsp2-3 in HEK293T cells, wild-type PLP2 mediated efficient cleavage 
of the nsp2|nsp3 junction (figure Iv-3A). As expected, a PLP2 active site mutant 
(C270A/H332A) did not display any processing of the nsp2|nsp3 site and only the 
nsp2-3 precursor was detected. Seven single-site mutants, in which the Ub-binding 
surface was targeted by replacement of Thr312 or Ile353, displayed wild-type levels 

































































































































































1 2 3 4 5 6 7 1098
figure Iv-3: Decoupling of the polyprotein processing and DUB activities of eAv PLP2. A) HEK293T 
cells were transfected with plasmids encoding nsp2-3 containing wild-type or mutant PLP2. After 
16 h at 37°C, cells were lysed and results were analyzed by Western blot. Proteolytic processing 
of the nsp2|nsp3 junction by wild-type PLP2 resulted in the release of HA-tagged nsp2 from the 
nsp2-3 precursor. B) HEK293T cells were transfected with a combination of plasmids encoding 
nsp2-3 containing wild-type or mutant PLP2 and FLAG-Ub. Expression of FLAG-Ub leads to FLAG-
tagged ubiquitination of a wide range of cellular proteins, which can be visualized on Western blot 
using an anti-FLAG antibody. Abbreviation: Ub, ubiquitin.
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notably affected. In addition, combinations of mutations at positions Thr312, Ile313, 
and Ile353 were tested, with similar results (figure Iv-3A). Longer exposure times did 
reveal some nsp2-3 precursor, even in the case of wild-type PLP2, but this amount 
only marginally increased when two or three mutations were combined (figure Iv-4B).
Next, we assayed the effect of these mutations on PLP2 DUB activity by transfecting 
mammalian cells with plasmids encoding FLAG-tagged Ub and nsp2-3 carrying wild-
type or mutant PLP2. FLAG-tagged ubiquitination of a wide range of cellular targets 
could be visualized by Western blot analysis using an anti-FLAG antibody (figure Iv-
3B). As expected, expression of wild-type PLP2 strongly decreased the accumulation 
of Ub-conjugates, while expression of the active site mutant (C270A/H332A) had a 
negligible effect. figure Iv-3B presents the results obtained with a selection of PLP2 
Ub-binding surface mutants with the most pronounced effect on DUB activity, some 
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figure Iv-4: PLP2 Ub-binding surface mutations attenuate inhibition of IfN-β promoter activa-
tion. A) Luciferase-based reporter assay to assess the effect of various Ub-binding surface muta-
tions on the inhibition of IFN-β promoter activity by PLP2. HEK293T cells were transfected with a 
combination of plasmids encoding firefly luciferase under control of the IFN-β promoter, renilla 
luciferase, RIG-I(2CARD), and nsp2-3 containing wild-type or mutant PLP2. Results were obtained in 
three independent experiments. Error bars represent standard deviations and p-values are relative 
to wild-type. B) Lysates obtained in each of the three experiments used for panel A were mixed in 
a 1:1:1 ratio and analyzed by Western blot for the expression of nsp2-3.
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surface mutations had only minor effects on the deISGylating activity of PLP2 (figure 
Iv-S1).
To corroborate our findings from the expression system showing that PLP2 DUB 
activity could be selectively removed without disturbing nsp2|nsp3 cleavage, an in 
vitro activity assay of recombinant PLP2 produced in E. coli was performed using the 
fluorescently labeled substrates Ub-aminomethylcoumarin (Ub-AMC) or RLRGG-AMC, 
representing the C-terminal peptide motif of Ub. By comparing the activity of PLP2 
mutants against Ub-AMC (which requires the Ub-binding surface) versus their activity 
against RLRGG-AMC (which binds to the active site region only), PLP2 mutants with a 
selective reduction in DUB activity could be identified. Indeed, compared to wild-type 
enzyme, mutants I353W and I353R exhibited ~10- and 20-fold reductions in specific-
ity (kcat/Km) toward Ub, respectively; in contrast, their activity towards RLRGG-AMC was 
unaltered (Table Iv-1). Expression of PLP2 containing additional mutations at Thr312 
and Ile313 yielded insoluble protein in E. coli, preventing analysis of these mutants. 
Nevertheless, the results of the in vitro activity assay further confirmed the successful 
decoupling of the polyprotein processing and DUB activities of EAV PLP2 by specifi-
cally targeting key residues of the Ub-binding surface.
The ability of PLP2 to suppress innate immune signalling depends on its DUB activ-
ity. The effect of the various PLP2 Ub-binding surface mutations on innate immune 
signalling was initially assessed in the context of ectopic nsp2-3 expression using a lu-
ciferase-based IFN-β promoter activity assay. For this, HEK293T cells were transfected 
with a combination of plasmids encoding firefly luciferase under control of the IFN-β 
promoter, renilla luciferase as an endogenous control, constitutively active RIG-I(2CARD) 
to induce innate immune signalling (52), and EAV nsp2-3 containing either wild-type 
or mutant PLP2. In this assay, reporter gene expression was reduced to approximately 
20% upon co-expression of wild-type PLP2, while 80% of the level of the untreated 
control was retained upon expression of the PLP2 active site mutant (C270A/H332A) 
(figure Iv-4A). Compared to wild-type PLP2, all mutants included in figure Iv-4A were 
significantly impaired in their inhibitory activity (p<0.01), with mutants I353R, I353W, 




Wild-type 45 ± 11 M-1s-1 17000 ± 4000 M-1s-1
I353r 65 ± 7 M-1s-1 413 ± 177 M-1s-1
i353W 155 ± 12 M-1s-1 1741 ± 850 M-1s-1
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T312A/I313V/I353R, and T312A/I313V/I353W displaying inhibition levels similar to 
that of the active site mutant (p>0.05). Western blot analysis confirmed equal expres-
sion of wild-type and mutant nsp2-3 (figure Iv-4B). These results demonstrated that, 
at least in the context of the nsp2-3 expression system, the selective removal of PLP2 
DUB activity significantly disrupted its ability to suppress IFN-β promoter activity.
Arteriviruses lacking PLP2 DUB activity elicit an enhanced host innate immune 
response. Having identified mutations in PLP2 that reduce its ability to suppress 
Ub-mediated innate immune signalling (figure Iv-4A) without adversely affecting 
nsp2|nsp3 cleavage (figure Iv-3A), we were in a position to directly evaluate the 
importance of PLP2 DUB activity for immune evasion during arterivirus infection. 
The six (combinations of) mutations used in figures Iv-3B and 4 were introduced into 
an EAV full-length cDNA clone and mutant viruses were launched by electropora-
tion of in vitro transcribed RNA into BHK-21 cells. Immunofluorescence microscopy 
subsequently confirmed expression of both nsp2 and the structural nucleocapsid (N) 
protein, followed by virus spread to initially untransfected cells. This indicated that 
viruses carrying these (combinations of) mutations were replication competent.
We next focused on the two mutants showing the greatest decrease in inhibitory 
activity in the IFN-β promoter activity assay: I353R and T312A/I313V/I353R (figure 
Iv-4A). We first characterized the replication kinetics of these mutants in a time-
course experiment in primary equine lung fibroblasts (ELFs), which are derived from 
the natural host species of EAV and are likely to maintain an intact innate immune 
response. ELFs were infected with wild-type or mutant EAV at a multiplicity of infec-
tion (MOI) of 0.5 or 5. The first-cycle replication kinetics as determined by quantita-
tive reverse transcriptase PCR (qRT-PCR) measurement of viral genome RNA levels 
did not notably differ between wild-type and mutant EAV (figures Iv-5A and B). In 
addition, viral titers in cell-culture supernatants harvested from infected ELFs at 24 
h p.i. revealed no significant difference between wild-type and mutant EAV (figure 
Iv-5C). Finally, immunofluorescence microscopy of ELFs infected with MOI 5 revealed 
expression of nsp2 from 6 h p.i. onward, and by 9 h p.i. also expression of N protein 
could be seen in all cells for both wild-type and mutant EAV (figure Iv-S2). These 
results demonstrated that the replication kinetics of the PLP2 Ub-binding surface 
mutants and wild-type control were essentially the same, in line with our previous 
conclusion that cleavage of the nsp2|nsp3 site is hardly affected by these mutations. 
At the same time, Western blot analysis showed that, compared to wild-type EAV, the 
DUB activity of both mutants was severely impaired during infection (figure Iv-5D).
Subsequently, we used qRT-PCR to measure the levels of mRNAs encoding IFN-β, the 
IFN-stimulated protein MX1, and the pro-inflammatory cytokine IL8 and investigated 
the effect of mutations I353R and T312A/I313V/I353R on innate immune signalling 
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during infection of ELFs. Initially, we infected ELFs with wild-type or mutant EAV at 
MOI 5, but in this set-up IFN-β mRNA levels remained below the detection limit at 
all time-points analyzed (from 3 to 12 h p.i.), suggesting that the innate immune 
response triggered by EAV upon initial infection is very limited. Therefore, we next 
infected ELFs with wild-type or mutant EAV at MOI 0.25, resulting in infection of about 
20% of cells. We hypothesized that this would allow for IFN-β-mediated priming of 
uninfected cells as a result of paracrine signalling from cells infected during the first 
round. The expression of IFN-stimulated genes would then result in a more potent 
response during the second cycle of infection. Indeed, following such a low MOI infec-
tion with wild-type EAV, low but detectable levels of IFN-β mRNA were induced by 20 
h p.i. (figure Iv-6A). Interestingly, at both 20 and 24 h p.i., cells infected with either 
mutant showed significantly increased levels of IFN-β mRNA compared to wild-type 
virus-infected cells (p<0.05), with mutant T312A/I313V/I353R showing the most pro-
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figure Iv-5: eAv PLP2 mutants display similar replication kinetics as wild-type virus. Equine lung 
fibroblasts were infected with wild-type or mutant EAV at MOI 0.5 (A) or 5 (B, C, D). A and B) At 
the indicated time-points, total RNA was isolated for qRT-PCR measurement of EAV genomic RNA 
levels. Results, which were obtained in three independent experiments, were analyzed using the 
standard curve method and normalized against the relative quantities of GAPDH and beta actin 
mRNA. Error bars represent standard deviations. C) At 24 h p.i., cell-culture supernatants were har-
vested and virus titers were determined by plaque assay on ELFs. Results were obtained in three 
independent experiments and error bars represent standard deviations. D) Cells were lysed at 10 
h p.i. and total ubiquitination was assessed by Western blot analysis. Abbreviations: Ub, ubiquitin; 
N, nucleocapsid; hpi, hours post infection; AU, arbitrary units; pfu, plaque forming units.
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wild-type and mutant EAV-infected cells at 24 h p.i. (figure Iv-6B). In contrast, at 20 
and 24 h p.i., no significant difference in the levels of IL8 mRNA was observed upon 
infection with wild-type or mutant EAV (figure Iv-6C). Equally efficient replication of 
wild-type and mutant EAV was corroborated by comparing viral genome RNA levels, 
for which no significant differences were measured (figure Iv-6D). In summary, these 
data show that the PLP2 DUB function is indeed involved in the inhibition of innate 
immune signalling during EAV infection in primary equine cells and that it is possible 










figure Iv-6: eAv lacking PLP2 DUB activity elicits an enhanced innate immune response. Equine 
lung fibroblasts were infected with EAV encoding wild-type or mutant PLP2 at MOI 0.25 and at 20 
and 24 h p.i. RNA was isolated for qRT-PCR measurement of the levels of A) IFN-β mRNA, B) MX1 
mRNA, C) IL8 mRNA, or D) EAV genomic RNA. Results, which were obtained in three independent 
experiments, were analyzed using the standard curve method and normalized against the relative 
quantities of GAPDH and beta actin mRNA. Error bars represent standard deviation and asterisks 
indicate a significant difference relative to wild-type at the same time-point. * p<0.05; ** p<0.01. 
Abbreviations: AU, arbitrary units; hpi, hours post infection.




Due to the widespread adoption of polyprotein synthesis and cleavage as a genome 
expression strategy in +RNA viruses and retroviruses, proteases have become key 
regulatory enzymes of the replication of many important human and animal patho-
gens. Moreover, virus-host co-evolution has offered ample opportunity to develop 
additional protease functions, which promote virus replication by targeting cellular 
rather than viral substrates. Since both functions depend on the same protease active 
site, it has been intrinsically difficult to study them independently during virus infec-
tion, mainly because protease inactivation per se is generally incompatible with virus 
viability. The independent assessment of the cleavage of host cell targets requires its 
decoupling from viral polyprotein processing, which to date has only been achieved 
for the poliovirus 2A protease (53-56). Our present work on EAV PLP2 illustrates how 
structure-guided mutagenesis can be applied to specifically disrupt the interaction of 
a viral protease with its cellular substrate. The identification of a Ub-binding surface 
that is distant from the PLP2 active site, allowed us to specifically inactivate the DUB 
function of the enzyme and - ultimately - probe its relevance in the context of the 
infected cell. Compared to wild-type EAV, viruses that lack PLP2 DUB activity induced 
a significantly enhanced innate immune response in primary equine cells, while dis-
playing essentially identical replication kinetics, thus demonstrating the importance 
of this activity in the evasion of innate immune signalling by arteriviruses.
Analysis of the EAV PLP2 fold using the DALI server identified members of the OTU 
superfamily as its closest structural relatives, supporting its classification as a mem-
ber of this superfamily. However, the limited sequence similarity between arterivirus 
PLP2 and other OTU proteases was previously rated as statistically insignificant (29) 
and our structure reveals topological features that deviate considerably from a typical 
OTU-fold. Domain I of known OTU-domain structures contains a pair of solvent exposed 
α-helices that pack perpendicularly against two internal helices (figures Iv-1e, G, and 
H). While the internal helices are conserved in PLP2 (a1 and a2), the solvent exposed 
helices have been replaced by a single helix (a4) that packs parallel to helices a1 and 
a2 to form a three-helix bundle that comprises most of domain I (figures Iv-1e and 
f). This topology subtly resembles the L domain of papain (57) and markedly reduces 
the size of domain I and its contribution to Ub binding relative to other OTU DUBs 
that have been determined in complex with Ub (38, 43-45, 48). The compact fold of 
arterivirus PLP2 may be required for its function in replicase polyprotein maturation, 
an activity that is not shared by cellular OTU DUBs or the OTU protease of CCHFV (58).
A more striking deviation from known OTU-domain structures is the presence of the 
zinc finger in PLP2 domain II (figure Iv-1C) and its critical importance for catalytic 
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activity (16). Ub-binding domains that contain zinc fingers exist within a number of 
OTU DUBs, but none comprise part of the distal Ub-binding site within the OTU-fold. 
Instead, they exist as accessory domains that are connected to the OTU-domain 
through flexible linkers (42), where, in the case of A20, they appear to provide ad-
ditional polyubiquitin linkage specificity and possibly target the protein to specific 
signalling complexes (59). For PLP2, the zinc finger is an integral part of the OTU-fold 
and it plays a central role in binding and positioning the distal Ub molecule on the 
protease surface (figure Iv-2A). Currently, OTU DUBs are grouped into three sub-
classes based on their structural characteristics: the Otubains, the A20-like OTU’s, and 
the OTU’s (42). Given the unique features of EAV PLP2, we propose that arterivirus 
PLP2 enzymes represent a new, fourth subclass of zinc-dependent OTU’s.
We believe that the structure-guided inactivation of the PLP2 DUB function may con-
tribute to the engineering of improved modified live vaccines (MLVs) for arteriviruses. 
Although generally effective strategies for the prevention and control of equine viral 
arteritis have been developed, several field strains are poorly neutralized by antibod-
ies from horses vaccinated with the ARVAC vaccine strain (60) and EAV outbreaks 
continue to cause significant disruptions of the horse breeding industry (61). While 
our current work focuses on EAV PLP2, the corresponding protease of PRRSV has been 
shown to have very similar immune evasive properties in a variety of experimental 
settings (18, 30, 31). Since its discovery in the late 1980s, PRRSV has spread around 
the globe and now ranks among the most important swine pathogens. PRRSV infec-
tion causes annual losses of approximately $664 million in the United States alone 
(62) and the emergence of highly virulent strains in China is of particular concern 
(63-65). Moreover, the virus has proven difficult to control and it has been suggested 
to counteract innate immunity, thus undermining the overall immune response and 
viral clearance in infected animals (66). Consequently, inactivation of the PLP2 DUB 
function may be an important step in the design of improved vaccine candidates. 
These should induce a more robust innate response and, therefore, also a more potent 
adaptive immune reaction than that achieved with the currently available MLVs. Mul-
tiple studies have suggested that additional arterivirus nsps may contribute to innate 
immune evasion (67, 68) and, consequently, vaccine efficacy may be further bolstered 
by targeting a combination of such functions. As in this study, detailed insight into the 
molecular interactions of these other arterivirus proteins and their host ligands will 
likely be required to achieve this goal without crippling the basic replication capacity 
of the virus. In cell culture, our most promising EAV PLP2 mutant, carrying mutations 
T312A/I313V/I353R, induced an approximately 8-fold increase in IFN-β mRNA levels 
compared to wild-type virus. Although we were unable to investigate this effect in 
vivo due to the lack of a small animal model for EAV infection, the disabling of immune 
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evasion mechanisms can result in significant virus attenuation. One striking example 
is the modification of the immune evasive influenza virus NS1 protein, which yielded 
attenuated viruses that are promising vaccine candidates (69).
In addition to opening new possibilities for vaccine development, the mutants de-
scribed in this paper should provide excellent tools for identifying the cellular targets 
of PLP2, which to date remain unknown. Although Western blot analysis suggests that 
PLP2 acts in a very promiscuous fashion, causing a general decrease in the levels of 
ubiquitinated host proteins (figure Iv-5D), our qRT-PCR results support the idea that 
there is at least some degree of specificity in the inhibition of innate immune signal-
ling, as evidenced by the PLP2-mediated inhibition of IFN-β mRNA transcription, but 
not IL8 mRNA transcription (figures Iv-6A, C). Since the expression of IFN-β depends 
largely on the activation of the transcription factor IRF3 and expression of pro-in-
flammatory cytokines like IL8 does not (27), our findings suggest that PLP2-mediated 
inhibition of innate immunity is primarily directed at IRF3-dependent signalling. 
Future experiments will aim at elucidating the target specificity of arterivirus PLP2.
Arteriviruses are not the only virus family harboring proteases with multiple substrate 
specificities. Especially interesting in this respect are the distantly related coronavi-
ruses (CoV), which infect a wide variety of species, including livestock, companion 
animals, bats, and humans. Six CoV species have now been found to infect humans, 
causing symptoms ranging from mild respiratory illness to acute respiratory syn-
dromes, as in the case of SARS-CoV (70) and the recently emerged HCoV-EMC/2012 
(71, 72). The replicase polyproteins of coronaviruses harbor one or two papain-like 
proteases (PLpro’s) that participate in polyprotein maturation and presumably 
promote evasion of innate immunity by means of their DUB activity (32, 34, 37, 73). 
Although the CoV PLpro’s belong to the Ub-specific protease (USP) (74, 75) rather 
than the OTU superfamily of DUBs, it is likely that also coronavirus PLpro substrate 
specificities can be decoupled using a similar structure-guided approach. Here we 
have illustrated how structure-guided mutagenesis of such a viral protease may be 
used to enhance the innate immune response to infection, a strategy that may be ap-




Plasmids, cells, and antibodies
The following mammalian expression plasmids were described elsewhere: pLuc-IFN-β 
(76), pRL-TK (Promega), pEBG-RIG-I(2CARD) (52), pcDNA-eGFP (31), pCMV-FLAG-Ub (77), 
pCAGGS-HA-mUbE1L, pCMV2-FLAG-UbcM8, and pCAGGS-V5-hISG15 (78).
HEK293T cells were cultured in Dulbecco’s modified Eagle medium (Lonza) supple-
mented with 10% fetal bovine serum (FBS), and 2 mM L-glutamine. BHK-21 cells were 
cultured in Glasgow minimum essential medium (Lonza) supplemented with 5% FBS, 
10% tryptose phosphate broth, and 10 mM HEPES (pH 7.4). Primary equine lung fibro-
blasts (ELF) were cultured in minimum essential medium (Lonza) supplemented with 
10% FBS and grown on collagen-coated plastics. All culture media contained 100 U/
ml of penicillin and 100 mg/ml of streptomycin.
The following commercially available antibodies were used: α-HA (ab18181; Ab-
cam), α-FLAG (F3165; Sigma-Aldrich), α-GST (sc459; Santa Cruz), α-ubiquitin (#3933; 
Cell Signaling Technology), α-β-actin (A5316; Sigma-Aldrich), donkey-α-mouse-Cy3 
(715-165-151; Jackson ImmunoResearch), and goat-α-rabbit-AL488 (A-11008; Invi-
trogen). The following antibodies were described elsewhere: α-EAV N protein (clone 
3E2) (79) and α-ISG15 (clone 2.1) (80). Rabbit antiserum recognizing the C-terminus 
of EAV nsp2 was raised using a mix of two peptides (ASTVDPHSFDQKK and GDFLKLNP-
GFRLIGG) and rabbit antiserum recognizing GFP was raised using recombinant protein 
purified from Escherichia coli.
PLP2 plasmids
For bacterial expression of EAV PLP2, a cDNA fragment encoding residues 261-392 of 
EAV pp1a and an in-frame C-terminal His6 purification tag was inserted downstream 
of a Ub fusion partner in the pASK3 vector (81), yielding plasmid pASK3-ePLP2. A 
mammalian expression construct encoding an EAV nsp2-3 polyprotein was made by 
cloning residues 261-1064 of EAV pp1a in-frame with an N-terminal HA tag in the 
pcDNA3.1 vector (Invitrogen). All mutants were engineered by site-directed muta-
genesis using Pfu DNA polymerase (Fermentas). Primer sequences are available upon 
request. All constructs were verified by sequence analysis.
purification and crystallization of eaV plp2 bound to Ub
E. coli BL21-Gold(DE3) cells were transformed with pASK3-ePLP2 and cultured to an 
optical density (OD600) of 0.7 in LB medium at 37°C. The culture was then supplemented 
with 200 ng/ml of anhydrous tetracycline and incubated for 3 h at 28°C with shaking 
to induce expression of the Ub-PLP2-His6 fusion protein. The cells were pelleted and 
resuspended in ice-cold lysis buffer (20 mM MES pH 7, 500 mM NaCl, 10% glycerol, 5 
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mM imidazole pH 7.4, 0.5 mM TCEP) and lysed using a French pressure cell (AMECO). 
The lysate was clarified by centrifugation and loaded onto a Ni-NTA column (Qiagen) 
pre-equilibrated with lysis buffer. After washing with lysis buffer supplemented with 
15 mM imidazole, recombinant PLP2 was eluted from the column using an equilibra-
tion buffer supplemented with 150 mM imidazole and exchanged into 50 mM Tris, pH 
8.0, 300 mM NaCl and 5 mM DTT before storing at 4 °C. The endogenous DUB activity 
of PLP2 resulted in the efficient removal of the N-terminal Ub-tag from the fusion 
protein during expression in E. coli; therefore, affinity chromatography yielded highly 
pure PLP2 carrying a C-terminal His6 purification tag only.
The mechanism-based suicide inhibitor Ub(1−75)–3–bromopropylamine (Ub–3Br) was 
prepared according to Messick et al (38) and Borodovsky et al (39), as described by 
James et al (43). Ub-3Br was covalently bound to purified PLP2 by gently mixing the 
proteins in a 3:2 molar ratio for one hour at 37°C. The resulting PLP2-Ub complex 
was purified by gel filtration (Superdex 75) followed by anion exchange (Source 15Q) 
chromatography and then exchanged into 20 mM Tris, pH 8.0, 50 mM NaCl before 
concentrating to 10 mg/ml and storing at 4°C.
The PLP2-Ub complex was crystallized by hanging-drop vapor diffusion at 10 mg/
ml in mother liquor consisting of 100 mM MES pH 6.2, 18% PEG 20,000. Crystals were 
flash-cooled and stored in liquid nitrogen after sweeping them through mother liquor 
supplemented with 20% glycerol.
X-ray data collection and crystal structure determination
X-ray diffraction data for a multiwavelength anomalous dispersion (MAD) experiment 
were collected at the Canadian Light Source (beam line 08ID-1). Data were collected 
at three different wavelengths over the absorption edge of zinc from a single crystal 
of the PLP2-Ub complex held at 100K in a N2 (g) stream. The data were processed 
using MOSFLM and SCALA (82) and structure factor phases were determined using 
phenix.autosol (83). Initial phases generated by SOLVE were improved by density 
modification using RESOLVE within the PHENIX package. After reserving a random 
subset of reflections for cross-validation using the free R-factor (84), a model was 
built using phenix.autobuild (83) and manually completed and refined using COOT 
(85) and phenix.refine (83). Crystallographic data and model refinement statistics are 
summarized in Table Iv-S1.
In vitro enzymatic assays
The DUB activity of PLP2 (wild type and mutants) was assayed using  7-amino-4-
methylcoumarin (AMC) labelled versions of Ub (Ub-AMC) (Boston Biochem) and the 
C-terminal peptide motif of Ub, RLRGG-AMC (Enzo Life Sciences). The enzymes cleave 
the AMC label causing a significant increase in the fluorescence quantum yield of the 
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dye. All reactions were performed in 20 mM tris-Cl buffer at pH 8 and 100 mM NaCl. 
Time-dependent fluorescence traces were collected by a Fluorolog-3 Horiba Jobin 
Yvon fluorimeter. The monochromators were set to 360 nm (excitation) and to 460 
nm (emission). The slits were set between 1-3 nm bandpass depending on substrate 
concentration. Enzyme activities in all mutants were characterized by the specificity 
constant 
kcat
Km . At substrate concentrations significantly smaller than Km the formation 
of product follows pseudo-first-order kinetics, therefore the temporal evolution of 
product fluorescence F follows the equation:
F=F∞ 1−exp − 
kcat [E]
Km  t   +F0  (1)
Where F∞ is the fluorescence when all AMC is liberated, F0 is the background fluo-
rescence, [E] is the total enzyme concentration and t is the time elapsed. From fitting 
the fluorescence time traces to equation 1, all parameters including the specificity 
constant kcatKm  are obtained. Our assays indicate that PLP2 exhibits pseudo-first-order 
kinetics for Ub-AMC at concentrations less than 0.2 μM and for RLRGG-AMC at concen-
trations less than 150 μM.
Cell culture-based assays
To assess nsp2|3 cleavage by the various PLP2 mutants, HEK293T cells were grown 
to 80% confluence in 10 cm2 wells and transfected using CaPO4 with 4 μg plasmid 
DNA encoding nsp2-3 containing wild-type or mutant PLP2. After 16 h at 37°C, cells 
were lysed in 2x Laemmli Sample Buffer (2xLSB; 250 mM Tris, 2% SDS, 20% glycerol, 
0.01% bromophenol blue, 2 mM DTT, pH 6.8). Samples were loaded on SDS-polyacryl-
amide gels, which were blotted to Hybond-P polyvinylidene difluoride membranes 
(GE Healthcare) using a semi-dry transfer cell (Bio-Rad). After incubation with the 
appropriate antibodies, protein bands were visualized using the Amersham ECL Plus 
detection reagent (GE Healthcare).
To assess the DUB activity of the various PLP2 mutants, HEK293T cells were grown 
to 80% confluence in 4 cm2 wells and transfected using CaPO4 with a combination of 
plasmids encoding FLAG-Ub (0.25 μg), GFP (0.25 μg), and nsp2-3 containing wild-type 
or mutant PLP2 (1.5 μg). After 16 h at 37°C, cells were lysed in 2xLSB and analyzed by 
SDS-PAGE as described above.
To assess the deISGylation activity of the various mutants, HEK293T cells were 
grown to 80% confluence in 12-well plates and transfected using CaPO4 with a com-
bination of plasmids encoding hISG15 (0.75 μg), HA-mUbE1L (0.25 μg), FLAG-UbcM8 
(0.25 μg), GFP (0.25 μg) and wild-type or mutant nsp2-3 (0.5 μg). After 48 h at 37°C, 
cells were lysed in 2xLSB and analyzed by SDS-PAGE as described above.
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Luciferase-based IfN-β promoter activity assay
HEK293T cells, grown to 80% confluence in 2 cm2 wells, were transfected in qua-
druplicate with a combination of plasmids encoding firefly luciferase under control 
of the IFN-β promoter (50 ng), renilla luciferase (5 ng), RIG-I(2CARD) (25 ng) and nsp2-3 
containing wild-type or mutant PLP2 (500 ng) using Lipofectamine2000 (Invitrogen). 
The total amount of DNA used for transfection was adjusted to 1 μg per well by the ad-
dition of the appropriate amount of empty vector. After 12 h at 37°C, three out of four 
wells were lysed in 100 μl passive lysis buffer (Promega), and samples were assayed 
for luciferase activity using the Dual-Luciferase reporter assay system (Promega) on a 
Mithras LB 940 multimode reader (Berthold Technologies). The remaining wells from 
each of three independent experiments were lysed in 2xLSB, mixed in a 1:1:1 ratio 
and analyzed by SDS-PAGE as described above. Using SPSS Statistics software, an 
unpaired two-tailed Student’s t test was used to determine the statistical significance 
of the results, which were obtained in three independent experiments. P values <0.05 
were considered to be statistically significant.
reverse genetics
Mutations in the EAV PLP2-coding sequence were engineered in an appropriate 
shuttle vector and subsequently transferred to pEAN551/AB, a derivative of EAV full-
length cDNA clone pEAN551 carrying additional (translationally silent) AflII and BspEI 
restriction sites (17, 86). The virus derived from pEAN551/AB was used as wild-type 
control in all experiments. All constructs were verified by sequence analysis.
In vitro RNA transcription from XhoI-linearized wild-type or mutant EAV full-length 
cDNA clones was performed using the mMESSAGE mMACHINE T7 Kit (Ambion). Five μg 
of full-length EAV RNA was electroporated into 5.0*106 BHK-21 cells using the Amaxa 
Cell Line Nucleofector Kit T and the program T-020 of the Amaxa Nucleofector (Lonza) 
according to the manufacturer’s instructions. Cells were incubated at 39.5°C and 
virus-containing supernatants were harvested at 24 h post transfection. Titers were 
determined by plaque assay on primary equine lung fibroblasts (ELFs) essentially as 
described before (87).
To verify the presence of the correct mutations, RNA was isolated from virus-
containing supernatants using the QIAamp Viral RNA Mini Kit (Qiagen) and converted 
to cDNA using RevertAid H Minus reverse transcriptase (Fermentas) and random 
hexameric primers. The region of PLP2 encoding the mutations was subsequently PCR 
amplified using Pfu DNA polymerase (Fermentas) and sequenced.
immunofluorescence microscopy
Confluent ELFs were infected with wild-type or mutant EAV at a multiplicity of infec-
tion (MOI) of 5 and incubated at 37°C. At 3, 6, and 9 h post infection (p.i.), cells were 
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fixed with 3% paraformaldehyde in phosphate buffered saline (PBS; pH 7.4). Follow-
ing permeabilization in 0.2% Triton X-100 in PBS, EAV nsp2 and N protein were visual-
ized by indirect immunofluorescence microscopy using the appropriate antibodies. 
Specimens were examined with a Zeiss Axioskop 2 fluorescence microscope with an 
Axiocam HRc camera and Zeiss Axiovision 4.2 software.
quantitative reverse transcriptase PCr
Confluent ELFs were infected with wild-type or mutant EAV at MOI 5, 0.5, or 0.25 and 
incubated at 37°C. At the indicated time-points, cell lysates were harvested in TriPure 
Isolation Reagent (Roche). After the addition of chloroform, the aqueous phase was 
mixed in a 1:1 ratio with buffer RA1 of the Nucleospin RNA II kit (Macherey-Nagel). 
RNA was isolated as per manufacturer’s instructions and reverse transcribed using Re-
vertAid H Minus RT (Fermentas) and oligo(dT)20 primer. Finally, samples were assayed 
by quantitative reverse transcriptase PCR (qRT-PCR) on a CFX384 Touch Real-Time 
PCR detection system (BioRad) using iTaq SYBR Green Supermix with ROX (BioRad). 
Primers (see Table Iv-S2) targeting mRNAs encoding equine GAPDH, Actin-β, IFN-β, 
MX1, and the EAV genome were designed using Primer3 (88) or kindly provided by 
Udeni Balasuriya in the case of IL8. The real-time PCR was followed by a melting-curve 
analysis, to verify the specificity of the reaction. Results were quantified using the 
standard curve method and normalized against the geometric mean of the relative 
quantities of GAPDH and Actin-β mRNA. Data from three independent experiments 
was analyzed with SPSS Statistics software using a one-sample t test or unpaired 
Student’s t test, where appropriate. P values <0.05 were considered to be statistically 
significant.
Deubiquitination during infection
Confluent ELFs were infected with wild-type or mutant EAV at MOI 5 and incubated for 
10 hours at 37°C. Cells were then lysed in 500 μl 2x Laemmli Sample Buffer (250 mM 
Tris, 2% SDS, 20% glycerol, 0.01% bromophenol blue, 2 mM DTT, pH 6.8) and total 
ubiquitination was assessed by Western blot analysis as described in the supplemen-
tal materials and methods section.
Atomic coordinates
Atomic coordinates and structure factors for the PLP2-Ub complex have been depos-
ited in the Protein Data Bank under the accession code: 4IUM.
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Figure iV-S1. the deiSgylating activity of plp2 is only mildly affected by Ub-binding surface mu-
tations. HEK293T cells were transfected with a combination of plasmids encoding nsp2-3 con-
taining WT or mutant PLP2, GFP, hISG15, and the E1 and E2 enzymes needed for its conjugation: 
HA-UbE1L and FLAG-UbcM8. ISGylation is visualized on Western blot using an anti-ISG15 antibody.
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Nuclei, EAV nsp2, EAV N protein
Figure iV-S2. immunofluorescence microscopy reveals similar replication kinetics for Wt and 
PLP2 mutant viruses. ELFs were infected with WT or mutant EAV at MOI 5. At 3, 6, and 9 hpi, cells 
were fixed for immunofluorescence microscopy, and EAV nsp2 (green), N protein (red), and nuclei 
(blue) were visualized using the appropriate antibodies or Hoechst dye, respectively. Abbrevia-
tion: N, nucleocapsid.
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table iV-S1: Crystallographic data and model refinement statistics.
Crystal geometry
Space group P21 21 21
a = 38.32, b = 62.23, c = 84.28
α = β = γ = 90°
Unit cell (Å)
Crystallographic data
Dataset Edge (Zinc) Peak (Zinc) Remote (Zinc)
Wavelength (Å) 1.28289 1.28243 1.27347
Resolution range (Å) 31.10-1.45 (1.53-1.45)* 31.11-1.45 (1.53-1.45) 31.02-1.45 (1.53-1.45)
Total observations 316923 (34142) 317730 (34806) 317984 (36992)
Unique reflections 36316 (5023) 36344 (5029) 36278 (5075)
Multiplicity 8.7 (6.8) 8.7 (6.9) 8.8 (7.3)
Completeness (%) 99.4 (95.9) 99.4 (96.2) 99.6 (97.1)
Anomalous completeness 99.1 (94.0) 99.2 (94.4) 99.4 (95.8)
Rmerge 0.054 (0.253) 0.049 (0.205) 0.079 (0.596)











Rwork (Rfree) 0.16 (0.18)
Mean B value (Å2) 19.90
RMSD from ideal geometry:
Bond lengths (Å)/angles (°) 0.013/1.47
Ramachandran plot:
Most favored/allowed (%) 98/2
* Values in parentheses refer to the highest resolution shell.
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Table Iv-S2: Primers used for quantitative real-time PCr.
Target (Accession) Forward primer (5’-3’) Reverse primer (5’-3’)
Equine GAPDH (NM_001163856) TGCCGCCTGGAGAAAGCTGC GAGGGCAATGCCAGCCCCAG
Equine Actin-β (NM_001081838) CCACGCCATCCTGCGTCTGG ACCGCTCGTTGCCGATGGTG
Equine IFN-β (NM_001099440) AGGTGGATCCTCCCAATGGCCC GGGGCAACGTTGAGGGGCTC
Equine MX1 (NM_001082492) CGGCCAGCAGCTGCAGAAGT GGCCTCCGCTCCCTGGAGAT
Equine IL8 (NM_001083951) GCCGTCTTCCTGCTTTCTG CCGAAGCTCTGCAGTAATTCTTGAT
EAV genome (NC_002532) CCGACCCGGTGTGACCGTTG AAGGGTCGCGGGTGCCAATG
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In vivo assessment of vaccine improvement by 
disabling the deubiquitinase activity of equine 
arteritis virus papain-like protease 2
Puck B. van Kasteren, Robert C.M. Knaap, Paul van den Elzen, Eric J. Snijder, 




Arteriviruses are a family of positive-stranded RNA viruses that includes the prototypic 
equine arteritis virus (EAV) and porcine reproductive and respiratory syndrome virus 
(PRRSV), which cause respiratory illness as well as reproductive failure in their respec-
tive hosts. Although several vaccines against these viruses are commercially available 
there is room for improvement, especially in the case of PRRSV, which causes serious 
economic losses to swine-farming industries worldwide. The ability of arteriviruses to 
evade or counteract the innate immune response is thought to decrease the efficacy 
of the current modified live virus vaccines. We have recently shown that the deu-
biquitinase (DUB) activity of the EAV papain-like protease 2 (PLP2) is important for 
the inhibition of innate immune activation during infection in cell culture. A vaccine 
virus lacking PLP2 DUB activity may therefore induce a better immune response and 
provide improved protection against subsequent challenge than its DUB-competent 
counterpart. To test this hypothesis, twenty Shetland mares that were seronegative 
for EAV were randomly assigned to one of three groups. Two groups were vaccinated, 
either with DUB-positive (Group 1, n=9) or DUB-negative (Group 2, n=9) recombi-
nant virus derived from the pEAV030 infectious cDNA clone of EAV. The third group 
(Group 3, n=2) was not vaccinated and served as a challenge control. All horses were 
subsequently challenged with the moderately virulent KY84 strain of EAV. The PLP2 
DUB-negative recombinant vaccine virus proved to be replication competent in vivo. 
Furthermore, the data suggested that the DUB-negative vaccine virus provides better 
protection against a heterologous challenge than its parental counterpart, since viral 
RNA was more readily detected after challenge in animals vaccinated with the parental 
virus. Finally, despite a minor decrease in replication efficiency of the DUB-negative 
vaccine virus compared to the parental virus, no major differences were detected in 
the induction of two interferon-stimulated genes. Taken together, the data obtained 
in this study warrant further in vivo investigations into the potential of using PLP2 
DUB mutant viruses for the improvement of arterivirus vaccines.




Arteriviruses are a family of animal viruses that includes the prototypic equine ar-
teritis virus (EAV) and porcine reproductive and respiratory syndrome virus (PRRSV). 
Although the diseases associated with each of these viruses are distinct, both are 
characterized by the occurrence of abortions in female animals and respiratory illness 
in young offspring (for reviews, see (1, 2)). Whereas outbreaks of equine viral arteritis 
(EVA) are only occasionally reported, infections with PRRSV pose a major threat to 
the swine-farming industries worldwide. Especially, the emergence of highly virulent 
strains of PRRSV in China since 2006 has been a major concern (3-5). Several vac-
cines are currently commercially available to prevent the spread of EAV and PRRSV. 
In the case of EAV, both an inactivated and a modified live virus (MLV) vaccine are 
commercially available: Artervac and ARVAC, respectively (both produced by Zoetis 
Animal Health Inc, Kalamazoo, MI, USA). The latter is considered to be safe and effica-
cious, although some concerns about cross protection against recent field isolates 
have been reported (1). Furthermore, the MLV vaccine is not recommended for use 
during the last stages of pregnancy (6), vaccination does not consistently prevent the 
replication of some field strains, and transient shedding of infectious virus in nasal 
secretions is sometimes observed in vaccinated animals (7). Thus, current vaccine-
based control strategies for EAV are considered adequate, but room for improvement 
remains. In contrast, even though several MLV vaccines against PRRSV are available, 
they do not always provide effective protection against the diversity of field strains 
observed for this virus. The current MLV vaccines for PRRSV generally provide protec-
tion against clinical disease, but do not consistently prevent replication of field strains 
and shedding of infectious virus by vaccinated animals (8, 9). Especially, the limited 
protection against heterologous field strains provided by current vaccines is a major 
issue that complicates the control of PRRSV (9). Importantly, PRRSV strains display 
a considerable genetic heterogeneity, which is exemplified by the existence of two 
very divergent genotypes (10). The design of improved PRRSV vaccines that provide 
protection against both homologous and heterologous field strains is therefore of 
significant importance.
It has been suggested that the immune-evasive capabilities of PRRSV play an impor-
tant role in reducing vaccine efficacy (9). Rationally decreasing the ability of a (vac-
cine) virus to interfere with the immune response of the host might therefore provide 
a means to improve vaccine efficacy. Arteriviruses have been reported to counteract 
both innate and adaptive immune responses in various ways (for reviews, see (6, 11)). 
In this study, we will focus in particular on inhibition of innate immune signalling 
mediated by one of the arterivirus nonstructural protease domains. The innate im-
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mune response constitutes the first line of defence against invading pathogens and 
plays an essential role in activating adaptive immunity (for reviews, see (12-14)). It 
is extensively regulated through ubiquitination (for reviews, see (15-17)), i.e. the 
covalent attachment of ubiquitin to target proteins, which can for example mediate 
protein-protein interactions in signalling cascades. Importantly, ubiquitination can 
be reversed through the action of deubiquitinases (DUBs) (for reviews, see (18, 19)). 
Arteriviruses, similar to other mammalian positive-stranded (+) RNA viruses, express 
their nonstructural proteins as part of two large replicase polyproteins that are co- 
and posttranslationally cleaved into their respective functional subunits (20-27). One 
of the viral protease domains involved in this process, papain-like protease 2 (PLP2), 
has previously been shown to also possess DUB activity, which was suggested to be 
important for the inhibition of innate immune signalling (28-31). This hypothesis 
could not be easily verified in the context of an infection due to the essential role of 
PLP2 in maturation of the replicase polyproteins, which precluded straightforward 
inactivation of this domain without consequences for virus viability. Nevertheless, 
based on the crystal structure of EAV PLP2 in complex with ubiquitin, we have recently 
succeeded in creating protease mutants that are defective in DUB activity yet are still 
capable of processing the viral replicase polyproteins (32). The rational design of 
these mutants consisted of substituting up to three of the amino acids in the PLP2 
region that are involved in the binding of ubiquitin, thus disturbing the interaction 
between protease and substrate. Using these mutants, we could show that the DUB 
activity of EAV PLP2 is indeed important for the evasion of innate immunity in infected 
host cells (32).
As a follow-up to the work described above, the aim of the current study was to deter-
mine whether a recombinant vaccine virus lacking PLP2 DUB activity provides better 
protection against a subsequent challenge infection than its parental DUB-competent 
counterpart in horses. Furthermore, we were interested to see whether the effect of 
such PLP2 mutations on innate immune signalling observed in cell-culture could also 
be seen in vivo. Since currently the concept of structure-based separation of the DUB 
and polyprotein processing functions of arterivirus PLP2 has only been developed for 
EAV, we have used this virus for the present animal study.
MateRialS aNd MetHOdS
Cells and viruses
BHK-21 cells were cultured in Glasgow minimum essential medium (Lonza) supple-
mented with 5% fetal bovine serum (FBS), 10% tryptose phosphate broth, and 10 
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mM Hepes (pH 7.4). Primary equine lung fibroblasts (ELFs) were cultured in minimum 
essential medium (Lonza) supplemented with 10% FBS and grown on collagen-coated 
plastics for a maximum of 10 passages. Vero cells were cultured in proprietary cell 
culture medium (MSD Animal Health) supplemented with 1% FBS. All culture media 
contained 100 U/mL of penicillin and 100 mg/mL of streptomycin or neomycin.
The vaccine viruses were derivatives of an infectious cDNA clone of EAV strain 
Bucyrus (pEAV030) (33, 34). Specifically, the parental cDNA clone used in this study is 
pEAN551A/B, which differs from pEAV030 by the absence of a strong-stop sequence 
for in vitro transcription and the addition of a number of silent mutations for the 
purpose of creating unique restriction sites (32, 35). The DUB-negative virus was 
produced from the pEAN551A/B T312A/I313V/I353R (numbering based on amino 
acid sequence of EAV replicase polyprotein 1a) mutant clone described previously 
(32). Virus stocks were produced essentially as described before (32). Briefly, in vitro 
transcribed RNA was was generated from the linearized full-length cDNA clones using 
the mMESSAGE Machine T7 kit (Ambion) and electroporated into BHK-21 cells using 
the AMAXA cell line nucleofector kit T (Lonza). After a 30-h incubation at 39.5°C, 
virus-containing supernatants were harvested, spun down to remove cellular debris, 
and stored at -80°C until further use. Viral titers were determined by standard plaque 
assay on ELFs. For experimental challenge, we used the moderately virulent Kentucky 
1984 (KY84) strain of EAV, which has been previously described (36, 37).
To confirm the use of the correct virus for vaccination, the presence or absence of 
PLP2 mutations was established, both before and after vaccination. Before vaccina-
tion, viral RNA was isolated from the produced virus stocks using the QIAamp viral 
RNA mini kit (Qiagen) and converted to cDNA using RevertAid H Minus reverse tran-
scriptase (Fermentas) and random hexamer primers. The PLP2-encoding region was 
subsequently PCR amplified using  Pfu   DNA polymerase (Fermentas) and sequenced. 
After vaccination, viral RNA present in the blood of four horses each from the vac-
cinated groups at 4 days post vaccination was subjected to sequencing. This was done 
essentially as described above with the exception that viral RNA in whole blood total 
RNA (see below) was converted to cDNA using a primer that is specific for the EAV 
genome. Primer sequences are available upon request.
experimental vaccination and challenge of horses
The experiment was performed in accordance with European Community guidelines 
and national laws on animal experiments. The design of the experiment was approved 
by the MSD Animal Health’s Committee on the Ethics of Animal Experiments (Dierex-
perimentencommissie), which is required by national legislation to include both MSD 
Animal Health employees and independent members, prior to the start of the trial 
(Permit Number: EXP 12.059). All efforts were made to minimize animal discomfort.
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Twenty female Shetland horses (Equus ferus caballus; average age 7.5 ±5.1 years) 
that tested negative for EAV-neutralizing antibodies (titers were determined as de-
scribed previously (36)) before the start of the experiment, were randomly assigned 
to one of three treatment groups. After a one-week acclimatization period, horses 
in Group 1 (n=9) and Group 2 (n=9) received an intramuscular (cervical muscle) vac-
cination of 1 ml phosphate-buffered saline containing 1x107 plaque-forming units 
(PFU) of parental or PLP2 DUB-negative EAV551A/B, respectively. Horses in Group 3 
(n=2) were not vaccinated and were housed outside the animal facilities until their 
inclusion in the study approximately one week before challenge. At 34 days post vac-
cination (dpv), all horses were challenged by intranasal inoculation with 1x105 PFU of 
EAV KY84 in a total volume of 5 ml phosphate-buffered saline.
Given the fact that the viruses used for vaccination qualify as genetically modified 
organisms (GMO), vaccinated horses were kept in BSL3 containment during the entire 
experiment. All horses were housed in groups, but Group 1 horses were kept separate 
from Group 2 horses to prevent any cross-contamination. Horses from Group 3 were 
divided among the two stables upon inclusion. Water was provided ad libitum and 
standard feeding procedures were applied.
The general health status of the animals was checked by a veterinarian before vac-
cination as well as before challenge, and daily by animal care-takers during the entire 
course of the experiment. In addition, clinical signs were recorded daily from 0 to 
14 days post challenge (dpc) and scored according to Table v-1. Rectal temperatures 
were taken daily from 0 to 14, and at 21 and 28 dpv, and daily from 0 to 14, and at 21 
and 27 dpc. Blood samples for serum and total RNA isolation were taken every other 
day between 0 and 14, and at 21 and 28 dpv, and every other day between 0 and 14, 
and at 21 and 27 dpc. Animals were euthanized according to standard procedures at 
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figure v-1. Schematic representation of the animal trial. Twenty female Shetland horses were 
randomly assigned to one of three groups. At the start of the experiment, horses from Groups 1 
and 2 (n=9 each) were vaccinated with PLP2 DUB-competent or DUB-negative EAV-551A/B, respec-
tively. Horses in Group 3 (n=2) were not vaccinated. At 34 dpv, all horses were challenged with 
moderately virulent EAV KY84. The experiment ended at 61 dpv. Blood samples for serum and total 
RNA isolation were taken at the indicated days (lower arrows).




Blood for serum neutralizing antibody analysis was collected in 8 ml Vacuette Se-
rum Clot Activator Tubes (Greiner Bio-One) and incubated for at least 4 h at room 
temperature to allow for clotting. Serum samples were subsequently collected by 
centrifugation at 700x g for 15 min at 4°C and stored at -20°C until further use. To 
determine EAV neutralizing antibody titers in the serum, a virus neutralization assay 
was performed similar to what was described before (36). Briefly, duplicate two-fold 
serial dilutions (1:2 to 1:4096) of serum samples were made in 96-well plates and 
mixed with a 50% tissue culture infective dose (TCID50) of 800 of EAV030 (33). After 
Table v-1. Clinical signs scoring table.
Clinical sign Score
No abnormality found 0 (daily)
Malaise/depression/normal eating 1 (daily)
Malaise/depression/reduced appetite 2 (daily)
Anorexia 4 (daily)
Dehydration 2 (daily)







Cough (2-5x in 10 minutes) 1 (daily)
Cough (6-20x in 10 minutes) 2 (daily)
Cough (>20x in 10 minutes) 3 (daily)
Lachrymation 1 (daily)
Mucopurulent eye discharge (mild) 2 (daily)
Mucopurulent eye discharge (marked) 4 (daily)
Conjunctivitis (mild) 2 (daily)
Conjunctivitis (marked) 4 (daily)
Nasal serous dicharge 1 (daily)
Nasal mucopurulent (mild) 2 (daily)
Nasal mucopurulent (marked) 4 (daily)
Sneeze (2-5x in 10 minutes) 1 (daily)
Sneeze (6-20x in 10 minutes) 2 (daily)
Sneeze (>20x in 10 minutes) 3 (daily)
Temperature 38.5-39.0 °C 1 (daily)
Temperature 39.1-39.5 °C 2 (daily)
Temperature 39.6-40.0 °C 3 (daily)
Temperature > 40 °C 4 (daily)
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a 1-h incubation at 37°C, 1.2x104 Vero cells were added to each well. Plates were 
subsequently incubated for 4 days at 37°C after which each well was scored (positive 
or negative) for cytopathic effect (CPE) by visual inspection. The EAV neutralizing 
antibody titer was finally determined as the reciprocal value of the highest serum 
dilution at which no CPE was observed.
quantitative reverse transcriptase PCr assay
Total RNA was isolated from whole blood collected in Tempus Blood RNA Tubes 
(Greiner Bio-One) using the MagMAX for Stabilized Blood Tubes RNA isolation kit 
(Life Technologies) according to the manufacturer’s instructions. Isolated RNA was 
converted to cDNA using RevertAid H Minus reverse transcriptase (Fermentas) and 
oligo(dT)20 primer. Samples were subsequently analysed by quantitative reverse-
transcriptase (qRT) PCR on a CFX384 Touch Real-Time PCR detection system (BioRad) 
using iTaq Sybr Green Supermix (BioRad). Primers (Table v-2) targeting mRNAs encod-
ing equine β-actin, ISG15, and MX1, or EAV RNA were designed using Primer3 (38). The 
EAV-specific primer set amplifies cDNA derived from both genomic and subgenomic 
viral mRNAs. The real-time PCR was performed in triplicate, included a standard dilu-
tion series, and was followed by a melting-curve analysis to confirm the identity of 
the reaction product.
reSULTS
Vaccine viruses do not differ in the induction of fever or neutralizing antibodies. 
To assess whether a vaccine virus lacking PLP2 DUB activity would provide better 
protection against heterologous challenge than its DUB-positive parental counter-
part, we performed a vaccination-challenge trial in horses. Twenty female Shetland 
horses were randomly assigned to one of three groups. Animals from two groups were 
subsequently vaccinated intramuscularly with cell culture-adapted DUB-competent 
(Group 1, n=9) or DUB-negative (Group 2, n=9) EAV551A/B. Horses from Group 3 (n=2) 
Table v-2. Primers used for quantitative rT-PCr.
Target (Accession) Forward primer (5’-3’) Reverse primer (5’-3’)
Equine beta-actin mRNA (NM_001081838) CCACGCCATCCTGCGTCTGG ACCGCTCGTTGCCGATGGTG
Equine ISG15 mRNA (XM_001496658) GAATTCCTGGTGCCCCTGAA CAGTTCTGCACGACAAGCAC
Equine MX1 mRNA (NM_001082492) CGGCCAGCAGCTGCAGAAGT GGCCTCCGCTCCCTGGAGAT
EAV RNA (NC_002532) GGTTCGCGGCAACGGGTACA1 GGTGGCGCGCTCCTGTTGAT2
1 Primer position in EAV genome: 12269-12288.
2 Primer position in EAV genome: 12488-12507.
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were not vaccinated and served as challenge controls. All horses were intranasally 
challenged with moderately virulent EAV KY84 at 34 dpv. A schematic representation 
of the experimental set-up including timing of vaccination, challenge, and sampling 
is depicted in figure v-1. The identity of the virus used for vaccination was confirmed 
by sequencing of viral RNA isolated from whole blood at 4 dpv for a random subset of 
four horses from Groups 1 and 2 (data not shown).
Upon vaccination, animals from Groups 1 and 2 (DUB-competent and DUB-negative, 
respectively) developed comparable levels of mild fever which reached an average 
maximum of 38.8°C at 3 dpv and subsided approximately 8 dpv in both groups (figure 
v-2A). Upon challenge, only the non-vaccinated animals in Group 3 developed a fever, 
which reached higher levels (average maximum 40.3°C) and lasted approximately two 
days longer than the fever that was observed after vaccination. Neutralizing antibod-
ies could be detected in both Groups 1 and 2 from 6 dpv onwards and no difference 
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Group 1 (DUB+) Group 2 (DUB-) Group 3 (Control)
Group 1 (DUB+) Group 2 (DUB-) Group 3 (Control)
Figure V-2. Rectal temperatures and neutralizing antibody titers. a) Rectal temperatures were 
taken daily for the first 14 days post vaccination/challenge and at 21, 28, 55, and 61 dpv. B) Neu-
tralizing antibody (NA) titers in serum were determined using a virus neutralization assay for sam-
ples obtained every other day during the first 14 days post vaccination/challenge and at 21, 28, 55, 
and 61 dpv. White, black, and grey circles represent data from animals in Group 1, 2, and 3, respec-
tively. The days of vaccination (0) and challenge (34) are depicted in bold face. The dotted line in 
panel B represents the limit of detection. Measurements/samples taken on the day of vaccination/
challenge were obtained before infection and horses in Group 3 were included in the experiment 
starting at the day of challenge. Abbreviations: DUB+, deubiquitinase-competent vaccine virus; 
DUB-, deubiquitinase-negative vaccine virus; NA, neutralizing antibody.
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in titers was observed between the two groups (figure v-2B). Titers remained stable 
during the course of the experiment and did not show an increase upon challenge. In 
the unvaccinated controls, neutralizing antibody titers could be detected at 8 days 
post challenge (dpc) and reached similar titers as observed after vaccination.
From 0 to 14 dpc, clinical signs (including for example fever, nasal secretions, and 
loss of appetite) were recorded daily for each animal. An overall clinical signs score 
was subsequently determined for each animal by scoring these clinical signs accord-
ing to Table v-1. For example, a horse that has diarrhoea on day 5, mild conjunctivitis 
and a temperature of 39°C on day 8, and no abnormalities on any of the other days 
has an overall clinical signs score of 4 (1+2+1). This resulted in an average score per 
animal of 4.2 (±3.3, Group 1) and 5.3 (±3.3, Group 2), which did not differ significantly 
between the two groups (Student’s t-test; p>0.05; Table v-3). The horses in Group 3 
reached an average score of 46.5 per animal, which is consistent with the fact that 
these animals had not been vaccinated. Thus, vaccination with either virus provided a 
similar degree of protection against clinical disease.
plp2 dUB-negative vaccine virus appears to replicate slightly less efficiently than 
parental virus in vivo. We then assessed viral replication from 0 to 10 dpv by perform-
ing real-time qRT-PCR analysis on total RNA isolated from whole blood. The quanti-
fication limit of this assay was set to the amount of EAV RNA (10 arbitrary units) that 
no longer yielded consistent read-outs in PCR triplicates, and this limit corresponded 
to a threshold cycle (CT) value of approximately 37. As can be seen in figure v-3A and 
Table v-4, all vaccinated horses showed viral replication which, on average, peaked at 
4 dpv in both groups. Notably, the DUB-negative virus (Group 2) appeared to replicate 
slightly less efficiently than its DUB-competent counterpart (Group 1). Whereas the 
Table v-3. Clinical signs score per animal at 0-14 dpc.
Group 1 (DUB+) Group 2 (DUB-)
Horse id Score Horse id Score
1 5 11 2
2 2 12 10
3 0 13 4
4 4 14 4
5 0 15 7
6 3 16 3
7 8 17 1
8 9 18 7
9 7 19 10
Average 4.2 (±3.3) Average 5.3 (±3.3)
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amount of parental DUB-competent virus was above the limit of quantification in all 
Group 1 horses at each of days 2 to 8 post vaccination, several of the horses in Group 
2 tested negative for viral RNA or had levels of viral RNA below the limit of quantifica-
tion at 2, 6, and/or 8 dpv (Table v-4). In addition, the average amount of viral RNA at 
each day post vaccination was lower in Group 2 compared to Group 1, although this 
difference was statistically significant only at 10 dpv (Student’s t-test; p<0.05).
Upon challenge with the moderately virulent EAV KY84 strain, both non-vaccinated 
control horses (Group 3) showed virus replication, with amounts of viral RNA reaching 
levels comparable to those produced by the vaccine viruses (figure v-3A and Table 
v-5). In contrast, in all vaccinated horses, except for one horse from Group 1 at 8 and 
10 dpc, the levels of viral RNA remained below the quantification limit from 2 to 10 
dpc (figure v-3B and Table v-5). This result was consistent with the observed appear-
ance of neutralizing antibodies after vaccination in all horses and the low clinical sign 
scores in both vaccinated groups after challenge.
Table v-4. Amounts of viral rNA (arbitrary units) as determined by qrT-PCr at 0-10 dpv.
Group Horse iD 0 dpv 2 dpv 4 dpv 6 dpv 8 dpv 10 dpv
Group 1
(DUB+)
1 ND - 1 743 1528 68 19
2 <102 20 835 1624 302 205
3 ND 229 438 142 107 89
4 ND 41 1440 578 55 61
5 <102 321 5367 3849 514 120
6 ND 43 78 30 12 <10
7 ND 107 5550 1445 1229 130
8 ND 105 1587 218 40 74
9 ND 37 170 16 12 <10
Group 2
(DUB-)
11 ND 150 1257 189 124 15
12 ND 197 2674 482 107 50
13 <102 23 885 63 25 17
14 ND 23 403 45 20 11
15 ND <10 28 <10 ND <10
16 ND 24 171 <10 ND <10
17 ND 15 246 13 18 <10
18 <102 <10 37 <10 17 ND
19 ND 38 320 12 13 <10
Abbreviations: dpv, days post vaccination; ID, identifier; ND, not detected.
1 No data available.
2 Considering that all horses tested negative for EAV neutralizing antibodies prior to the start of 
the experiment, these signals are likely due to a contamination event during processing of the 
samples.
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Upon closer examination of the data, we did occasionally observe specific signal 
representative of viral RNA, as assessed by melting curve analysis, below the quantifi-
cation limit (i.e. CT values between approximately 37 and 40) in samples of vaccinated 
animals between 4 and 10 dpc (figure v-3B). Interestingly, this appeared to be the 
case only in animals from Group 1 (n=4/9) and not Group 2 (n=0/9). Although this 
difference was not statistically significant (Fisher’s exact test; p=0.08), it is sugges-
tive of a trend towards the DUB-negative virus (Group 2) providing better protection 
against challenge than its parental DUB-competent counterpart (Group 1). It needs to 
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figure v-3. quantitative rT-PCr analysis of viral rNA and cellular mrNA encoding ISG15 and mX1.
A) Viral replication from 0 to 10 dpv (Groups 1 and 2) or dpc (Group 3) was assessed by real-time 
qRT-PCR analysis on total RNA isolated from whole blood using EAV-specific primers. White, black, 
and grey circles represent animals from Group 1, 2, and 3, respectively. Horizontal bars represent 
the mean for all animals on that day and the dotted line represents the limit of quantification, 
which was set at 10 arbitrary units (AU). B) The presence of viral RNA in animals from each group 
at 4 to 10 dpc was assessed as in panel A. The bars represent the number of animals per group that 
tested positive (over 10 AU; black bars) or nearly positive (under 10 AU, hatched bars) for viral 
RNA on at least one of the indicated days, or that remained negative (white bars) for viral RNA on 
each of the indicated days. Activation of the innate immune response was assessed by real-time 
qRT-PCR on total RNA isolated from whole blood using primers specific for C) ISG15- or D) MX1-
encoding mRNA. Values obtained for ISG15 and MX1 mRNA levels were normalized to the amount 
of β-actin mRNA. The dotted lines represent average baseline levels, error bars represent standard 
deviations, and asterisks indicate statistical significance (Student’s t-test; p<0.05). Abbreviations: 
AU, arbitrary units; DUB+, deubiquitinase-competent vaccine virus; DUB-, deubiquitinase-negative 
vaccine virus.
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for viral RNA but below the limit of quantification could also be observed at 0 and 2 
dpc (Table v-5). Since the 0 dpc samples were taken before inoculation, the signal 
observed in these samples most likely represents progeny of the vaccine virus.
No major differences in the induction of iSg15 and MX1 mRNa expression could be 
detected between vaccine viruses. Finally, we assessed the induction of an innate 
immune response by parental and PLP2 DUB-negative virus from 0 to 10 dpv by 
means of real-time qRT-PCR. Since we were unable to detect mRNA encoding type 
I interferons (a hallmark of innate immune activation), we instead focussed on two 
highly expressed interferon-stimulated genes encoding ISG15 and MX1, respectively. 
Both of these genes showed an approximately 2-log increase of expression at 2 dpv, 
which did not significantly differ between animals from Groups 1 and 2 (figures v-3C 
and D). At 6 and 8 dpv, the expression of ISG15 and MX1 mRNA was significantly lower 
in the animals vaccinated with the PLP2 DUB-negative virus (Group 2) than in those 
vaccinated with the parental virus (Group 1) (Student’s t-test; p<0.05), which might 
be explained by the slight decrease in replication efficiency of the former virus. How-
Table v-5. Amounts of viral rNA (arbitrary units) as determined by qrT-PCr at 0-10 dpc.
Group Horse id 0 dpc 2 dpc 4 dpc 6 dpc 8 dpc 10 dpc
Group 1
(DUB+)
1 <10 <10 <10 <10 <10 ND
2 ND ND ND ND ND ND
3 ND ND ND ND ND <10
4 ND ND ND ND ND ND
5 ND ND ND ND 263 20
6 ND ND ND ND ND ND
7 ND ND <10 ND <10 <10
8 ND ND ND ND ND ND
9 <10 ND ND ND ND ND
Group 2
(DUB-)
11 ND <10 ND ND ND ND
12 <10 <10 ND ND ND ND
13 ND ND ND ND ND ND
14 <10 ND ND ND ND ND
15 <10 ND ND ND ND ND
16 <10 ND ND ND ND ND
17 ND ND ND ND ND ND
18 ND ND ND ND ND ND
19 ND <10 ND ND ND ND
Group 3
(control)
10 ND ND 2376 592 9037 766
20 ND 42 642 1041 286 229
Abbreviations: dpc, days post challenge; ID, identifier; ND, not detected.
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ever, this apparently did not adversely affect the levels of protection provided by the 
DUB-negative vaccine virus. Overall, no major differences between parental and PLP2 
DUB-negative virus in the induction of ISG15 and MX1 expression were found.
DISCUSSION
We have previously shown that mutant EAV lacking PLP2 DUB activity induces a 
more potent innate immune response than its DUB-competent parental virus upon 
infection in cell culture (32), and hypothesized that this feature might be included 
in an improved arterivirus vaccine. In order to assess whether a PLP2 DUB-negative 
vaccine virus provides better protection than its DUB-competent counterpart against 
challenge with a virulent EAV strain, we performed a vaccination-challenge trial in 
horses. The data obtained in this study showed that although the PLP2 mutant virus 
appears to replicate slightly less efficiently than its parental virus, it is definitely 
replication-competent in vivo (figure v-3A). In addition, despite this decrease in 
replication efficiency, both the antibody response (figure v-2B) and innate immune 
response (assessed based on the expression of two interferon-stimulated genes; 
figures v-3C and D) induced by the PLP2 DUB-negative virus was comparable to that 
induced by the parental virus. Surprisingly, we did not observe an increase in EAV-
neutralizing antibody titers upon challenge infection of vaccinated animals (figure 
v-2B). A possible explanation for this finding is that the virus dose used for challenge 
was too low, resulting in its efficient clearance before (re-)activation of the antibody 
response. Finally, although the data hinted at the PLP2 DUB-negative virus providing 
a better protection than its parental DUB-competent virus, the already high degree of 
protection that was provided by vaccination with the latter virus made it impossible 
to substantiate this conclusion.
In contrast to what was previously found in cell culture-based assays (32), we did not 
detect an increased activation of innate immunity by the PLP2 DUB-negative virus 
compared to its parental virus in vivo. However, it needs to be noted that we have thus 
far assessed the expression of only two interferon-stimulated genes, whereas many 
more exist. It therefore remains a possibility that differences do exist in the expression 
of other interferon-stimulated genes. Similarly, the induction of interferon-stimulated 
genes is only one of several consequences of the activation of innate immune signal-
ling. It therefore remains possible that the DUB-negative vaccine virus differs from the 
parental virus in some other respect pertaining to immunity, for example the activa-
tion of cell-mediated adaptive immunity. Also, PLP2 DUB activity likely constitutes 
only one of several innate immune evasion strategies employed by arteriviruses. 
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For example, nonstructural protein 1 (nsp1) of EAV was recently shown to inhibit the 
induction of interferon beta in a luciferase reporter assay (39) and the EAV nsp4 main 
protease was recently shown to cleave the innate immune signalling factor NEMO 
(40). More studies have been performed with PRRSV, for which it was suggested that 
in addition to PLP2, also nsp1α (41-47), nsp1β (48-50), nsp4 (48), and nsp11 (48, 51), 
and the structural nucleocapsid protein (52) are involved in counteracting innate im-
mune activation. It needs to be noted though that the observed effect of nsp11 on the 
induction of interferon beta was likely due to toxicity of this endoribonuclease (53). 
Taken together, the PLP2 DUB activity appears to constitute only a part of the total 
repertoire of arteriviral innate immune evasion strategies, which perhaps cannot be 
readily detected in the in vivo experimental set-up used here. For example, detecting 
more prominent consequences of its inactivation may depend on the details of the 
animal study, including specific properties of viruses and horses used. Nevertheless, 
the apparently limited negative effect on viral replication of PLP2 DUB-mutations 
does open up possibilities for combining mutations in multiple domains involved in 
immune evasion, thereby potentially synergistically increasing the overall immuno-
genicity of the virus.
Furthermore, the data obtained in this study did not allow us to firmly substantiate 
(or refute) our hypothesis that a PLP2 DUB-negative mutant vaccine provides better 
protection against subsequent challenge than its parental DUB-competent counter-
part. The main reason for this seems to be the fact that the parental virus already 
provides a very high degree of protection, which as it turned out could not be detect-
ably improved using this experimental set-up. In hindsight, one solution might have 
been to perform a more severe challenge, for example by using a higher virus dose for 
inoculation or a more heterologous strain than KY84. As PRRSV vaccines are in general 
less efficacious than EAV vaccines, another option would be to perform a similar trial 
with a PRRSV vaccine in pigs, but this will first require the design of viable PRRSV PLP2 
DUB-negative mutants.
Notably, arteriviruses are not the only group of viruses that were shown to harbour DUB 
activity. For example, coronaviruses (including SARS- and MERS-CoV) encode papain-
like proteases that display DUB activity (54-61). Additionally, the OTU proteases of 
nairoviruses have been found to possess DUB activity (28). Like arterivirus PLP2, these 
viral DUBs have also been implicated in innate immune evasion (28, 57-60, 62-67) 
and are therefore potential targets for the design of novel vaccines. Taken together, 
the data obtained in this study definitely warrant further in vivo examination of the 
consequences of knocking out arterivirus PLP2 DUB activity as well as other immune-
evasive activities to improve vaccine efficacy. The data obtained in such studies could 
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subsequently also be used as preliminary proof of principle for the design of novel 
vaccines for other viruses, including corona- and nairoviruses.
aCKNOWledgeMeNtS
We would like to thank the animal caretakers at the MSD-AH animal facility for their 
efforts. This research was supported in part by the Division of Chemical Sciences of 
the Netherlands Organization for Scientific Research (NWO-CW) through ECHO grant 
700.59.008 to MK and EJS.




 1. Balasuriya UB, go yy, Maclachlan NJ. 2013. Equine arteritis virus. Vet Microbiol 167:93-
122.
 2. Cho JG, Dee SA. 2006. Porcine reproductive and respiratory syndrome virus. Theriogenol-
ogy 66:655-662.
 3. li y, Wang X, Bo K, tang B, yang B, Jiang W, Jiang p. 2007. Emergence of a highly patho-
genic porcine reproductive and respiratory syndrome virus in the Mid-Eastern region of 
China. Vet J 174:577-584.
 4. tian K, yu X, Zhao t, Feng y, Cao Z, Wang C, Hu y, Chen X, Hu d, tian X, liu d, Zhang S, 
deng X, ding y, yang l, Zhang y, Xiao H, Qiao M, Wang B, Hou l, Wang X, yang X, Kang l, 
Sun M, Jin p, Wang S, Kitamura y, yan J, gao gF. 2007. Emergence of fatal PRRSV variants: 
unparalleled outbreaks of atypical PRRS in China and molecular dissection of the unique 
hallmark. PLoS One 2:e526.
 5. tong gZ, Zhou yJ, Hao XF, tian ZJ, an tQ, Qiu HJ. 2007. Highly pathogenic porcine repro-
ductive and respiratory syndrome, China. Emerg Infect Dis 13:1434-1436.
 6. Balasuriya UB, macLachlan NJ. 2004. The immune response to equine arteritis virus: 
potential lessons for other arteriviruses. Vet Immunol Immunopathol 102:107-129.
 7. McCollum WH, timoney pJ, Roberts aW, Willard Je, Carswell gd. 1987, p 13-18. Fifth 
International Conference on Equine Infectious Diseases, Lexington, Kentucky.
 8. Huang yW, Meng XJ. 2010. Novel strategies and approaches to develop the next genera-
tion of vaccines against porcine reproductive and respiratory syndrome virus (PRRSV). 
Virus Res 154:141-149.
 9. Kimman TG, Cornelissen LA, moormann rJ, rebel Jm, Stockhofe-Zurwieden N. 2009. 
Challenges for porcine reproductive and respiratory syndrome virus (PRRSV) vaccinology. 
Vaccine 27:3704-3718.
 10. meng XJ. 2000. Heterogeneity of porcine reproductive and respiratory syndrome virus: 
implications for current vaccine efficacy and future vaccine development. Vet Microbiol 
74:309-329.
 11. Snijder eJ, Kikkert M, Fang y. 2013. Arterivirus molecular biology and pathogenesis. J Gen 
Virol 94:2141-2163.
 12. Jensen S, Thomsen Ar. 2012. Sensing of RNA viruses - A review on innate immune recep-
tors involved in recognizing RNA virus invasion. J Virol86:2900-2910.
 13. O’Neill la, Bowie ag. 2010. Sensing and signaling in antiviral innate immunity. Curr Biol 
20:R328-333.
 14. Takeuchi O, Akira S. 2009. Innate immunity to virus infection. Immunol Rev 227:75-86.
 15. Jiang X, Chen ZJ. 2012. The role of ubiquitylation in immune defence and pathogen eva-
sion. Nat Rev Immunol 12:35-48.
 16. Oudshoorn D, versteeg GA, Kikkert m. 2012. Regulation of the innate immune system by 
ubiquitin and ubiquitin-like modifiers. Cytokine Growth Factor Rev 23:273-282.
 17. Bhoj vG, Chen ZJ. 2009. Ubiquitylation in innate and adaptive immunity. Nature 458:430-
437.
 18. Komander D, Clague mJ, Urbe S. 2009. Breaking the chains: structure and function of the 
deubiquitinases. Nat Rev Mol Cell Biol 10:550-563.
 19. Reyes-turcu Fe, Ventii KH, Wilkinson Kd. 2009. Regulation and cellular roles of ubiquitin-
specific deubiquitinating enzymes. Annu Rev Biochem 78:363-397.
132 Chapter 5
 20. Snijder eJ, Wassenaar al, Spaan WJ. 1992. The 5’ end of the equine arteritis virus repli-
case gene encodes a papainlike cysteine protease. J Virol 66:7040-7048.
 21. Snijder eJ, Wassenaar al, Spaan WJ. 1994. Proteolytic processing of the replicase ORF1a 
protein of equine arteritis virus. J Virol 68:5755-5764.
 22. Snijder eJ, Wassenaar al, Spaan WJ, gorbalenya ae. 1995. The arterivirus Nsp2 protease. 
An unusual cysteine protease with primary structure similarities to both papain-like and 
chymotrypsin-like proteases. J Biol Chem 270:16671-16676.
 23. den Boon Ja, Faaberg KS, Meulenberg JJ, Wassenaar al, plagemann pg, gorbalenya ae, 
Snijder eJ. 1995. Processing and evolution of the N-terminal region of the arterivirus 
replicase ORF1a protein: identification of two papainlike cysteine proteases. J Virol 
69:4500-4505.
 24. van dinten lC, Wassenaar al, gorbalenya ae, Spaan WJ, Snijder eJ. 1996. Processing 
of the equine arteritis virus replicase ORF1b protein: identification of cleavage products 
containing the putative viral polymerase and helicase domains. J Virol 70:6625-6633.
 25. Snijder eJ, Wassenaar al, van dinten lC, Spaan WJ, gorbalenya ae. 1996. The arterivirus 
nsp4 protease is the prototype of a novel group of chymotrypsin-like enzymes, the 3C-
like serine proteases. J Biol Chem 271:4864-4871.
 26. van Dinten LC, rensen S, Gorbalenya Ae, Snijder eJ. 1999. Proteolytic processing of the 
open reading frame 1b-encoded part of arterivirus replicase is mediated by nsp4 serine 
protease and Is essential for virus replication. J Virol 73:2027-2037.
 27. Han J, Rutherford MS, Faaberg KS. 2009. The porcine reproductive and respiratory 
syndrome virus nsp2 cysteine protease domain possesses both trans- and cis-cleavage 
activities. J Virol 83:9449-9463.
 28. frias-Staheli N, Giannakopoulos Nv, Kikkert m, Taylor SL, Bridgen A, Paragas J, richt JA, 
Rowland RR, Schmaljohn CS, lenschow dJ, Snijder eJ, garcia-Sastre a, Virgin HWt. 2007. 
Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent 
innate immune responses. Cell Host Microbe 2:404-416.
 29. Sun Z, Chen Z, lawson SR, Fang y. 2010. The cysteine protease domain of porcine repro-
ductive and respiratory syndrome virus nonstructural protein 2 possesses deubiquitinat-
ing and interferon antagonism functions. J Virol 84:7832-7846.
 30. van Kasteren PB, Beugeling C, Ninaber DK, frias-Staheli N, van Boheemen S, Garcia-
Sastre A, Snijder eJ, Kikkert m. 2012. Arterivirus and Nairovirus Ovarian Tumor Domain-
Containing Deubiquitinases Target Activated RIG-I To Control Innate Immune Signaling. J 
Virol 86:773-785.
 31. li H, Zheng Z, Zhou p, Zhang B, Shi Z, Hu Q, Wang H. 2010. The cysteine protease domain 
of porcine reproductive and respiratory syndrome virus non-structural protein 2 antago-
nizes interferon regulatory factor 3 activation. J Gen Virol 91:2947-2958.
 32. van Kasteren pB, Bailey-elkin Ba, James tW, Ninaber dK, Beugeling C, Khajehpour M, 
Snijder eJ, mark BL, Kikkert m. 2013. Deubiquitinase function of arterivirus papain-like 
protease 2 suppresses the innate immune response in infected host cells. Proc Natl Acad 
Sci U S A 110:E838-847.
 33. van dinten lC, den Boon Ja, Wassenaar al, Spaan WJ, Snijder eJ. 1997. An infectious 
arterivirus cDNA clone: identification of a replicase point mutation that abolishes discon-
tinuous mRNA transcription. Proc Natl Acad Sci U S A 94:991-996.
Vaccination trial in horses 133
C
hapter 5
 34. Balasuriya UB, Zhang J, go yy, Maclachlan NJ. 2014. Experiences with infectious cDNA 
clones of equine arteritis virus: Lessons learned and insights gained. Virology 462-
463:388-403.
 35. posthuma CC, pedersen KW, lu Z, Joosten Rg, Roos N, Zevenhoven-dobbe JC, Snijder 
eJ. 2008. Formation of the arterivirus replication/transcription complex: a key role for 
nonstructural protein 3 in the remodeling of intracellular membranes. J Virol 82:4480-
4491.
 36. Zhang J, go yy, Huang CM, Meade BJ, lu Z, Snijder eJ, timoney pJ, Balasuriya UB. 2012. 
Development and characterization of an infectious cDNA clone of the modified live virus 
vaccine strain of equine arteritis virus. Clin Vaccine Immunol 19:1312-1321.
 37. Balasuriya UB, Heidner HW, davis Nl, Wagner HM, Hullinger pJ, Hedges JF, Williams JC, 
Johnston Re, david Wilson W, liu iK, James Maclachlan N. 2002. Alphavirus replicon 
particles expressing the two major envelope proteins of equine arteritis virus induce 
high level protection against challenge with virulent virus in vaccinated horses. Vaccine 
20:1609-1617.
 38. Rozen S, Skaletsky HJ. 1998. Primer3 on the WWW for general users and for biologist pro-
grammers, p. pp 365-386. In S. K, Misener S (ed.), Bioinformatics Methods and Protocols: 
Methods in Molecular Biology. Humana Press, Totowa, NJ.
 39. go yy, li y, Chen Z, Han M, yoo d, Fang y, Balasuriya UB. 2014. Equine arteritis virus 
does not induce interferon production in equine endothelial cells: identification of 
nonstructural protein 1 as a main interferon antagonist. BioMed research international 
2014:420658.
 40. Huang C, Zhang Q, guo XK, yu ZB, Xu at, tang J, Feng WH. 2014. Porcine Reproductive and 
Respiratory Syndrome Virus Nonstructural Protein 4 Antagonizes IFNbeta Expression by 
Targeting NEMO. J Virol 88:10934-10945.
 41. Chen Z, lawson S, Sun Z, Zhou X, guan X, Christopher-Hennings J, Nelson ea, Fang y. 
2010. Identification of two auto-cleavage products of nonstructural protein 1 (nsp1) in 
porcine reproductive and respiratory syndrome virus infected cells: nsp1 function as 
interferon antagonist. Virology 398:87-97.
 42. Song C, Krell p, yoo d. 2010. Nonstructural protein 1alpha subunit-based inhibition of NF-
kappaB activation and suppression of interferon-beta production by porcine reproductive 
and respiratory syndrome virus. Virology 407:268-280.
 43. Shi X, Zhang g, Wang l, li X, Zhi y, Wang F, Fan J, deng R. 2011. The nonstructural protein 
1 papain-like cysteine protease was necessary for porcine reproductive and respiratory 
syndrome virus nonstructural protein 1 to inhibit interferon-beta induction. DNA Cell Biol 
30:355-362.
 44. Subramaniam S, Beura LK, Kwon B, Pattnaik AK, Osorio fA. 2012. Amino acid residues 
in the non-structural protein 1 of porcine reproductive and respiratory syndrome virus 
involved in down-regulation of TNF-alpha expression in vitro and attenuation in vivo. 
Virology 432:241-249.
 45. Shi X, Chen J, Xing g, Zhang X, Hu X, Zhi y, guo J, Wang l, Qiao S, lu Q, Zhang g. 2012. 
Amino acid at position 176 was essential for porcine reproductive and respiratory syn-
drome virus (PRRSV) non-structural protein 1alpha (nsp1alpha) as an inhibitor to the 
induction of IFN-beta. Cell Immunol 280:125-131.
134 Chapter 5
 46. Han M, du y, Song C, yoo d. 2013. Degradation of CREB-binding protein and modulation 
of type I interferon induction by the zinc finger motif of the porcine reproductive and 
respiratory syndrome virus nsp1alpha subunit. Virus Res 172:54-65.
 47. Shi X, Zhang X, Wang F, Wang l, Qiao S, guo J, luo C, Wan B, deng R, Zhang g. 2013. The 
zinc-finger domain was essential for porcine reproductive and respiratory syndrome virus 
nonstructural protein-1alpha to inhibit the production of interferon-beta. J Interferon 
Cytokine Res 33:328-334.
 48. Beura LK, Sarkar SN, Kwon B, Subramaniam S, Jones C, Pattnaik AK, Osorio fA. 2010. Por-
cine reproductive and respiratory syndrome virus nonstructural protein 1beta modulates 
host innate immune response by antagonizing IRF3 activation. J Virol 84:1574-1584.
 49. li y, Zhu l, lawson SR, Fang y. 2013. Targeted mutations in a highly conserved motif of 
the nsp1beta protein impair the interferon antagonizing activity of porcine reproductive 
and respiratory syndrome virus. J Gen Virol 94:1972-1983.
 50. Wang R, Nan y, yu y, Zhang yJ. 2013. Porcine reproductive and respiratory syndrome 
virus Nsp1beta inhibits interferon-activated JAK/STAT signal transduction by inducing 
karyopherin-alpha1 degradation. J Virol 87:5219-5228.
 51. Shi X, Wang l, li X, Zhang g, guo J, Zhao d, Chai S, deng R. 2011. Endoribonuclease 
activities of porcine reproductive and respiratory syndrome virus nsp11 was essential for 
nsp11 to inhibit IFN-beta induction. Mol Immunol 48:1568-1572.
 52. Sagong m, Lee C. 2011. Porcine reproductive and respiratory syndrome virus nucleo-
capsid protein modulates interferon-beta production by inhibiting IRF3 activation in 
immortalized porcine alveolar macrophages. Arch Virol 156:2187-2195.
 53. Nedialkova DD, Ulferts r, van den Born e, Lauber C, Gorbalenya Ae, Ziebuhr J, Snijder 
eJ. 2009. Biochemical characterization of arterivirus nonstructural protein 11 reveals the 
nidovirus-wide conservation of a replicative endoribonuclease. J Virol 83:5671-5682.
 54. Barretto N, Jukneliene D, ratia K, Chen Z, mesecar AD, Baker SC. 2005. The papain-like 
protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity. 
J Virol 79:15189-15198.
 55. lindner Ha, Fotouhi-ardakani N, lytvyn V, lachance p, Sulea t, Menard R. 2005. The 
papain-like protease from the severe acute respiratory syndrome coronavirus is a deubiq-
uitinating enzyme. J Virol 79:15199-15208.
 56. Chen Z, Wang y, Ratia K, Mesecar ad, Wilkinson Kd, Baker SC. 2007. Proteolytic process-
ing and deubiquitinating activity of papain-like proteases of human coronavirus NL63. J 
Virol 81:6007-6018.
 57. Zheng d, Chen g, guo B, Cheng g, tang H. 2008. PLP2, a potent deubiquitinase from 
murine hepatitis virus, strongly inhibits cellular type I interferon production. Cell Res 
18:1105-1113.
 58. Xing y, Chen J, tu J, Zhang B, Chen X, Shi H, Baker SC, Feng l, Chen Z. 2013. The papain-
like protease of porcine epidemic diarrhea virus negatively regulates type I interferon 
pathway by acting as a viral deubiquitinase. J Gen Virol 94:1554-1567.
 59. yang X, Chen X, Bian g, tu J, Xing y, Wang y, Chen Z. 2013. Proteolytic processing, 
deubiquitinase and interferon antagonist activities of Middle East respiratory syndrome 
coronavirus papain-like protease. J Gen Virol 95:614-626.
 60. Mielech aM, Kilianski a, Baez-Santos yM, Mesecar ad, Baker SC. 2014. MERS-CoV papain-
like protease has deISGylating and deubiquitinating activities. Virology 450-451:64-70.
Vaccination trial in horses 135
C
hapter 5
 61. Wojdyla Ja, Manolaridis i, van Kasteren pB, Kikkert M, Snijder eJ, gorbalenya ae, tucker 
PA. 2010. Papain-like protease 1 from transmissible gastroenteritis virus: crystal struc-
ture and enzymatic activity toward viral and cellular substrates. J Virol 84:10063-10073.
 62. devaraj Sg, Wang N, Chen Z, tseng M, Barretto N, lin R, peters CJ, tseng Ct, Baker SC, 
Li K. 2007. Regulation of IRF-3-dependent innate immunity by the papain-like protease 
domain of the severe acute respiratory syndrome coronavirus. J Biol Chem 282:32208-
32221.
 63. frieman m, ratia K, Johnston re, mesecar AD, Baric rS. 2009. Severe acute respiratory 
syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain 
regulate antagonism of IRF3 and NF-kappaB signaling. J Virol 83:6689-6705.
 64. Clementz Ma, Chen Z, Banach BS, Wang y, Sun l, Ratia K, Baez-Santos yM, Wang J, 
Takayama J, Ghosh AK, Li K, mesecar AD, Baker SC. 2010. Deubiquitinating and interferon 
antagonism activities of coronavirus papain-like proteases. J Virol 84:4619-4629.
 65. Wang g, Chen g, Zheng d, Cheng g, tang H. 2011. PLP2 of mouse hepatitis virus A59 
(MHV-A59) targets TBK1 to negatively regulate cellular type I interferon signaling path-
way. PLoS One 6:e17192.
 66. Chen X, yang X, Zheng y, yang y, Xing y, Chen Z. 2014. SARS coronavirus papain-like 
protease inhibits the type I interferon signaling pathway through interaction with the 
STING-TRAF3-TBK1 complex. Protein Cell 5:369-381.
 67. Bakshi S, Holzer B, Bridgen a, McMullan g, Quinn dg, Baron Md. 2013. Dugbe virus 
ovarian tumour domain interferes with ubiquitin/ISG15-regulated innate immune cell 
signalling. J Gen Virol 94:298-307.

Chapter 6 
viral OTU Deubiquitinases: a Structural and 
functional Comparison
Ben A. Bailey-Elkin1, Puck B. van Kasteren1, Eric J. Snijder, 
Marjolein Kikkert2, and Brian L. Mark2
PLoS Path (2014) 10:e1003894
1 Both authors contributed equally to this work.
2 Both authors contributed equally to this work.
138 Chapter 6
ABSTrACT
Recent studies have revealed that proteases encoded by three very diverse RNA virus 
groups share structural similarity with enzymes of the Ovarian Tumor (OTU) superfam-
ily of deubiquitinases (DUBs). The publication of the latest of these reports in quick 
succession prevented proper recognition and discussion of the shared features of 
these viral enzymes. Here we provide a brief structural and functional comparison 
of these virus-encoded OTU DUBs. Interestingly, although their shared structural 
features and substrate specificity tentatively place them within the same protease 
superfamily, they also show interesting differences that trigger speculation as to their 
origins.




The covalent attachment of ubiquitin (Ub) to protein substrates, i.e. ubiquitination, 
plays a pivotal regulatory role in numerous cellular processes (1-5). Ubiquitination 
can be reversed by deubiquitinases (DUBs) (6) and, not surprisingly, various virus 
groups encode such DUBs to influence ubiquitin-mediated host cell processes (7-21). 
Some of these viral DUBs resemble proteases belonging to the Ovarian Tumor (OTU) 
superfamily (22-28). Makarova et al. previously identified OTU proteases as a novel 
superfamily of cysteine proteases from different organisms (29), and their bioinfor-
matics-based analysis included several of the viral enzymes discussed here. Recently 
reported structures of these viral DUBs include the OTU domains of the nairoviruses 
Crimean-Congo hemorrhagic fever virus (CCHFV) (22-24) and Dugbe virus (DUGV) 
(25), the papain-like protease (PLP2) domain of the arterivirus equine arteritis virus 
(EAV) (26), and the protease (PRO) domain of the tymovirus turnip yellow mosaic virus 
(TYMV) (figure vI-1A to D) (27, 28). These viruses are strikingly diverse, considering 
that nairoviruses are mammalian negative-strand RNA viruses, while the mammalian 
arteriviruses and plant tymoviruses belong to separate orders of positive-strand RNA 
viruses.
Ubiquitination often involves the formation of polyubiquitin chains (1), which can 
target the ubiquitinated substrate to the proteasome for degradation (2) or modulate 
its protein-protein interactions, as in the activation of innate immune signalling path-
ways (3, 4). Interestingly, several cellular OTU DUBs were found to negatively regulate 
innate immunity (30-33). Likewise, both nairovirus OTU and arterivirus PLP2 were 
recently shown to inhibit innate immune responses by targeting ubiquitinated signal-
ling factors (7-9, 26, 34, 35). In contrast to eukaryotic OTU DUBs, both of these viral 
proteases were found to also deconjugate the Ub-like protein interferon-stimulated 
gene 15 (ISG15) (7, 36), which inhibits viral replication via a mechanism that is cur-
rently poorly understood (37). Interestingly, coronaviruses (which, together with the 
arteriviruses, belong to the nidovirus order) also encode papain-like proteases target-
ing both Ub and ISG15 that were shown to inhibit innate immunity (11-13, 38-42), but 
belong to the ubiquitin-specific protease (USP) class of DUBs (6, 43, 44). The presence 
of functionally similar, yet structurally different proteases in distantly related virus 
families highlights the potential benefits to the virus of harboring such enzymes.
The proteasomal degradation pathway is an important cellular route to dispose of 
viral proteins, as exemplified by the turnover of the TYMV polymerase (45). Moreover, 
the degradation of this protein is specifically counteracted by the deubiquitinase 














       site
Active 
       site
Active 
       site
Active 
       site
Active 
       site
Active 










CCHFV (genus Nairovirus; family Bunyaviridae; -RNA) - L protein
3175 aa









figure vI-1: viral and eukaryotic OTU domain structures and viral protein context. Crystal struc-
tures of (A) CCHFV OTU (3PT2) (23), (B) DUGV OTU (4HXD) (25), (C) EAV PLP2 (4IUM) (26), (D) TYMV 
PRO (4A5U) (27, 28), (e) yeast OTU1 (3BY4) (57), and (f) human OTUD3 (4BOU) (46). The β-hairpin 
motifs of CCHFV OTU and DUGV OTU are indicated in boxes in panels A and B, respectively, and the 
zinc-fi nger motif of EAV PLP2 is boxed in panel C. Active sites are indicated with arrows. The CCHFV 
OTU, DUGV OTU, EAV PLP2, and yeast OTU1 domains were crystallized in complex with Ub, which 
has been removed for clarity. Structure images were generated using PyMol (60). (G) Schematic 
representation of the CCHFV large (L) protein (61, 62). A similar organization is found in the DUGV 
L protein, but is not depicted. The OTU domain resides in the N-terminal region of this protein and 
is not involved in autoproteolytic cleavage events (48). (H) Schematic representation of the EAV 
polyprotein 1ab (63). PLP2 resides in nonstructural protein 2 (nsp2) and is responsible for the 
cleavage between nsp2 and nsp3 (51). (I) Schematic representation of the TYMV ORF1 polyprotein 
(50). PRO resides in the N-terminal product of this polyprotein and is responsible for two internal 
cleavages (49, 50). Key replicative enzymes are indicated in G, H, and I. Coloured arrowheads de-
note cleavage sites for the indicated protease domains. Abbreviations: HEL, helicase; PLP, papain-
like protease; RdRp, RNA-dependent RNA polymerase; SP, serine protease.
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characterization of viral OTU DUBs remains incomplete and future studies will likely 
reveal additional roles in replication and virus-host interplay.
Polyubiquitin chains can adopt a number of different configurations, depending on 
the type of covalent linkage present within the polymer (1). A distal Ub molecule 
can be linked via its C-terminus to one of seven internal lysine residues present in 
a proximal Ub molecule via an isopeptide bond. Alternatively, in the case of linear 
chains, the C-terminus of the distal Ub is covalently linked to the N-terminal methio-
nine residue of the proximal Ub via a peptide bond. While human OTU proteases often 
show a distinct preference for one or two isopeptide linkage types (46), nairovirus 
OTUs and TYMV PRO appear to be more promiscuous in their substrate preference 
(22, 25). However, like most human OTU proteases they seem unable to cleave linear 
polyubiquitin chains in vitro (22, 25, 46). Arterivirus PLP2 has not been extensively 
studied in this respect.
It is important to note that many positive-strand RNA viruses, including arterivi-
ruses and tymoviruses, encode polyproteins that are post-translationally cleaved by 
internal protease domains (47). Thus, while CCHFV OTU is not involved in viral protein 
cleavage and its activity seems dispensable for replication (figure vI-1G) (48), both 
arterivirus PLP2 and tymovirus PRO are critically required for viral replication due to 
their primary role in polyprotein maturation (figure vI-1H and i) (49-53). Interestingly, 
while both EAV PLP2 and TYMV PRO can process peptide bonds in cis and in trans (50, 
51), PRO does not cleave peptide bonds in linear polyubiquitin chains in vitro (25). To 
date, activity of EAV PLP2 towards linear polyubiquitin chains has not been reported.
Based on mutagenesis of putative catalytic residues, arterivirus PLP2 and tymovirus 
PRO were initially generally classified as papain-like cysteine proteases (51, 54, 
55). Now that crystal structures of these proteases are available, it is possible to 
search the DALI server (56) in order to identify structurally similar domains. Using 
the 3-dimensional coordinates of TYMV PRO, the most recently solved structure of a 
viral OTU protease, such a query identifies structural similarity with eukaryotic OTU 
DUBs as well as the nairovirus OTU domains and EAV PLP2 (Table vI-1). A superposi-
tion of these viral protease structures with yeast OTU1 (57) further highlights their 
similarities (figure vI-2A to C), and these comparisons together clearly position them 
within the OTU DUB superfamily. Sequence comparisons alone were insufficient to 
demonstrate this conclusively, as the similarity of viral OTU domains to each other 
and to eukaryotic OTU proteases is very limited and mostly restricted to the areas 
surrounding the active site residues (29).
Structural characterization of nairovirus (CCHFV and DUGV) OTU domains and EAV 
PLP2 in complex with Ub revealed that while these viral proteases adopt a fold that 
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figure vI-2: Superpositions of the viral OTU proteases with yeast OTU1 and one another. Super-
positions of yeast OtTU1 (3BY4) (57) with (A) CCHFV OTU (3PT2) (23), RMSD: 1.8Å over 112 resi-
dues, (B) EAV PLP2 (4IUM) (26), RMSD: 2.8Å over 69 residues, and (C) TYMV PRO (4A5U) (27, 28), 
RMSD: 1.4Å over 76 residues. Superpositions of the yeast OTU1-Ub complex with (D) the CCHFV 
OTU-Ub complex and (e) the EAV PLP2-Ub complex, highlighting the diff erence in the orientation 
of Ub between the two viral OTU domains versus the eukaryotic yeast OTU1 domain. The Ub that 
is complexed with yeast OTU1 is depicted in yellow, while the Ub complexed with CCHFV OTU or 
EAV PLP2 is depicted in orange. (f) Superposition of EAV PLP2 and TYMV PRO, RMSD: 2.5Å over 
53 residues. (G) Close-up of the active site region (boxed) of the superposition depicted in F. Side 
chains of the catalytic cysteine (Cys270 and Cys783 for EAV PLP2 and TYMV PRO, respectively) 
and histidine (His332 and His869 for EAV PLP2 and TYMV PRO, respectively) residues are shown as 
sticks, as well as the active site Asn263 for EAV PLP2. The backbone amide group of Asp267 likely 
contributes to the formation of the oxyanion hole in the active site of EAV PLP2, yet a functionally 
equivalent residue is absent in TYMV PRO. The Gly266 and Gly268 residues fl anking Asp267 in EAV 
PLP2 are depicted as sticks as well, for clarity. Note the alternative orientation of the active site 
cysteine residue of TYMV PRO which, unlike EAV PLP2, was not determined in covalent complex 
with a Ub suicide substrate. All alignments were generated using the PDBeFOLD server (64), and 
thus the reported RMSD values diff er from those reported in Table 1, in which the DALI server was 
used. The yeast OTU1, CCHFV OTU, and EAV PLP2 domains were all crystallized in complex with 
Ub, which has been removed in panels A, B, C, F, and G for clarity. All images were generated using 
PyMol (60). Abbreviation: RMSD, root-mean-square deviation.
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their S1 binding site that rotate the distal Ub relative to the binding orientation ob-
served in eukaryotic OTU enzymes (figure vI-2D and e) (22-26). In the case of CCHFV 
OTU, this alternative binding mode was shown to expand its substrate repertoire by 
allowing the enzyme to also accommodate ISG15. Since TYMV PRO was crystallized in 
its apo form (27, 28), it remains to be determined whether its S1 site binds Ub in an 
orientation similar to nairovirus OTU and EAV PLP2 or eukaryotic OTU DUBs.
A remarkable feature of EAV PLP2 is the incorporation within the OTU-fold of a zinc 
finger that is involved in the interaction with Ub (figures vI-1C and 2e). The absence 
of similar internal zinc-finger motifs in other OTU superfamily members prompted us 
to propose that PLP2 prototypes a novel subclass of zinc-dependent OTU DUBs (26).
Finally, an interesting structural difference between TYMV PRO and other OTU 
proteases of known structure is the absence of a loop that generally covers the active 
site (figure vI-2f and G). Because of this, TYMV PRO lacks a complete oxyanion hole. 
It also lacks a third catalytic residue that would otherwise form the catalytic triad that 
has been observed in other OTU proteases (figure vI-2G). Lombardi et al. suggested 
that the resulting solvent exposure of the active site may contribute to the broad sub-
strate specificity of TYMV PRO (28). Interestingly, EAV PLP2 also has broad substrate 
specificity, cleaving Ub, ISG15, and the viral polyprotein, even though it does possess 
an intact oxyanion hole and an active site that is not solvent exposed. Future work 
may uncover additional aspects relating to the unusual architecture of the TYMV PRO 
active site.
The presence of structurally similar proteases, each displaying unique features, in 
these highly diverse virus groups suggests that their ancestors have independently 
acquired their respective OTU enzymes. Although their origins remain elusive, one 
possible scenario is the scavenging of an OTU DUB-encoding gene that directly enabled 
the ancestral virus to interact with the cellular ubiquitin landscape (29). The absence 
of an OTU homologue in other lineages of the bunyavirus family strongly suggests 
that a nairoviral ancestor acquired an OTU DUB through heterologous recombination. 
In this scenario, the current differences between the nairoviral and eukaryotic OTU do-
mains would reflect divergent evolution. In the case of arteriviruses however, it is also 
conceivable that a preexisting papain-like protease that was initially only involved in 
polyprotein maturation acquired OTU-like features through a process of convergent 
evolution. Although rare, such a scenario would account for the limited structural 
similarity between eukaryotic OTU domains and EAV PLP2, which contrasts with that 
observed for nairovirus OTU (figure vI-2A and B; Table vI-1). For tymoviruses, which 
encode one (OTU) protease, the existence of related viruses that do not encode a pro-
tease domain or that encode one (papain-like) or two (OTU combined with a second 
papain-like) protease domains complicates the development of a straightforward 
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scenario describing PRO acquisition and evolution (58). These and other intriguing 
unsolved questions should be addressed through structural and functional studies of 
additional OTU-like proteases, be they viral or cellular, the results of which may shed 
more light on the various scenarios explaining the evolution of viral OTU domains.
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Table vI-1: Three-dimensional structural alignment of viral OTU domains against selected struc-
tures in the Protein Data Bank using the DALI server (56).
DALI query: CCHFV OtU DUGv OTU tyMV pRO eAv PLP2
3PT2 (23) 4HXD (25) 4A5U (27, 28) 4IUM (26)
Human OtUd3 14.5; 12%* 14.4; 15% 7.6; 12% 4.2; 13%
4BOU (46) 2.1 Å (123)** 2.1 Å (123) 1.9 Å (85) 2.4 Å (69)
yeast OtU1 11.8; 16% 11.6; 20% 7.3; 12% 5.1; 9%
3BY4 (57) 2.9 Å (126) 2.5 Å (123) 2.3 Å (91) 3.3 Å (81)
CCHFV OtU 28.1; 55% 6.8; 15% 4.6; 19%
3PT2 (23) 0.9 Å (157) 3.0 Å (91) 2.6 Å (74)
DUGv OTU 6.9; 12% 4.5; 19%
4HXD (25) 2.8 Å (90) 2.6 Å (74)
tyMV pRO 3.2; 13%
4A5U (27, 28) 2.8 Å (64)
*z-score (>2 indicates significant structural similarity (59)); % sequence identity.
**Root-mean-square deviation (RMSD) values are indicated, followed by the number of residues 
used for RMSD calculation in brackets. Value represents the average distance (Å) between alpha 
carbons used for comparison.
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a deUBiQUitiNaSe tHat COUNteRaCtS iNNate iMMUNity
As is the case for many proteases encoded by mammalian +RNA viruses, the arterivirus 
proteases play a crucial role in the viral replication cycle. Together, they are respon-
sible for sculpting the replicase polyproteins into active replication and transcription 
complexes and without their activity viral infection would quickly come to a grinding 
halt. Consequently, identification and design of specific protease inhibitors form 
promising approaches in the search for antiviral drugs, which can greatly benefit from 
the in-depth characterization of the structural and functional aspects of viral prote-
ases. In addition to playing a direct role in replication, one of the arterivirus protease 
domains (papain-like protease 2; PLP2) has previously been suggested to be involved 
in the evasion of innate immune activation by means of its putative deubiquitinase 
(DUB) activity (1). Since the innate immune response is presumed to be pivotal for 
eliciting a timely and adequate adaptive immune response, increased knowledge of 
viral innate immune evasion strategies will likely make an important contribution to 
the future design of improved vaccines.
The work described in this thesis provides novel insights into the structural features 
and (multi)functionality of arterivirus PLP2. Not only have we clearly demonstrated 
the in vitro DUB activity of this enzyme and the conservation of this activity across 
the arterivirus family (Chapter 2), we have also shown how this DUB activity can be 
exploited in the search for antiviral compounds (Chapter 3). Furthermore, the crystal 
structure of equine arteritis virus (EAV) PLP2 answered some long-standing questions 
regarding the architecture of this domain and allowed us to demonstrate the impor-
tance of its DUB activity in counteracting the innate immune response (Chapter 4). 
By means of targeted mutagenesis, we have succeeded in separating the polyprotein 
processing and DUB functions of PLP2, which finally allowed for a direct assessment 
of the role of this enzyme in innate immune evasion during infection. Following up 
on this work, an in vivo experiment was performed to evaluate the potential use of 
PLP2 DUB-negative viruses in arterivirus vaccine design (Chapter 5). Below, this newly 
obtained information will first be discussed in the context of the existing framework 
of knowledge regarding arterivirus proteases in general and PLP2 in particular. Next, I 
will discuss our current understanding of arterivirus innate immune evasion strategies 
and the potential use of this knowledge in the design of novel arterivirus vaccines. 
Some future research directions will then be delineated, in particular concerning the 
target specificity and putative deISGylating activity of arterivirus PLP2. This general 
discussion will be concluded with some words on the multifunctional nature of prote-
ases encoded by diverse +RNA virus groups.
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StRUCtURal aNd FUNCtiONal CHaRaCteRiZatiON OF aRteRiViRUS plp2
Characterization of arterivirus proteases
The identification of arterivirus protease domains commenced with the elucidation of 
the EAV genome sequence in 1991, which revealed the presence of a chymotrypsin-
like serine protease (SP) consensus sequence in the subunit that would later be named 
nsp4 (2). Further studies confirmed the SP to be the main arterivirus protease, which 
is responsible for processing of the majority of ORF1a-encoded cleavage sites and all 
ORF1b-encoded cleavage sites in the replicase polyproteins (pp1a and pp1ab) (3, 4). 
In addition, initial sequence analysis of the EAV polyproteins revealed some similar-
ity with cellular papain-like proteases in the C-terminal region of the protein now 
known as nsp1 (2), and later studies confirmed the activity of this domain towards the 
nsp1|nsp2 cleavage site (5, 6). Because of the subsequent identification in other ar-
teriviruses of one or two additional upstream papain-like protease domains (7, 8), the 
nsp1 protease domains are now referred to as papain-like protease 1α (PLP1α), PLP1β, 
and PLP1γ. In porcine reproductive and respiratory syndrome virus (PRRSV) and lactate 
dehydrogenase-elevating virus (LDV), which both contain two active nsp1 proteases, 
PLP1α and PLP1β mediate the release of two nsp1 subunits, nsp1α and nsp1β. In the 
case of EAV, a presumed substitution of the PLP1α catalytic cysteine has rendered this 
domain inactive (7), resulting in the release of a single nsp1 subunit encompassing 
only one active protease domain, i.e. PLP1β. In the case of simian hemorrhagic fever 
virus (SHFV), a combination of sequence analysis and recent functional studies has 
revealed an even more complicated organisation of the nsp1 region, encompassing 
three active papain-like protease domains (9).
Finally, the analysis of EAV pp1a processing revealed the involvement of a third (vi-
ral or cellular) protease that was responsible for cleavage of the nsp2|nsp3 site (5). An 
extensive search involving both bioinformatics analysis and mutagenesis eventually 
lead to the identification in the N-terminal region of nsp2 of a cysteine protease (CP) 
with both papain-like and chymotrypsin-like amino acid sequence characteristics (10). 
The subsequent discovery of a cellular papain-like protease with similar sequence 
characteristics (11), prompted the eventual renaming of this CP domain into papain-
like protease 2 (PLP2). Later, protease activity was also experimentally confirmed for 
the PLP2 domain of PRRSV (12). Presumably, all arterivirus proteases have now been 
identified, although the possibility of future additions cannot be excluded.
the road to structural clarification
The three-dimensional structures of the arterivirus proteases were resolved in the 
same order in which they were initially described. The first was that of the EAV SP 























































figure vII-1: Overview of nidovirus protease crystal structures. Crystal structures of (A) EAV nsp4 
(PDB ID: 1MBM) (13), (B) SARS-CoV nsp5 (PDB ID: 1UJ1) (15), (C) PRRSV nsp1α (PDB ID: 3IFU) (16), 
(D) PRRSV nsp1β (PDB ID: 3MTV) (17), (e) EAV PLP2 (PDB ID: 4IUM) (Chapter 4), (f) transmissible 
gastroenteritis virus (TGEV) PL1pro (PDB ID: 3MP2) (21), and (G) SARS-CoV PL2pro (PDB ID: 2FE8) 
(29). Chymotrypsin-like main proteases are depicted in green and papain-like accessory proteases 
are depicted in blue. Active site residues are shown in red as sticks. EAV PLP2 was crystallized in 
complex with ubiquitin, which is not shown here for clarity. Abbreviations: CTD, C-terminal do-
main; CTE, C-terminal extension; NTD, N-terminal domain; UBL, ubiquitin-like domain; ZF, zinc fi n-
ger; ZFD, zinc fi nger domain.
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crystal structure (14). As predicted (4), the arterivirus SP adopts the two β-barrel fold 
that is characteristic of chymotrypsin-like proteases. In this respect, it resembles the 
main proteases found in the distantly related subfamily Coronavirinae (figure vII-1B 
and (15)), with the exception that the latter exploit a cysteine instead of a serine 
as the nucleophilic residue that drives catalysis. Next, the crystal structures of the 
PRRSV nsp1α and nsp1β subunits (encompassing the PLP1α and PLP1β domains) 
became available (figure vII-1C and D and (16, 17)), which both display the predicted 
papain-like α+β fold.
With the addition of the EAV PLP2 domain, the collection of arterivirus protease 
structures is now nearing completion, with only PLP1γ lacking (figure vII-1e and 
Chapter 4). The structure of PLP2 remained elusive for a long time due to difficul-
ties with its purification, but these were solved, in part, by switching to the use of 
a covalent protease-substrate complex that stabilized the protein. The PLP2 domain 
indeed also proved to adopt the α+β fold that is characteristic of papain-like pro-
teases, but in addition displayed similarity with enzymes belonging to the ovarian 
tumor (OTU) superfamily of proteases, as had previously been suggested (18). The 
functional implications of this resemblance will be addressed below. Furthermore, 
the three-dimensional structure of EAV PLP2 confirmed the previous suggestion of a 
nucleophilic cysteine (Cys270) and histidine (His332) being responsible for catalysis 
(10), and revealed that an additional residue (Asn263) completes the catalytic triad 
(figure Iv-1D). Finally, the PLP2 crystal structure also confirmed the presence of a pre-
viously predicted zinc finger (10), which seems to be involved in protease-substrate 
interaction (figure Iv-2A). The incorporation of a zinc finger motif within the OTU-fold 
appears to be unique for arterivirus PLP2, which is why we have proposed that this 
enzyme prototypes a novel subclass of zinc-dependent OTU proteases (Chapter 4).
Arterivirus PLP2 is an OTU deubiquitinase
Several years after its identification in 1995, an extensive bioinformatics analysis 
revealed that the arterivirus PLP2 domain shares remote sequence similarity with en-
zymes belonging to the OTU superfamily of proteases (18), which consists of papain-
like cysteine proteases that often display DUB activity (19). Subsequent work by Frias-
Staheli et al. (2007) showed that ectopic expression of EAV and PRRSV nsp2 resulted in 
an overall decrease of the level of ubiquitinated proteins, which was consistent with 
the hypothesis that the PLP2 domain functions as a DUB (1). In Chapter 2 of this thesis 
we provided the first in vitro evidence that purified recombinant EAV PLP2 exhibits 
DUB activity (figure II-1). Moreover, our in vitro results uncovered a slight preference 
of EAV PLP2 for Lys63- over Lys48-linked polyubiquitin chains. These findings are 
in line with a recent report in which it is shown that also PRRSV PLP2 displays an 




preference) Lys11-, Lys29-, Lys6-, Lys27-, and Lys48-linked di-ubiquitin (20). Activity 
towards linear chains could not be detected. Whether EAV PLP2 displays a similar 
pattern of linkage preferences, and to what extent these in vitro results correspond 
to the natural situation, remains to be investigated. In addition to firmly establishing 
the DUB activity of PLP2, we showed that this property is very likely conserved among 
all four currently recognized arterivirus species (figure II-3). This study also provided 
the first (preliminary) experimental evidence of proteolytic activity for the LDV and 
SHFV PLP2 domains.
Importantly, the finding that arterivirus PLP2 functions as a DUB had implications 
for the delineation of the nsp2|nsp3 cleavage site. Based on estimated nsp2 and 
nsp3 sizes, the idea that papain-like proteases often cleave between two small amino 
acid residues, and a mutagenesis experiment showing that a Gly831Pro mutation 
hampered cleavage, it had previously been suggested that EAV PLP2 cleaves between 
pp1a residues Gly831 and Gly832 (4). According to this scenario, the nsp2|nsp3 
cleavage site would be 827FRLIG|GW833. However, the fact that DUBs generally cleave 
directly downstream of a C-terminal LRLRGG sequence, now made it much more likely 
that cleavage actually occurs downstream rather than upstream of residue Gly832, 
thus changing the cleavage site to 827FRLIGG|W833. This idea was further supported 
by the crystal structure of PLP2 in complex with ubiquitin, which showed that the 
two C-terminal glycine residues of ubiquitin (the second having been replaced with 
a reactive group) fit nicely into the groove leading up to the active site (Chapter 4). 
Given the similarity between the C termini of ubiquitin and EAV nsp2, it seems likely 
that the latter is also cleaved downstream of the double glycine motif. Nevertheless, 
definitive confirmation of this hypothesis still requires additional experimental work, 
such as sequencing of viral cleavage products.
Interestingly, arteriviruses are not the only viruses that harbour DUB activity. For 
example, also the distantly related coronaviruses encode papain-like proteases with 
DUB activity (21-28). In contrast to the arterivirus OTU DUBs, these coronavirus en-
zymes belong to the ubiquitin-specific protease (USP) class of DUBs (figure vII-1f and 
G and (21, 29)). Other viral proteases suggested to act as DUBs are the USP-like leader 
protease of the picornavirus foot-and-mouth disease virus (FMDV) (30) and the OTU-
like protease domain encoded by turnip yellow mosaic virus (TYMV) (31), which as the 
name indicates is a plant virus. Although these are all examples of DUBs encoded by 
+RNA viruses, their presence is certainly not restricted to this particular group of vi-
ruses. Also the negative-strand RNA viruses belonging to the nairovirus genus encode 
an OTU DUB in the N-terminal region of their polymerase protein (1, 32-34) and DUBs 
are expressed by a number of DNA viruses, including several herpesviruses (35-39) 
and an adenovirus (40). Since bioinformatics-based analyses have been instrumental 
in the discovery of DUB activity for many of these viral proteases (18, 30, 41), the 
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increased analytical power of such techniques in combination with the increasing 
number of available genome sequences might lead to the future identification of 
even more virus-encoded DUBs.
Deubiquitinase-based screens for antiviral compounds
In addition to being an interesting feature of arterivirus PLP2 in itself, the DUB activity 
of this and other +RNA viral enzymes opens up novel possibilities for the search for 
antiviral protease inhibitors since it can be used as a read-out for proteolytic activity. 
Because of their essential role in replicase maturation, +RNA viral proteases form a 
promising target for the design of antiviral drugs. This is exemplified by the recent 
FDA approval for clinical use of two compounds that inhibit the main protease of 
hepatitis C virus and the use of several protease inhibitors for the treatment of HIV 
infection (for reviews, see (42, 43)). However, the search for such compounds often 
depends on time-consuming cell culture-based infection assays and would therefore 
likely benefit from the design of (high-throughput) in vitro screens that allow for initial 
selection of promising compounds without the safety constraints imposed by working 
with live viruses. One of the advantages of using a DUB-based screening approach 
is that a similar experimental set-up can be used to identify inhibitors of proteases 
encoded by different viruses, without the need to design specific substrates for each 
individual protease.
Using EAV PLP2 as a model, we showed that a recently developed in vitro DUB as-
say based on fluorescence polarization (44-47) can be applied for high-throughput 
in vitro screens to identify inhibitors that decrease viral replication (Chapter 3). This 
assay depends on a ubiquitin substrate that is covalently linked via an isopeptide 
bond to a rhodamine-based fluorophore (TAMRA) and on a decrease in polarization of 
the emitted light that is used as a read-out for substrate cleavage. Because of the ease 
of production of the substrate and the low reaction volumes required, this DUB assay 
is particularly well suited for use in high-throughput experimental set-ups. Using this 
assay, we have screened a library of 335 suspected DUB inhibitors for activity against 
EAV PLP2. Of the five compounds that were found to inhibit PLP2 DUB activity in vitro 
(figure III-1C), four also inhibited replication of a GFP-expressing reporter virus to a 
reasonable extent (figure III-2). Although the demand for antiviral compounds target-
ing viruses of livestock and other, especially non-domesticated, animals is extremely 
limited, these results do show that this DUB-based in vitro screen can, in principle, be 
applied for the identification of compounds that inhibit replication of DUB-encoding 
viruses. It would therefore be interesting to use this set-up to screen for compounds 
that inhibit the DUBs encoded by for example the SARS- and MERS-coronaviruses, 





eVaSiON OF iNNate iMMUNity By aRteRiViRUSeS
PLP2 inhibits innate immune activation
As described above, the PLP2 domain was one of the last arterivirus proteases both 
to be identified and to be crystallized. In contrast, this enzyme was actually the first 
arterivirus protein domain suggested to be involved in the evasion of innate immune 
activation. It had long been established, in particular for PRRSV, that arteriviruses in-
duce only very low levels of type I interferons (IFNs) (49-51), but the first viral proteins 
and mechanisms responsible for counteracting the IFN response were not identified 
until years later. The extensive ubiquitin-mediated regulation of innate immunity first 
prompted Frias-Staheli et al. (2007) to suggest a possible role for arterivirus PLP2 
in innate immune evasion (1). This hypothesis was supported by their finding that 
ectopic expression of arterivirus nsp2 inhibited TNFα-mediated activation of NF-κB, 
an important transcription factor for innate immune signalling. Subsequent work, per-
formed in several laboratories including our own, provided further support for a role 
of arterivirus PLP2 in innate immune evasion ((52-54) and Chapter 2). For example, we 
showed that ectopic expression of nsp2 or PLP2 inhibited RIG-I-mediated activation 
of the IFNβ-promoter in a luciferase-based reporter assay (figure II-5) and in addition 
decreased the level of RIG-I ubiquitination (figure II-7). Nevertheless, definitive proof 
for such a role during infection remained elusive mainly because of the primary role 
of arterivirus PLP2 in replicase maturation, which precluded straightforward inactiva-
tion of this domain.
To overcome this problem, we initially attempted to decouple the proteolytic ac-
tivity of the PLP2 domain from processing of the nsp2|nsp3 junction by replacing 
the latter with a “self-cleaving” peptide sequence from the 2A protein of FMDV. 
This sequence has been shown to induce a ribosomal skipping event that prevents 
the formation of a particular peptide bond, thereby resulting in the co-translational 
formation of two discrete protein products from one open reading frame (55, 56). The 
insertion of the FMDV 2A sequence in an nsp2-nsp3 expression construct resulted in 
the near-complete and PLP2 activity-independent separation of nsp2 and nsp3 upon 
transfection in eukaryotic cells (unpublished data). However, recombinant EAV encod-
ing this sequence turned out to be non-viable, preventing further analysis.
In Chapter 4, we described how the elucidation of the crystal structure of EAV PLP2 
allowed for the separation of its polyprotein processing and DUB functions by site-
directed mutagenesis of the ubiquitin interaction site (figure Iv-3), which opened up 
the possibility of studying the role of PLP2 DUB activity independently of its role in 
replicase maturation. Using this approach, we could show that virus mutants lacking 
PLP2 DUB activity showed similar replication kinetics as wild-type virus (figure Iv-5A 
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to C), yet induced approximately 8-fold higher levels of interferon beta (IFNβ) mRNA 
upon infection of primary equine cells (figure Iv-6). We were thus able to show for the 
first time that the DUB activity of arterivirus PLP2 is indeed important for the evasion 
of innate immune activation during infection. Notably, the replication kinetics of the 
above-mentioned mutants was tested in a single-cycle infection experiment and was 
likely for this reason not affected by the observed enhanced innate immune activa-
tion. However, these mutants did show an altered plaque phenotype in primary equine 
cells, with plaques of the mutant viruses being more diffuse than those induced by 
the wild-type virus (unpublished data, figure vII-2). This observation suggested that 
viruses lacking PLP2 DUB activity induce a less pronounced cytopathic effect, which 
is likely due to the enhanced activation of innate immunity. In addition to an effect of 
PLP2 DUB-mutations on the expression of IFNβ mRNA, we also observed a significantly 
enhanced expression of the interferon-stimulated gene MX1 (figure Iv-6B). Whether 
this is due to a secondary effect of increased IFNβ production, or whether PLP2 can 
also inhibit downstream interferon-mediated signalling remains to be investigated.
Interestingly, DUB-mediated evasion of innate immunity appears to be a strategy 
that is commonly used by diverse virus groups. Although not yet confirmed in infected 
cells, several coronaviruses have been suggested to counteract innate immune acti-
vation by means of the DUB activity of their papain-like protease domains (25-28, 
57-61). In addition, ectopic expression of the FMDV leader protease was shown to 
decrease Sendai virus-mediated activation of the IFNβ-promoter (30). Finally, also the 
OTU DUBs encoded by nairoviruses (1, 62, 63) and some herpesvirus-encoded DUBs 
(wild-type) (T312A/I313V/I353R)
DUB-positive EAV DUB-negative EAV
figure vII-2. Plaque assay with DUB-positive and DUB-negative eAv. A standard plaque assay was 
performed on primary equine lung fibroblasts. On the left are plaques formed by wild-type EAV 





(64, 65) have been suggested to be responsible for innate immune evasion by these 
viruses.
Teaming up against the host
In addition to nsp2, several other arterivirus proteins have been suggested to be 
involved in the evasion of innate immune responses. For example, an early study 
by Beura et al. showed that individual expression of PRRSV nsp1α-β, nsp4, or nsp11 
inhibits activation of the IFNβ-promoter by the transcription factor IRF3 (66). Follow-
ing up on this work, research efforts have mainly focused on elucidating the roles 
of PRRSV nsp1α and nsp1β in innate immune evasion (8, 66-74). Although both of 
these proteins encompass protease domains, their immune evasive activities do 
not appear to rely on proteolytic activity per se (67, 75). This is consistent with the 
notion that arterivirus PLP1 domains cleave only in cis, as was found for EAV PLP1β 
(6). Structural analysis showed that, following cleavage, the C-terminal tails of nsp1α 
and -β remain in the catalytic cleft, obstructing further proteolytic activity (16, 17). 
In the case of PRRSV nsp1α, innate immune evasion was shown to depend on the 
induction of proteasomal degradation of CREB-binding protein (CBP) (67, 71), which 
normally interacts with dimerized IRF3 upon translocation into the nucleus and is 
essential for its transcriptional activity. The nsp1α-mediated degradation of CBP thus 
prevents IRF3-mediated activation of the IFNβ-promoter. Mutational analysis further-
more showed that the activity of nsp1α towards CBP likely depends on its zinc finger 
domain (67, 68).
Nsp1β has been shown to inhibit both activation of the IFNβ-promoter and IFN-
induced JAK-STAT signalling (8, 66, 76). Whereas the exact mechanism of inhibition 
of IFNβ-promoter activation remains unclear, the inhibition of JAK-STAT signalling 
was reported to depend on nsp1β-mediated degradation of karyopherin-α1 (KPNA1) 
(73). This nuclear pore protein is responsible for the IFN-induced nuclear import of 
IFN-stimulated gene factor 3 (ISGF3), which consists of a heterotrimeric complex 
including the transcription factors STAT1, STAT2, and IRF9. Once transported into the 
nucleus, ISGF3 binds to promoter regions encompassing IFN-stimulated response 
elements (ISREs) to induce the transcription of IFN-stimulated genes (ISGs). The 
nsp1β-mediated degradation of KPNA1 thus prevents the expression of ISGs and 
thereby the induction of an antiviral state. To date, three reports have been published 
showing that viruses harboring certain mutations in PRRSV nsp1α or nsp1β induce 
higher expression levels of genes involved in innate immunity than wild-type virus 
upon infection in cell culture or in vivo, although these observations were not directly 
linked to a particular activity or target of these proteins (72, 75, 77).
Besides the above-mentioned preliminary work by Beura et al. (66), the effect of 
nsp4 on innate immune signalling has not been thoroughly investigated. Neverthe-
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less, it was recently reported that the PRRSV main protease specifically cleaves the 
innate immune signalling factor NEMO, thereby preventing its activation (78). This 
finding nicely adds to the already considerable number of +RNA virus-encoded main 
proteases that have previously been shown or suggested to inhibit innate immune 
signalling pathways (79-90). Regarding PRRSV nsp11, there is one study that shows 
that, in a luciferase-based reporter assay, ectopic expression of this protein inhibits 
activation of the IFNβ-promoter upon stimulation with the dsRNA analogue poly(I:C), 
an effect suggested to depend on the endoribonuclease activity of the protein (91). 
However, because of this activity, ectopic expression of nsp11 has previously been 
suggested to be extremely toxic to eukaryotic cells (92) and the obtained results con-
cerning a direct role in innate immune evasion for this enzyme should therefore be 
interpreted with extreme caution. Finally, ectopic expression of the nucleocapsid (N) 
protein of PRRSV has been shown to inhibit the expression of IFNβ and ISG15 mRNA 
upon stimulation with poly(I:C) (93). For both nsp11 and N, elucidation of their exact 
mechanisms of action and an assessment of the importance of their putative immune 
evasive activities during infection await further experimental clarification. figure vII-
3 provides a schematic overview of the current status of knowledge concerning the 
evasion of innate immunity mediated by arterivirus proteins.
In addition to actively interfering with innate immune signalling, arteriviruses ap-
pear to have evolved mechanisms to prevent the initial recognition of their RNA by 
cellular sensors. For example, arteriviruses are presumed to have 5’-capped genomes 
(94), which is an effective means of hiding the phosphorylated 5’ end of an RNA from 
recognition by the pattern-recognition receptor RIG-I. Another feature of arterivirus 
replication is the formation of extensive intracellular membrane modifications, 
consisting predominantly of double-membrane vesicles (DMVs). The interior of these 
DMVs has been shown to contain (presumably viral) double-stranded RNA and does 
not appear to be connected to the cytosol (95). For this reason, one of the hypotheses 
concerning DMV formation is that they are employed to shield viral RNA from pattern-
recognition receptors, thereby preventing innate immune activation.
Increasing interferon induction to improve arterivirus vaccines
It has been suggested that the ability of arteriviruses to evade innate immune activa-
tion is one of the reasons why vaccines do not provide optimal protection against 
infection with these viruses (96). Especially in the case of PRRSV, the virus appears to 
induce suboptimal levels of IFNs, which ultimately results in late and very limited neu-
tralizing antibody and cell-mediated (i.e. adaptive) immune responses. In support of 
this idea, recent work has shown that infection with a particular PRRSV strain (A2MC2) 
that induces higher levels of IFN than other strains (including a MLV strain), triggers an 
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figure vII-3. Overview of innate immune evasion mediated by arterivirus nonstructural proteins.
Arteriviruses have been suggested to counteract innate immune signalling pathways in a variety 
of ways. Firstly, PrrSv nsp1α was found to induce the proteasomal degradation of CBP, and PrrSv 
nsp1β was shown to mediate the degradation of KPNA1. In addition, PrrSv nsp4 was recently 
found to cleave the innate immune signalling factor NEMO. Finally, the arterivirus PLP2 domain 
has been shown to decrease the ubiquitination of RIG-I in an ectopic expression system and of 
IκBα in vitro. Abbreviations: CBP, CREB-binding protein; IFN-β, interferon beta; IFNR, interferon re-
ceptor; IKK, IκB kinase; IκBα, inhibitor of NF- κB; IRF, interferon regulatory factor; ISGF3, interferon-
stimulated gene factor 3; JAK/STAT, janus kinase/signal transducers and activators of transcription; 
KPNA1, karyopherin alpha 1; MAVS, mitochondrial antiviral signalling protein; MDA5, melanoma 
differentiation-associated protein 5; NEMO, NF-κB essential modulator; NF-κB, nuclear factor 
kappa B; RIG-I, retinoic acid-inducible gene-encoded protein I; RLR, RIG-I-lile receptors; STAT1/2, 
signal transducers and activators of transcription 1/2; TBK1, tank-binding kinase 1; TRAF3/6, TNF 
receptor-associated factor 3/6.
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induce lower IFN levels (97). Moreover, the neutralizing antibodies induced by the 
A2MC2 strain even proved to possess in vitro cross-reactivity towards a heterologous 
strain (97). Whereas for arteriviruses the available data on this subject is limited, a 
considerable body of work is available on the potential of increasing IFN induction in 
the context of the rational design of improved influenza vaccines. Specifically, non-
structural protein 1 (NS1) of this virus has been found to possess pleiotropic immune 
evasive capabilities and deletion or mutation of this protein results in an enhanced 
induction of type I IFNs (for a review, see (98)). Interestingly, a large number of stud-
ies (including several in vivo trials) support the idea that mutating the influenza NS1 
protein provides a promising strategy for the design of live attenuated vaccines (for 
a review, see (99)), which might also be applied to other virus groups that evade the 
host innate immune response.
Once we had established that arterivirus PLP2 DUB activity is important for the eva-
sion of innate immunity during infection (Chapter 4), we hypothesized that a vaccine 
virus lacking PLP2 DUB activity provides better protection against subsequent chal-
lenge than its DUB-competent counterpart. To test this hypothesis, we performed an 
in vivo trial in which we vaccinated horses with PLP2 DUB-negative or DUB-competent 
cell culture-adapted EAV and challenged them with moderately virulent EAV KY84 
(Chapter 5). The results of this trial show that PLP2 DUB-negative and DUB-competent 
EAV induce similar neutralizing antibody titers which do not increase upon challenge 
(figure v-2B). In addition, when used as a vaccine both viruses were shown to induce 
similar levels of ISG15 and MX1 mRNA (figure v-3C and D). This result suggests that 
there are no (detectable) differences in the activation of innate immunity between 
these two viruses, but assessment of additional targets is needed to confirm this. 
Furthermore, we could show that PLP2 DUB-negative EAV replicates in vivo, although 
slightly less efficiently than its DUB-competent counterpart (figure v-3A). Finally, it 
turned out that the DUB-competent vaccine virus already provided such high levels 
of protection in our experimental set-up, that we could barely detect viral RNA in the 
blood of vaccinated horses after challenge. This unfortunately made it very difficult 
to assess differences between the two viruses, although close examination of the data 
did suggest that we could detect low levels of viral RNA more often in horses that had 
received the DUB-competent vaccine virus than in horses that had received the PLP2 
DUB-negative virus (figure v-3B).
Taken together, these results support the idea that a vaccine virus lacking PLP2 
DUB activity can provide better protection against a challenge infection than its 
DUB-competent counterpart, but additional experiments are definitely required. In 
hindsight, we should perhaps have performed a more stringent challenge, for ex-
ample by using a higher dose of challenge virus. However, the best option will likely 




vaccine, preferably one of the PRRSV modified live virus (MLV) vaccines. To this end, 
it will be essential to first design a viable mutant PRRSV that lacks PLP2 DUB activity. 
Furthermore, our results have shown that knocking out PLP2 DUB activity has only a 
minimal effect on virus replication. This opens up the possibility of combining PLP2 
mutations with mutations in other immune evasive domains, e.g. nsp1α or nsp1β, in 
order to potentially increase the immunogenicity of the vaccine virus in a synergistic 
manner. As a point of caution however, it needs to be noted that increasing innate 
immune activation too strongly can have unwanted effects. Not only can this result in 
over-attenuation leading to a lack of replication that is not beneficial to the induction 
of protective adaptive immunity, it can also result in increased pathogenesis due to 
immunopathology, as was previously reported for a certain PRRSV strain (100). The 
effects of reducing the immune evasive capacity of a vaccine candidate should thus 
be carefully monitored and a delicate balance is likely to be required. In conclusion, 
the results obtained by us and others definitely warrant further investigations into 
the potential of targeting (PLP2) DUB and other immune evasive activities to increase 
the efficacy of (arterivirus) vaccines.
iN SeaRCH OF tHe (SpeCiFiC) taRget(S) OF aRteRiViRUS plp2
The interaction of PLP2 with the viral polyprotein
The crystal structure of EAV PLP2 in complex with ubiquitin nicely defined the interac-
tion surface between these two proteins (Chapter 4). Furthermore, mutations in this 
area were shown to specifically affect only the DUB activity of PLP2, which suggested 
that the interaction with the viral polyprotein relies on an alternative interaction 
surface of the protease. However, the exact location of the latter remains to be de-
termined, just like the exact sequences flanking the nsp2|nsp3 cleavage site that are 
required for this interaction. Considering that PLP2 appears to use alternate surfaces 
for its interaction with ubiquitin and the viral polyprotein, it seems unlikely that the 
C-terminal domain of nsp2 adopts a ubiquitin-like fold to support the interaction with 
the PLP2 domain. Comparative sequence analysis does reveal a cluster of conserved 
cysteine residues in the C-terminal region of nsp2, which might be part of a structural 
element that is involved in the interaction with PLP2. Crystallization of a (covalent) 
complex consisting of PLP2 and the C-terminal region of nsp2 might shed more light 
on the interaction between the two. However, to date our preliminary attempts to 
obtain such a complex have been unsuccessful due to the instability of an expression 
product representing the C-terminal domain of nsp2. In the future, this problem might 
be solved by optimization of the precise region incorporated in this expression con-
struct. An enhanced understanding of the interaction of PLP2 with its viral substrate 
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might reveal additional options for the separation of DUB and polyprotein processing 
activities.
The promiscuous nature of arterivirus deubiquitinases
One of the most striking and perhaps puzzling features of arterivirus PLP2 DUB activ-
ity is its apparent promiscuity. From the ectopic expression experiments described 
in literature and in this thesis it is evident that this enzyme can have a dramatic and 
seemingly nonspecific effect on the levels of ubiquitination of cellular proteins (see 
for example figure II-3B and C and (1, 53)). This promiscuity is not unique for arteri-
virus PLP2, since it has also been demonstrated for coronavirus papain-like proteases 
upon ectopic expression of SARS-CoV, MERS-CoV, HCoV-NL63, and PEDV PL2pro (26, 
28, 60). Under these experimental conditions, one might assume that the observed 
general effect on ubiquitination is merely an artefact of ectopic expression. Indeed, 
the respective protease domains were removed from their natural context, in which 
they are part of a much larger multi-domain nonstructural protein that resides in a 
multi-subunit replication and transcription complex and localizes to an intricate 
network of membrane modifications, all of which may influence their substrate ac-
cess. However, although somewhat less pronounced, also in infected cells arterivirus 
PLP2 appears to have a strikingly general effect on the endogenous ubiquitination 
levels of cellular proteins, which correlates with the functionality of its DUB activ-
ity (figure Iv-5D). Moreover, a similarly general effect on ubiquitination levels has 
been reported in cells expressing epitope-tagged ubiquitin that are subsequently 
infected with SARS-CoV, MHV, or PEDV (26, 59). It should be noted though that for 
these coronaviruses, this effect has not yet been demonstrated to depend directly on 
the catalytic activity of PL2pro, meaning that secondary effects of the infection on cel-
lular ubiquitination levels cannot be formally excluded as a (partial) explanation for 
the observed decrease. Considering the importance of ubiquitination as a regulatory 
mechanism in a multitude of cellular processes and the fact that for example innate 
immune signalling is both positively and negatively regulated via ubiquitination (for 
a review see (101)), it would seem counterproductive for the virus to have such a 
dramatic and seemingly random effect on the level of ubiquitination. However, as 
in many aspects relating to virus replication, timing might be of the essence in this 
case. One can for example imagine that target specificity is of greater importance 
at early time-points after infection than at later time-points, when the infection is 
already well underway and only limited additional time is required to reach peak viral 
titers. Indeed, for MHV in a time-course experiment a general effect on ubiquitination 
started to be observed at about 12 hours post infection (59), which is approximately 
when peak viral titers are reached (102). The general effect of EAV on protein ubiqui-




few hours away from the moment at which peak viral titers are reached. The effect on 
ubiquitination levels at earlier time points has however not yet been assessed for EAV. 
A possible explanation for the observed promiscuity of these viral DUBs might thus 
be that after a certain point in infection, they become so abundant that restrictions on 
target specificity diminish or no longer exist. In contrast, at earlier stages the activity 
of these DUBs might still be kept in check by for example protein-protein interac-
tions, localization, and lower concentrations. Additional experimental work will have 
to establish whether the promiscuity of viral DUBs changes in the course of infection. 
If this indeed turns out to be the case, efforts can be directed at delineating what the 
specific early targets of these enzymes are.
A recent discovery that might have interesting implications for the target specificity 
of arterivirus PLP2 is the presence of a programmed ribosomal frameshift (PRF) site in 
the nsp2-coding region of all arteriviruses except EAV (103). In a substantial fraction 
of translation events, this PRF (which can be either -1 or -2) produces two truncated 
forms of nsp2: nsp2TF (~20%) and nsp2N (~7%). Both these proteins encompass the 
PLP2 domain but only nsp2TF contains a (predicted) transmembrane domain. The 
fact that nsp2N is possibly not anchored to membranes may have implications for 
its subcellular localization and probably also its substrate access. Interestingly, also 
nsp2TF was shown to not localize to replication and transcription complexes but to 
an alternative location that awaits further experimental clarification (103). The EAV 
nsp2-coding region does not contain a PRF site, yet in some cell types a small protein 
product encompassing the PLP2 domain but not the downstream transmembrane 
domain was observed during infection ((104) and our unpublished data). The rel-
evance of this observation needs to be further investigated, but EAV might thus have 
evolved an alternative mechanism to produce a PLP2-containing cytosolic protein, as 
possibly achieved with the PRF in other arteriviruses. Taken together, the alternative 
localization and protein-protein interactions of these truncated forms of nsp2 might 
create possibilities for PLP2 to interact with different substrates. It would therefore 
be interesting to investigate the importance of this PRF event for the immune evasive 
activity and target specificity of PLP2.
Identifying the targets of arterivirus PLP2 DUB activity
Assuming that they exist, the search for specific targets of arterivirus PLP2 will likely 
be a daunting task and confirmation of the involvement of any target will probably 
require a combination of different experimental approaches. To date, arterivirus PLP2 
and coronavirus PL2pro have been shown to decrease the level of ubiquitination of 
a number of suspected targets in ectopic expression and in vitro assays (Table vII-1) 
(Chapter 2 and (25, 26, 53, 61, 105)). However, considering the promiscuous nature 
of these DUBs, such an effect could likely be demonstrated for virtually any ubiqui-
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tinated substrate under these experimental conditions. Ideally, the search for specific 
substrates should therefore focus on endogenous proteins at early time-points during 
infection. For example, one could envision an unbiased proteomics-based approach in 
which the level of ubiquitination of all cellular proteins is assessed during infection. 
Enrichment for ubiquitinated proteins can be achieved in different ways. For example, 
one can perform immunoprecipitations (IPs) targeting endogenous ubiquitin with 
ubiquitin-specific antibodies or antibodies specific for peptides harbouring the 
double-glycine motif that remains after trypsin digestion of a ubiquitinated substrate 
(106). Alternatively, experiments can be performed in cell lines stably expressing 
epitope-tagged ubiquitin, which can then be used for IPs as has been described for the 
ubiquitin-like protein SUMO (107). Combining such approaches with stable isotope 
labelling with amino acids in cell culture (SILAC) (108) will allow for a comparison 
between the effects of wild-type and PLP2 DUB-negative viruses.
It needs to be noted though, that any differences in ubiquitination levels revealed 
by such a comparison cannot be directly attributed to PLP2 DUB activity, since for 
example the ubiquitination status of one protein can affect that of another protein 
downstream in a signalling cascade. Additional experimental work will therefore be 
needed to establish a direct interaction between PLP2 and the identified putative 
substrate. One approach would be to perform a co-IP, as was successfully used for the 
identification of TRAF3 as a target of the cellular deubiquitinase DUBA (109). How-
ever, since these interactions will likely be of a transient nature, as is often the case 
with protease-substrate interactions, confirming their existence in this manner might 
prove to be very difficult. One often-used trick to increase the duration of protease-
substrate interactions is to mutate catalytic residues. However, in the context of an 
infection this will not be possible because of the dependence of the virus on PLP2 
proteolytic activity for replicase maturation. Alternatively, this approach can be used 
in the context of ectopic expression, which will however increase the risk of obtaining 
false-positive results. Another option to potentially increase the sensitivity of co-IPs 
during infection is to cross-link interacting proteins with for example formaldehyde 
(110).
Table vII-1. Suggested targets of nidovirus deubiquitinases.
enzyme Target Type of experiment references
EAV PLP2 RIG-I Ectopic expression Chapter 2
PRRSV PLP2 IκBα In vitro (53)
MHV PL2pro TBK1, IRF3 Ectopic expression (25, 61)
PEDV PL2pro RIG-I, STING Ectopic expression (26)




When a direct interaction of PLP2 with a putative substrate would be confirmed, 
future research should focus on elucidating the effects of its deubiquitination during 
infection. While to date most research concerning both arteri- and coronavirus DUBs 
has focussed on their role in innate immune evasion, it should not be forgotten that 
ubiquitin plays a role in a variety of cellular processes, many of which might somehow 
influence viral replication and might thus be relevant targets for viral DUBs. Especially 
the ubiquitin-proteasome system might prove of particular importance, for example 
in directing the degradation of viral proteins, which could in turn be prevented by 
viral DUBs. An example of such a role for a viral DUB is provided by the TYMV protease, 
which prevents the proteasomal degradation of the viral polymerase via its deubiq-
uitination (31).
aSSeSSiNg tHe ROle OF aRteRiViRUS plp2 deiSgylatiNg aCtiVity
Viral deiSgylating enzymes
Whereas eukaryotic DUBs are generally considered (with some exceptions (111, 112)) 
to be specific for either ubiquitin or a ubiquitin-like protein, several of their viral coun-
terparts have been found to target both ubiquitin and ISG15. Since the latter has been 
shown to inhibit replication of a large variety of viruses (for a review, see (113)), it is 
not surprising that several viruses have evolved enzymes with deISGylating activity. 
Examples of viral proteases that were shown to harbour both DUB and deISGylating 
activity include coronavirus PL2pro (23, 27, 28, 60) and nairovirus OTU (1, 32, 33). Of 
these, the deISGylating activities of SARS-CoV PL2pro (114) and the OTU protease 
encoded by the nairovirus Crimean-Congo hemorrhagic fever virus (CCHFV) (32, 33) 
have been clearly demonstrated using in vitro assays with 7-amino-4-methylcoumarin 
(AMC)-tagged ISG15. Interestingly, these assays show that the specificity constant 
of SARS-CoV PL2pro for ISG15-AMC is approximately one order of magnitude larger 
table Vii-2. Reported specificity constants (kcat/Km in m-1 s-1) for Ub- and human ISG15-AmC.
enzyme Substrate reference
Ub-AMC hISG15-AMC
CCHFV OTU 2.9 x 105 1.4 x 105 (32)
CCHFV OTU 3.41 x 105 3.6 x 105 (33)
SARS-CoV PL2pro 1.31 x 104 ND (23)
SARS-CoV PL2pro 1.98 x 104 6.02 x 105 (114)
EAV PLP2 1.7 x 104 ND Chapter 4
Abbreviations: AMC, 7-amino-4-methylcoumarin; hISG15, human interferon-stimulated gene-en-
coded protein of 15 kDa; ND, not determined; Ub, ubiquitin.
170 Chapter 7
than that found for Ub-AMC, while the specificity constants of CCHFV OTU for both 
substrates lie within the same order of magnitude (Table vII-2). These results seem 
to suggest that the deISGylating activity of SARS-CoV PL2pro is more important than 
its DUB function, but some caution should be taken in the interpretation of these 
findings. Notably, these AMC-linked substrates differ significantly from the naturally 
occurring substrates of these enzymes in that they do not contain isopeptide bonds. 
Indeed, there is evidence to suggest that the activity of SARS-CoV PL2pro towards 
Lys48-linked tetra-ubiquitin chains is comparable to its activity towards ISG15-AMC 
(114). Another study showed that the quantitatively assessed in vitro activity of 
CCHFV OTU towards a Lys63-linked di-Ub is over one order of magnitude higher than 
its activity towards Ub-AMC (32). Additional characterization of the enzymatic activity 
of DUBs and deISGylating viral enzymes will likely benefit from the use of substrates 
that more closely resemble naturally occurring isopeptide-linked substrates, such as 
the fluorescence polarization-based ubiquitin(-like) substrates described in Chapter 
3 (44, 115) and polyubiquitin substrates. Another important consideration is the lack 
of amino acid sequence conservation of ISG15 between species, which stands in stark 
contrast to the almost complete conservation of the ubiquitin sequence across eu-
karyotes (figure vII-4A and B). Notably, in vitro assays with the CCHFV OTU protease 
revealed a distinct preference for human over mouse ISG15 (116).
is arterivirus plp2 also a deiSgylating enzyme?
Although arterivirus PLP2 has also been suggested to act both as a DUB and a de-
ISGylating enzyme, the latter activity remains poorly characterized and conflicting 
data on this subject have been reported. The (putative) deISGylating activity of 
EAV and PRRSV PLP2 has been demonstrated using ectopic expression systems and 
in infected cells (1, 54). However, the possibility that the observed decrease in the 
level of ISGylation was the result of an indirect or nonspecific effect of the ectopic 
expression of PLP2 or infection cannot be formally excluded. In addition, prelimi-
nary in vitro experiments with EAV PLP2 using human ISG15-TAMRA as a substrate 
revealed only very limited proteolytic activity (personal communication: P. Geurink, 
NKI, Amsterdam). Considering the narrow host range of arteriviruses, we reasoned 
that the arterivirus PLP2 domains might have evolved to preferentially accommodate 
only the ISG15 encoded by their respective hosts. In support of this idea, a structural 
model of EAV PLP2 in complex with human ISG15, based on the crystal structure of 
EAV PLP2 in complex with ubiquitin (PDB ID: 4IUM), shows that some non-conserved 
residues indeed localize to the area that potentially forms the PLP2-ISG15 interface, 
thereby supporting the hypothesis that species-specificity matters (figure vII-4C 
and D). Notably, we have been able to show in vitro complex formation between EAV 
PLP2 and an equine ISG15 suicide probe (see below), which at least suggests the pos-
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hapter 7sibility of an interaction between the two. However, according to a recent publication 
by Deaton et al. (2014), in vitro activity of PRRSV PLP2 towards human ISG15-AMC 
and, strikingly, also human and porcine proISG15 (i.e. ISG15 with a short C-terminal 
extension) could hardly be demonstrated, suggesting that the lack of cleavage in this 
particular experiment was not due to the use of non-porcine ISG15 (20). It needs to 
be noted though, that an approximately 14- to 20-fold lower PLP2 concentration was 












Horse (NM_001081862)   MQIFVKTLTG KTITLEVEPS DTIENVKAKI QDKEGIPPDQ QRLIFAGKQL EDGRTLSDYN IQKESTLHLV LRLRGG
Swine (XM_003483411)   MQIFVKTLTG KTITLEVEPS DTIENVKGKI QEKEGIPPDQ QRLIFAGKQL EDGRTLSDYN IQKESTLHLV LRLRGG
Human (NM_021009)   MQIFVKTLTG KTITLEVEPS DTIENVKAKI QDKEGIPPDQ QRLIFAGKQL EDGRTLSDYN IQKESTLHLV LRLRGG
Macaque (NM_001193586)  MQIFVKTLTG KTITLEVEPS DTIENVKAKI QDKEGIPPDQ QRLIFAGKQL EDGRTLSDYN IQKESTLHLV LRLRGG
Mouse (NM_019639)   MQIFVKTLTG KTITLEVEPS DTIENVKAKI QDKEGIPPDQ QRLIFAGKQL EDGRTLSDYN IQKESTLHLV LRLRGG
Yeast (NM_001181859)   MQIFVKTLTG KTITLEVESS DTIDNVKSKI QDKEGIPPDQ QRLIFAGKQL EDGRTLSDYN IQKESTLHLV LRLRGG
ISG15
Horse (XM_005607605)   MRRGGELKVK MLGG-EFLVP LKDSMLVSEL KQQIAQKTGV PPFQQRLATH PAGMVLQDRV PLVSQGLGPG STVVLVVQNC  
Swine (NM_001128469)   M--GRELKVK MLGGKEILVP LRDCMMASDL KQQIAREIGV PAFQQRLA-H PAGNVLQDGV PLVNQGLGPG SMVLLMVQSF 
Human (NM_005101)   M--GWDLTVK MLAGNEFQVS LSSSMSVSEL KAQITQKIGV HAFQQRLAVH PSGVALQDRV PLASQGLGPG STVLLVVDKC  
Macaque (NM_001266806)          M--SWDLKVK MLGGNEFQVS LSNSMSVSEL KAKIAQKIGV HAFQQRLAVH PSGATLQDRV PLANQGLGPG STVLLVVDKC  
Mouse (NM_015783)   M--AWDLKVK MLGGNDFLVS VTNSMTVSEL KKQIAQKIGV PAFQQRLA-H QT-AVLQDGL TLSSLGLGPS STVMLVVQNC  
Horse    DTPLSILVRN GKGRSSAYEV RLTQTVAELK QQVCLRESVQ ADQFWLTFEG KPMDDQLHLG EYELTAGCTV YMNLRLRGG  
Swine    RDPLSILVRN DKGRSNAYEV WLTQTVAELK QQVCQLEGVQ ADHFWLTFEG KPMEDEHQLG EYDLKPMCTV YMNLRLRGG
Human    DEPLSILVRN NKGRSSTYEV RLTQTVAHLK QQVSGLEGVQ DDLFWLTFEG KPLEDQLPLG EYGLKPLSTV FMNLRLRGG
Macaque   DEPLSILVRN DKGRSSTYEV QLTQTVAHLK QQVSRQEGVQ DDLFWLTFEG KPLENQLPLG EYGLKPLSTV FMNLRLRGG
Mouse    SEPLSILVRN ERGHSNIYEV FLTQTVDTLK KKVSQREQVH EDQFWLSFEG RPMEDKELLG EYGLKPQCTV IKHLRLRGG
figure vII-4. Ub and ISG15 sequence conservation. Sequence alignments of A) ubiquitin and B) 
ISG15 encoded by various species. Residues highlighted in orange are not fully contserved be-
tween all depicted species, but do not diff er between equine and human proteins. In contrast, 
residues highlighted in yellow and green do diff er between equine and human proteins. In ad-
dition, residues highlighted in green localize to the predicted PLP2-binding interface. Accession 
numbers are indicated between brackets; note that the status of the equine ISG15 is “predicted”. 
Alignments were made in Geneious (Biomatters Ltd, Auckland, New Zealand). C) Model of EAV PLP2 
in complex with human ISG15. The model was made by B.A. Bailey-Elkin (University of Manitoba, 
Canada) using the Modeller program (143) and is based on a superposition of the crystal structures 
of PLP2 in complex with ubiquitin (PDB ID: 4IUM, Chapter 4) and ISG15 from the CCHFV OTU-ISG15 
crystal structure (PDB ID: 3PT2, (33)). Residues that are not conserved between human and equine 
ISG15 are depicted in green. D) Close-up of the residues in the PLP2-ISG15 interaction region that 
diff er between human and equine ISG15. Images were generated in Pymol (144).
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this difference was not provided. Finally, it is conceivable that the PLP2s encoded by 
EAV or PRRSV inherently differ from each other in their activity towards ISG15. Taken 
together, the postulated deISGylating activity of arterivirus PLP2 has not yet been 
firmly established and additional work on this subject is required.
Further assessment of the role of arterivirus PLP2 deISGylating activity should pref-
erably start with the in vitro characterization of this activity using (isopeptide-linked) 
ISG15 substrates derived from the appropriate species. Once deISGylating activity 
would indeed have been demonstrated, efforts can be directed at establishing the 
role of this activity during infection. To this end, one approach would be to specifically 
decrease the deISGylating activity through targeted mutagenesis and assess the ef-
fect of such mutations on viral replication, similar to what was described for EAV PLP2 
DUB activity in Chapter 4. Several PRRSV PLP2 mutants with decreased deISGylating 
activity (assessed in cell culture using monkey ISG15) have been described previ-
ously (54). However, when transferred to the full-length clone most of these mutants 
proved nonviable, possibly due to problems with polyprotein maturation, and the ef-
fect on DUB activity of these mutations was not further assessed. The rational design 
of mutations that only affect deISGylating activity would benefit from the availability 
of a three-dimensional structure of PLP2 in complex with ISG15. As briefly mentioned 
above, it is possible to produce a covalent complex of EAV PLP2 and an equine ISG15 
suicide substrate in sufficient quantities to screen for crystallization and initial crys-
tallization trials have been performed (unpublished data). Future efforts should now 
focus on obtaining diffraction-quality crystals that will open the way for a thorough 
assessment of arterivirus PLP2 deISGylating activity during infection.
CONCLUDING remArKS
The multifunctional nature of arterivirus PLP2 is a fascinating but by no means unique 
feature of this protease. In fact, many +RNA virus proteases have been found to target 
both viral and cellular substrates (for an overview, see Table vII-3). For example, the 
PRRSV nsp4 protease was recently shown to be responsible for the cleavage of the in-
nate immune signalling factor NEMO (78). Similarly, several flavivirus main proteases 
have been shown to cleave innate immune signalling factors such as MAVS and STING 
(79, 80, 87, 88). Most work on multifunctional viral proteases has been reported for 
the picornaviruses, whose main and accessory proteases have been shown to target 
among others the innate immune signalling factors MAVS, MDA5, and RIG-I (82-86). 
Their host substrate-directed proteolytic activity is however not limited to proteins 
involved in innate immunity. For example, also several host proteins involved in 




suming that (especially in the case of the main proteases) the primary role of these 
viral enzymes is in replicase maturation, and that the host-directed activities were 
acquired at a later stage, one might wonder how the latter could have evolved without 
negatively affecting the activity of the protease towards its viral substrate. It seems 
difficult to reconcile the need for strict specificity towards (often multiple) sites within 
the replicase polyprotein, with the development of activity towards unrelated host 
proteins. A possible solution for this apparent problem is to exploit different regions 
of the protease to support an interaction with viral versus host substrates. In the case 
of arterivirus PLP2 for example, it seems that its interaction with ubiquitin relies on 
residues that are not involved in the interaction with the viral polyprotein (Chapter 
4). Crystal structures of other multifunctional viral proteases in complex with their 
respective cellular substrates will be needed to answer the question whether such 
differential sites of interaction are a common feature. If this indeed turns out to be the 
case, this opens up possibilities for the separation of the activities towards their viral 
and host substrates, as was done for EAV PLP2.
Cleavage of MAVS by the hepatitis C virus main protease can be almost completely 
abrogated by a single amino acid substitution within the cleavage site (79, 80). Con-
sidering that such small changes can protect the host against virus-induced cleavage, 
it seems rather odd that so many (innate immune signalling) proteins remain targets 
of these multifunctional proteases. This implies that the selective pressure on the 
host to escape from these viral proteases is not strong enough to drive evolution of 
these cellular targets. An alternative explanation for the apparent lack of adaptation 
of these cellular targets is the possibility that the host actually benefits from the 
imposed brake on innate immune activation provided by the virus. The activation of 
immune signalling needs to be carefully balanced to prevent immunopathology, and 
both the virus and the host will likely fare better when this balance is not disturbed 
too much. These considerations do not readily apply to viral DUB activity because 
of the importance of the LRLRGG sequence for the correct functioning of the entire 
ubiquitin conjugation system. DUB activity is thus a viral property from which the host 
can hardly escape, which is likely one of the reasons why various virus groups have 
acquired this ability.
In conclusion, the results described in this thesis have provided novel insights in the 
structural features of arterivirus PLP2, in addition to confirming its putative DUB ac-
tivity and establishing its role in innate immune evasion. Future research should now 
focus on identifying the host and/or viral protein target(s) of this intriguing protease 
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An OTU deubiquitinase that counteracts innate immunity
Despite their limited size, viruses can have a massive impact on their hosts on both 
the individual and population level. This becomes even more fascinating when taking 
into consideration the fact that viruses are in essence lifeless entities, only capable of 
replicating within a permissive host. A proper understanding of the viral “life cycle” 
can therefore only be obtained when, in addition to the replication mechanism of the 
virus itself, also the virus-host interactions are elucidated.
In the case of mammalian positive-stranded (+) RNA viruses, proteases can fulfil an 
important role in the interplay between the virus and its host. This group of viruses of-
ten produces (part of) their proteins in the form of a polyprotein, that is subsequently 
cleaved into functional subunits by viral proteases residing within these polyproteins. 
In addition to playing this vital role in polyprotein maturation, these proteases can 
exert other functions by also cleaving host factors. The work described in this thesis 
demonstrates how an arterivirus protease (PLP2) interacts with the cellular ubiquitin 
system and thereby inhibits activation of the innate immune response.
Formally, the arterivirus family currently encompasses four members, including the 
equine arteritis virus (EAV) and the porcine reproductive and respiratory syndrome 
virus (PRRSV). Especially the latter poses a great burden on swine-farming industries 
worldwide, through the loss of piglets and reduced fertility of sows. Vaccines are 
available for both these viruses, although their efficacy is suboptimal. This is thought 
to be caused in part by the capability of these viruses to counteract the innate im-
mune response, which in turn prevents full-blown activation of the adaptive immune 
response.
The replication of arteriviruses commences with the production of two partly 
overlapping polyproteins, which are the precursors of the viral nonstructural proteins 
(nsps). These polyproteins are co- and posttranslationally cleaved into their respec-
tive functional subunits by three to five internal proteases. Together, the nsps form 
the viral replication- and transcription complex, which is responsible for the replica-
tion of the viral genome and the transcription of subgenomic messenger RNAs. The 
proteolytic cleavage of the viral polyproteins is a highly regulated process and muta-
tions of the proteases or cleavage sites involved are generally not well tolerated. One 
of the proteases that are responsible for the maturation of the arterivirus replicase 
polyproteins is papain-like protease 2 (PLP2), which is located in nsp2 and performs 






The innate immune response constitutes the first line of defence against invading 
pathogens and relies on the recognition of pathogen-associated molecular patterns 
by specific pattern-recognition receptors. Activation of the innate immune response 
ultimately leads to the transcription of genes encoding type I interferons and other 
pro-inflammatory cytokines, which together are responsible for the induction of an 
antiviral state in both infected and neighbouring cells and the stimulation of the 
adaptive immune response.
The activation of the innate immune response is strictly regulated, among others 
via the process of ubiquitination, i.e. the conjugation of the small ubiquitin protein to 
specific target proteins. This conjugation can lead to the proteasomal degradation of 
the ubiquitinated substrate, but can also support certain protein-protein interactions. 
Ubiquitination is a posttranslational modification that is particularly suitable for the 
regulation of signal transduction routes since it is readily reversible through the ac-
tion of deubiquitinating enzymes (DUBs).
Comparative sequence analyses performed by Makarova et al. (2000) have shown 
that arterivirus PLP2 resembles proteases belonging to the OTU family of DUBs. 
Later, Frias-Staheli et al. (2007) have demonstrated that ectopic expression of EAV or 
PRRSV PLP2 in cell culture leads to a decrease of the levels of ubiquitinated proteins. 
Considering the importance of ubiquitination for the activation of innate immunity, 
it seemed likely that the putative DUB activity of arterivirus PLP2 plays a role in 
counteracting this response. However, the essential role of PLP2 in the maturation of 
the viral polyproteins precluded its straightforward deletion or inactivation, and thus 
made it difficult to provide proof for this hypothesis.
For this reason, our first aim was to confirm the DUB activity of arterivirus PLP2 and to 
further characterize its putative role in the evasion of the innate immune response. 
In Chapter 2, we have firmly established the DUB activity of EAV PLP2 using in vitro 
cleavage assays and, using transfection experiments, we have shown that this activity 
is likely conserved across the arterivirus family. Furthermore, we have demonstrated 
that the ectopic expression of arterivirus PLP2 leads to a decreased expression of a 
luciferase-reporter gene under control of the interferon beta promoter. The pattern-
recognition receptor RIG-I is an important, ubiquitin-regulated factor in the innate 
immune response. By means of a transfection experiment we were able to show that 
arterivirus PLP2 decreases the ubiquitination of RIG-I in cell culture. These data sup-
ported the hypothesis that the DUB activity of arterivirus PLP2 is important for the 
inhibition of the innate immune response.
198 Summary
Due to their essential role in the replication of mammalian +RNA viruses, proteases 
have proven to be a good target for the development of antiviral compounds. Since 
in addition to arteriviruses, several other viruses encode proteases with DUB activity, 
we investigated whether this activity could be exploited to identify potential antiviral 
compounds. Chapter 3 includes the result of a fluorescence polarization-based in 
vitro screen, by which from a library of 335 compounds, five were found to inhibit 
the DUB activity of EAV PLP2. Of these, two turned out to also inhibit replication of a 
GFP-encoding EAV reporter virus in cell culture to a considerable extent. It thus seems 
that it is indeed possible to identify antiviral compounds using a DUB-based screen, 
although additional work is required.
To establish the role of PLP2 DUB activity during infection, it was important to sepa-
rate this activity from its essential function in the maturation of the viral replicase 
polyproteins. In collaboration with Canadian structural biologists, we therefore 
solved the crystal structure of EAV PLP2 in complex with ubiquitin (Chapter 4). From 
the three-dimensional structure it was evident that PLP2 indeed belongs to the OTU 
family and that the interaction with ubiquitin partly relies on a surface of PLP2 that 
is distant from the active site. This enabled us to design mutations that specifically 
interfered with the interaction with ubiquitin, without disrupting the activity of PLP2 
towards the viral polyproteins. Using these mutations, we were able to demonstrate 
that the DUB activity of arterivirus PLP2 is indeed important for the inhibition of in-
nate immunity during infection.
Chapter 5 encompasses a small-scale vaccination experiment in horses in which we 
tested whether an EAV vaccine that lacks PLP2 DUB activity (DUB-) provides better 
protection against challenge with a heterologous EAV isolate than a vaccine virus in 
which PLP2 DUB activity is still intact (DUB+). This experiment showed that both vac-
cine viruses are replication competent. However, we did not observe a clear difference 
in the level of protection between the two vaccine viruses. The fact that the DUB+ 
vaccine virus already provided a very high level of protection against a challenge 
infection in this experiment, may have been the reason why it was difficult to detect 
any further improvement. Additional experiments are needed to establish whether 
the inactivation of PLP2 DUB activity yields better results in a different experimental 
setting.
In addition to arteriviruses, both nairoviruses (-RNA) and tymoviruses (+RNA) encode 
OTU DUBs. Chapter 6 presents a concise structural and functional comparison be-
tween these viral enzymes. While both arteri- and nairovirus DUBs seem to function 






preventing the proteolytic degradation of the viral RNA polymerase. The most strik-
ing structural difference between these enzymes is the fact that the catalytic core 
of the tymovirus DUB seems to be incomplete in comparison with that of arteri- and 
nairoviruses.
The work described in this thesis provides novel insights into the structural and (multi)
functional characteristics of arterivirus PLP2. We have demonstrated for the first time 
the importance of a viral DUB in the evasion of innate immunity in the context of 
an infection. The acquired knowledge can now be applied to the design of improved 
arterivirus vaccines and studies of other viral DUBs, including those encoded by the 
zoonotic coronaviruses that cause severe acute respiratory syndrome (SARS) and 






een OTU deubiquitinase dat het aangeboren immuunsysteem onderdrukt
Ondanks hun geringe afmetingen kunnen virussen enorme schade berokkenen, zowel 
aan het individu als aan de samenleving. Dit gegeven wordt nog fascinerender wan-
neer men beseft dat een virusdeeltje in essentie levenloos is en slechts kan repliceren 
met behulp van een gastheer. Een goed begrip van de “levenscyclus” van een virus 
kan daarom alleen verkregen worden wanneer, naast het replicatiemechanisme van 
het virus zelf, ook de virus-gastheer interacties in kaart zijn gebracht.
In het geval van positiefstrengige (+) RNA virussen die zoogdieren infecteren kun-
nen proteases een belangrijke rol vervullen in het samenspel tussen virus en gastheer. 
Deze groep virussen produceert (een deel van) de virale eiwitten vaak in de vorm 
van een polyproteïne, dat vervolgens in functionele eenheden wordt gekliefd door 
proteases die deel uitmaken van dit polyproteïne. Deze proteases kunnen echter ook 
nog andere functies uitoefenen, door naast virale eiwitten ook gastheerfactoren te 
klieven. Het werk beschreven in dit proefschrift laat zien hoe een arterivirus protease 
(PLP2) aangrijpt op het cellulaire ubiquitine systeem en daarmee de aangeboren im-
muunrespons dwarsboomt.
De arterivirus familie omvat op dit moment formeel vier leden, waaronder het 
equine arteritis virus (EAV) en het porcine respiratory and reproductive syndrome virus 
(PRRSV). Met name de laatste veroorzaakt wereldwijd aanzienlijke schade in de var-
kenshouderij door het verlies van biggen en verminderde vruchtbaarheid van zeugen. 
Voor beide virussen zijn vaccins beschikbaar, hoewel de werking ervan niet optimaal 
is. Een mogelijke oorzaak hiervan is dat deze virussen in staat zijn het aangeboren 
immuunsysteem te onderdrukken en daarmee volledige activatie van het adaptieve 
immuunsysteem kunnen voorkomen.
De replicatie van arterivirussen begint met de productie van twee deels overlap-
pende polyproteïnen die zijn opgebouwd uit de niet-structurele eiwitten (nonstruc-
tural proteins, nsps). Deze polyproteïnen worden tijdens en na translatie gekliefd 
door drie tot vijf interne proteases, waarna de nsps tezamen het virale replicatie- en 
transcriptiecomplex vormen. Dit complex is verantwoordelijk voor de replicatie van 
het genoom en de transcriptie van subgenome mRNAs. De proteolytische klieving van 
de polyproteïnen is een strikt gereguleerd proces en mutaties aan proteases en/of 
klievingssequenties worden over het algemeen slecht getolereerd. Eén van de prote-
ases die een rol spelen in dit proces is PLP2 (papain-like protease 2), dat zich bevindt 





De aangeboren immuunrespons vormt de eerste verdedigingslinie tegen binnen-
dringende pathogenen en berust op de herkenning van pathogeen-gerelateerde 
moleculaire patronen door specifieke sensor-eiwitten. Activatie van de aangeboren 
immuunrespons leidt uiteindelijk tot de productie van type I interferon en andere pro-
inflammatoire cytokinen. Tezamen zorgen deze voor een antivirale staat van zowel de 
geïnfecteerde als naburige cellen en de stimulatie van het adaptieve immuunsysteem.
De activatie van het aangeboren immuunsysteem is zeer strikt gereguleerd. Een 
van de regulatiemechanismes die hiervoor worden gebruikt is ubiquitinylatie, het 
proces waarbij het kleine eiwit ubiquitine aan andere eiwitten wordt geconjugeerd. 
Deze koppeling kan leiden tot afbraak van het geubiquitinyleerde substraat, maar kan 
ook bepaalde eiwit-eiwit interacties mogelijk maken. Ubiquitinylatie is zeer geschikt 
voor de regulatie van signaaltransductieroutes omdat het een reversibele modificatie 
is. De ubiquitine moleculen kunnen door deubiquitinylerende enzymen (DUBs) weer 
verwijderd worden.
Uit sequentie-vergelijkingen uitgevoerd door Makarova et al. (2000) is gebleken 
dat arterivirus PLP2 overeenkomsten vertoont met proteases die behoren tot de 
OTU familie van DUBs. Frias-Staheli et al. (2007) hebben later aangetoond dat het 
tot expressie brengen van EAV of PRRSV PLP2 in celkweek leidt tot een afname van 
de hoeveelheid geubiquitinyleerde eiwitten. Gezien het belang van ubiquitinylatie 
in de activering van de aangeboren immuunrespons leek het aannemelijk dat de 
mogelijke DUB activiteit van arterivirus PLP2 een rol speelt bij het tegenwerken van 
deze respons. Bewijs hiervoor was echter tot nu toe moeilijk te verkrijgen omdat 
PLP2 vanwege zijn essentiële rol in de virusreplicatie niet simpelweg verwijderd of 
geïnactiveerd kon worden.
Allereerst hadden wij daarom tot doel de DUB activiteit van arterivirus PLP2 te 
bevestigen en de mogelijke rol van dit enzym in het remmen van de aangeboren im-
muunrespons verder te karakteriseren. In Hoofdstuk 2 hebben wij met behulp van in 
vitro klievingsexperimenten aangetoond dat EAV PLP2 inderdaad een DUB is en door 
middel van transfectie-experimenten konden wij aantonen dat deze activiteit waar-
schijnlijk binnen de gehele arterivirus familie geconserveerd is. Vervolgens hebben 
we laten zien dat expressie van arterivirus PLP2 leidt tot een afname van de expressie 
van een luciferase-reporter gen dat onder controle staat van de interferon-beta pro-
moter. Het sensor-eiwit RIG-I is een belangrijke, door ubiquitine gereguleerde factor 
in de aangeboren immuunrespons. Door middel van een transfectie-experiment 
hebben wij kunnen aantonen dat arterivirus PLP2 de ubiquitinylatie van RIG-I kan 
verminderen in celkweek. Deze data ondersteunt de hypothese dat de DUB activiteit 
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van arterivirus PLP2 een rol speelt in de onderdrukking van de activatie van het aan-
geboren immuunsysteem.
Vanwege de essentiële rol die proteases spelen in de replicatie van +RNA virussen 
zijn zij goede doelwitten voor het ontwikkelen van antivirale middelen. Aangezien 
naast arterivirussen nog een aantal andere virussen beschikken over proteases met 
DUB activiteit, onderzochten wij of deze activiteit gebruikt kon worden voor het iden-
tificeren van potentiële antivirale verbindingen. Hoofdstuk 3 toont het resultaat van 
een op fluorescentie polarisatie gebaseerde in vitro screeningsmethode, waarmee in 
een bibliotheek van 335 kandidaten een vijftal verbindingen zijn geïdentificeerd die 
de DUB activiteit van EAV PLP2 remmen. Van deze moleculen bleken er twee ook een 
noemenswaardig effect op de replicatie van een EAV GFP-reporter virus in celkweek 
te hebben. Het lijkt dus inderdaad mogelijk te zijn om antivirale verbindingen te iden-
tificeren door middel van een op DUB activiteit gebaseerde selectiemethode, maar 
aanvullend onderzoek blijft noodzakelijk.
Om aan te kunnen tonen dat de DUB activiteit van arterivirus PLP2 daadwerkelijk van 
belang is voor het remmen van de aangeboren immuunrespons tijdens een infectie 
was het noodzakelijk deze activiteit te scheiden van de essentiële rol van PLP2 in de 
klieving van de virale replicase polyproteïnen. Om dit te kunnen realiseren hebben 
wij in Hoofdstuk 4 in samenwerking met Canadese structuurbiologen de kristalstruc-
tuur van EAV PLP2 in complex met ubiquitine opgehelderd. Uit deze structuur bleek 
dat PLP2 inderdaad behoort tot de OTU familie en dat de binding van ubiquitine mede 
afhankelijk is van een PLP2 oppervlak dat enigzins verwijderd is van het katalytisch 
centrum van het protease. Dit maakte het mogelijk mutaties aan te brengen die de 
interactie met ubiquitine verstoren zonder de maturatie van de polyproteïnen te 
verhinderen. Met behulp van deze mutaties konden wij aantonen dat de DUB activiteit 
van arterivirus PLP2 inderdaad van belang is voor het remmen van de aangeboren 
immuunrespons tijdens een infectie.
Hoofdstuk 5 omvat een kleinschalig vaccinatie experiment in paarden waarmee werd 
onderzocht of een EAV vaccin waarin de DUB activiteit van PLP2 door middel van 
mutaties is uitgeschakeld (DUB-) beter beschermt tegen infectie met een heteroloog 
EAV isolaat dan een vaccin waarin de DUB activiteit van PLP2 nog intact is (DUB+). 
De resultaten van dit experiment lieten zien dat beide vaccinvirussen replicatie-
competent zijn, maar dat er geen duidelijk aantoonbaar verschil was in de mate van 
bescherming die zij konden bieden. Het feit dat het DUB+ vaccin al een zeer hoge 
mate van bescherming bood in dit experiment heeft er mogelijk voor gezorgd dat 





zoek moet dan ook uitwijzen of het uitschakelen van de DUB activiteit in een andere 
experimentele opzet wellicht een beter aantoonbaar effect heeft.
Naast arterivirussen beschikken ook nairovirussen (-RNA) en tymovirussen (+RNA) 
over OTU DUBs. Hoofdstuk 6 biedt een beknopte structurele en functionele verge-
lijking tussen deze enzymen. Terwijl zowel arteri- als nairovirus DUBs een rol lijken 
te spelen in het onderdrukken van de aangeboren immuunrespons, lijken tymovirus 
DUBs verantwoordelijk voor het verhinderen van proteosomale afbraak van het virale 
replicase. Het meest opvallende structurele verschil tussen de besproken enzymen is 
het feit dat het katalytische centrum van het tymovirus DUB incompleet lijkt te zijn in 
vergelijking met dat van arteri- en nairovirussen.
Het werk beschreven in dit proefschrift verschaft nieuwe inzichten in de structurele 
en (multi)functionele eigenschappen van arterivirus PLP2. Voor het eerst is de rol van 
een viraal DUB in het onderdrukken van de aangeboren immuunrespons tijdens infec-
tie aangetoond. De verworven kennis kan nu worden aangewend voor het ontwerpen 
van verbeterde vaccins tegen arterivirussen en voor studies aan andere virale DUBs, 
zoals die van de zoönotische coronavirussen die severe acute respiratory syndrome 
(SARS) en Middle East respiratory syndrome (MERS) veroorzaken.
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